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DEDICATION
This journey started almost twenty years ago, when as a ten year old kid, I used to dream
about owning a BMW like the local pharmacist of my neighborhood. Back then, all I
could think of was getting out of poverty, becoming someone highly educated, respected,
and wealthy who could one day come back to his hometown and give back to the
community. Someone, who could tell the youngsters that everything is achievable with
hard work, dedication, and passion, no matter where you come from. As I was trying to
figure out how to achieve my dreams, sports and education became for me the only
options. I became obsessed with basketball despite growing up in a country where soccer
was king. I do still remember practicing for hours, working on my jump shots, my drives,
and my post game every single day in order to be the best I could ever be. And during
these long nights when my legs were cramping up so bad that I couldn’t sleep anymore,
my mother always came to my room with a glass of water for me to drink while my
father was massaging my calves and thighs in order to make sure that I was ready for the
next day of school and practice. All this hard work finally paid off when I received a full
scholarship in 2005 to play at Kansas State University. Even though basketball will
always remain my #1 passion, my aspiration of being involved in pharmaceutical
research and make significant contribution to the health care system, especially in
developing countries, is what drives me right now. And now my dreams of driving a
BMW and owning a pharmacy store have transformed to owning a multi-national
pharmaceutical company because as a gamecock, my drive has “NO LIMIT”.
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ABSTRACT
Overactive bladder (OAB) is a pathophysiological condition which is
characterized by the urinary bladder’s failure to achieve proper storage of urine. OAB has
a tremendous impact on the patient’s quality of life by disturbing his sleep, work, and
sexual activity. About 17% of Americans are affected with this disease and most patients
experience symptoms of urgency, frequent urination, and abnormally elevated detrusor
smooth muscle (DSM) contractility. Despite, numerous attempts to treat the disorder in
the past with antimuscarinics and now with beta3 adrenergic receptors (beta3-AR
agonists), OAB still remains a serious public health issue because the long term efficacy
of these drugs remains questionable. Therefore, it is critical to explore new avenues and
design new strategies in order to help improve the quality of life of more than 33 million
people. K+ channels and beta3-AR have been shown to be key regulators of smooth
muscle excitability and contractility in various species; however, information about their
expression and functional role in the DSM of humans was limited. In our study, we first
investigated the molecular expression of several K+ channels in human DSM cells using
RT-PCR, qPCR, western blot, and immunostaining techniques, then tested their ability to
affect DSM contractility by using isometric DSM tension recordings and selective
pharmacological modulators. We found that two Ca2+-activated K+ channels including
BK and SK3 channels as well as several voltage-gated K+ channels including Kv2.1,
Kv2.2, Kv7.4, and Kv7.5 channels were expressed in human DSM cells. We also found
that pharmacological inhibition of BK or SK3 channels with iberiotoxin, a BK channel
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blocker or apamin, a SK channel blocker, respectively, significantly increased human
DSM spontaneous and nerve-evoked contractions in vitro. Similarly, pharmacological
inhibition of Kv2 channels with stromatoxin-1, a Kv2 channel antagonist or Kv7
channels with XE991, a Kv7 channel antagonist, also increased human DSM spontaneous
phasic and nerve-evoked contractions in vitro. On the other hand, application of
retigabine, a Kv7 channel activator induced relaxation of human DSM strips spontaneous
phasic and nerve-evoked contractions. As for the role of beta3-AR in human DSM, we
found that pharmacological activation of beta3-AR with BRL37344, a beta3-AR agonist
causes relaxation of human DSM nerve-evoked contractions in vitro. We further
demonstrated that the beta3-AR mediated relaxation observed during nerve-evoked
contractions was facilitated by BK channel activity. Finally, we obtained direct evidence
suggesting that the decrease in BK channels expression and function is associated with
symptoms of neurogenic detrusor overactivity.
In conclusion our study suggest that pharmacological modulation of K+ channels (BK,
SK3, Kv2, and Kv7 channels) or beta3-AR affect DSM contractility, therefore making K+
channels and beta3-AR likely drug targets for the treatment of OAB.
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CHAPTER 1
INTRODUCTION

1.1 ANATOMY OF THE LOWER URINARY TRACT
The basic function of the lower urinary tract (LUT) is to secure urine storage in the
bladder and achieve voluntary evacuation of the stored urine. The LUT is composed of
two main parts: the urinary bladder and the urethra.
The urinary bladder is a distensible reservoir which initiates urine voiding by contracting
its muscular wall composed essentially of detrusor smooth muscles (DSM) (102). The
urinary bladder has a triangular pyramidal shape and is located in the anterior part of the
pelvis (102). It is composed of the fundus, superior surface; the base, posterior surface;
and two triangular side walls. The lowest part of the bladder where the lateral walls meet
the base is called the bladder neck and the lowest part of the neck is the trigone (Fig.
1.1.1). The bladder has three distinct tissue layers which are the serosa, the DSM, and the
urothelium. The serosa is the outer layer which is composed of adventitial connective
tissue. The DSM is the middle layer- it comprises interlacing fibers which can either be
randomly oriented or oriented in longitudinal, circumferential, and longitudinal patterns.
The urothelium is the innermost layer- it is composed of transitional cell epithelium (Fig.
1.1.1).
The urethra is the portion of the lower urinary tract by which the urine is expelled. In
females, the urethra is relative short (only few centimeters) while in males, the total
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length approximates 20 cm. The urethra is composed of four sections in males which
include prostatic, membranous, bulbar, and penile sections (Fig. 1.1.1). The membranous
urethra is approximatively 2 cm long and is surrounded by the striated external urethral
sphincter (EUS) which is innervated by pudental nerves. The external urethral sphincter
is under the subject voluntary control and relaxes during urine voiding to allow urine
flow.

Figure 1.1.1 Anatomy of the urinary bladder. (a) Anterior view of the urinary bladder. Urine enters the urinary
bladder via the ureters and exit via the urethra. Inset: cross-section of the bladder wall. Reprinted with permission from
McGraw-Hill companies. http://academic.kellogg.edu/herbrandsonc/bio201_McKinley/f27-9a_urinary_bladder_c.jpg
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1.2 THE MICTURITION PROCESS
The micturition process is a complex mechanism which requires a synergy of action
between myogenic and neurogenic components. It includes a filling or storage phase and
an emptying or voiding phase. The three major structures of the LUT which are the
bladder, the urethra, and the EUS are innervated by afferent nerves which play different
roles in urine storage and voiding (Fig. 1.2.1). During the bladder filling phase,
information concerning the degree of distention of the bladder as well as the amount of
stored urine is transmitted to the brain via several mechanosensitive afferent nerves
present in the bladder (38). These nerves have been identified as Aδ afferent nerves. It
has been reported that when the bladder is filled at 60-90% of its capacity, the desire to
void exists but can be delayed by the subject if necessary. However, behind 90%
capacity, a strong desire to void is reported and accidental urine leakage becomes
common because the subject can no longer control his external urethral sphincter (38,
44).

Sympathetic Storage Reflexes
The filling phase of the micturition is an involuntary process shown to be under the
control of sympathetic nerves input (38). During the filling phase, Aδ vesical afferents
nerves are activated to induce the sacrolumbar intersegmental spinal reflex which in
response causes an increase in urethral outflow resistance. This reflex also increases the
tonic discharge of motoneurons innervating the striated muscles of the EUS (25, 152).
Normally, this reflex pathway becomes inhibited when the intravesical pressure raises to
the level required to producing voiding (Fig. 1.2.1). Inhibition of the sympathetic
innervation can reduce urethral outflow resistance, reduce bladder capacity, and increase
3

the

frequency and

amplitude

of

bladder

contractions

(38).

Therefore,

this

vesicosympathetic reflex represents a negative-feedback mechanism that allows the
bladder to accommodate considerable amount of urine (38).

Voiding Reflexes
The voiding phase of the micturition has both voluntary and involuntary components
which are regulated at the pontine micturition center (PMC) and the spinal cord levels,
respectively (Fig. 1.2.1) (38). The involuntary/reflex pathway becomes activated when
the mechanosensitive Aδ afferents present in the bladder are sensitized by the increase in
intravesical pressure. The influx travels to the sacral spinal cord and initiate the voiding
reflex (Fig. 1.2.1). During urine voiding, it has been shown that the urethral smooth
muscles are relaxed and nitric oxide, an inhibitory neurotransmitter is released in the
urethra. Additionally, PMC becomes activated which further leads to the inhibition of
sympathetic storage reflexes. Finally, during micturition, the excitatory bladder reflex
pathway is also activated by the flow of urine through the urethra and the sensitization of
urethral afferents nerves (38).
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Figure 1.2.1 Neural circuits controlling continence and micturition. (a) Urine storage reflexes. During the storage
of urine, distension of the bladder produces low-level afferent firing in the pelvic nerve, which in turn stimulates (1) the
sympathetic outflow to the bladder outlet (base and urethra) and (2) pudendal outflow to the external urethral sphincter.
These responses occur by spinal reflex pathways and represent guarding reflexes, which promote continence.
Sympathetic firing also inhibits detrusor muscle and modulates transmission in bladder ganglia. A region in the rostral
pons (the pontine storage center) increases external urethral sphincter activity. (b) Voiding reflexes. During elimination
of urine, intense bladder afferent firing activates spinobulbospinal reflex pathways passing through the pontine
micturition center, which stimulate the parasympathetic outflow to the bladder and internal sphincter smooth muscle
and inhibit the sympathetic and pudendal outflow to the urethral outlet. Ascending afferent input from the spinal cord
may pass through relay neurons in the periaqueductal gray (PAG) before reaching the pontine micturition center.
Reprinted with authorization from (De Groat et al. 2009).
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Neural and hormonal control of the micturition process
The contraction and relaxation of the urinary bladder are regulated by cholinergic,
adrenergic, and non-adrenergic non-cholinergic (NANC) mechanisms.
The cholinergic mechanism is mainly involved in the urinary bladder emptying phase.
This pathway is mediated via activation of muscarinic receptors (7). In most species,
including humans, the M2/M3 muscarinic receptors are the most physiologically relevant
(7). During the bladder emptying phase, acetylcholine (ACh) an excitatory
neurotransmitter is released from nerve terminals and activates M2/M3 muscarinic
receptors. Acetylcholine activation of M2 muscarinic receptors causes inhibition of
adenylyl cyclase activity while activation of M3 receptors triggers the inositol 1,4,5trisphosphate pathway (55, 104) (Fig. 1.2.2). In normal humans, nearly 100% of bladder
contraction is due to muscarinic activation (11, 142).

Figure 1.2.2 Transmitter signal pathway (1 – 4) involved in activation of detrusor contraction via muscarinic M3
receptors. Ach, acetylcholine; PLC, phospholipase C; DAG, diacylglycerol; PKC, protein kinase C; MLC, myosin
light chain; SR, sarcoplasmic reticulum; CIC, calcium-induced calcium release. There seem to be differences between
species in the contribution of the different pathways in contractile activation. In human detrusor, Ca 2+ influx (3) is of
major importance. Reprinted from Andersson et al. 2004 with permission.
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The adrenergic mechanism is mainly involved in the bladder filling phase.
Norepinephrine is released from bladder nerve terminals and activates beta1-, beta2-, and
beta3- adrenergic receptors to cause DSM relaxation (7, 79, 130). In the human DSM,
beta3- ARs are suggested to be the most important as they represent more than 90% of all
beta-AR (168). Activation of beta adrenergic receptors stimulates adenylyl cyclase to
increase cAMP production. In turn, cAMP activates the protein kinase A pathway to
further induce DSM relaxation (7, 79, 130). This beta3-AR induced relaxation of the
DSM has recently been shown to be mediated by the large conductance-calcium activated
K+ channel (Fig. 1.2.3) (79, 130).

Figure 1.2.4. Schematic illustration of the functional coupling between the beta3-AR and the BK channel in the
detrusor smooth muscle cell. The BK channel control the opening and the closing of the L-type Cav channels by
depolarizing or hyperpolarizing the cell membrane, this regulating the global Ca 2+ influx and spontaneous phasic
contractions. BK channels are activated by localized Ca2+ signals (“Ca2+ sparks”) caused by Ca2+ release from the
RyRs of the SR, adjacent to the cell membrane. Stimulation of the beta3-AR with selective agonists leads to PKA
activation, PLN phosphorylation, and activation of the SR Ca2+ pump and RyRs, which causes an increase in Ca2+
spark and TBKC activity. The increased TBKC frequency results in a sustained membrane hyperpolarization, closure
of the L-type Cav channels, reduction in the global Ca2+ concentration, and detrusor smooth muscle relaxation. When
Ca2+ spark are blocked with ryanodine and/or thapsigargin (a SR Ca2+-pump inhibitor), the functional coupling between
beta3-AR and BK channels is disrupted. Abbreviations: beta3-AR, beta3 adrenergic receptor; BK channel, large
conductance voltage-activate and Ca2+-activated K+ channel; PKA, protein kinase A; PLN, phospholamban; RyR,
ryanodine receptor; SR, sarcoplasmic reticulum; TBKC, transient BK current. Reprinted from Petkov (2012) with
permission.
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The NANC mechanism is mainly involved in the bladder emptying phase of the
micturition process and is characterized by a fast contractile response upon
neurotransmitter release (7). During the voiding phase of the micturition process, two
major neurotransmitters ATP and acetylcholine are released from bladder nerves (59, 64,
119, 142, 161). In in vitro systems, neurotransmitters release can be achieved by applying
electrical field stimulation (EFS) to DSM isolated strips (Fig. 1.2.5). While ACh is
responsible for the cholinergic response, ATP will activate a NANC pathway, namely the
purinergic pathway. Both pathways contributing to DSM contraction (24, 59, 64, 105,
119, 142, 160, 161). ATP activates purinergic (P2X1) receptors and therefore causes an
increase in DSM cell excitability via an increase in Na+ and Ca2+ intracellular
concentrations (59, 172). Evidence suggests that the contribution of the purinergic
pathway to DSM contraction may become preponderant under pathophysiological
condition of overactive bladder (OAB) in humans (6, 124, 171).
In addition to the release of ATP and ACh, calcitonin gene-related peptides and other
substances such as nitric oxide are also released from nerves and have a relaxing effect
on DSM (7, 48).
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Figure 1.2.5. Schematic showing activation of purinergic and muscarinic pathways following release of
neurotransmitters ATP and ACh from parasympathetic varicosities. Purinergic signalling rapidly evokes Ca2+
flashes during EFS whereas muscarinic signalling evokes Ca2+ waves during stimulation and Ca2+ flashes following
stimulation. Purinergic activation appears to inhibit the muscarinic response. Ca2+ flashes from both purinergic and
muscarinic pathways contribute to contraction. Reprinted from Heppner et al. (2009) with permission.
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1.3 BLADDER DYSFUNCTIONS
The role of the LUT is to realize the storage and voiding of urine. This function is
accomplished by a synergy of action between the autonomous and the central nervous
systems, which control DSM relaxation and contraction during the filling and voiding
phases, respectively (38). Any alterations in DSM contractility due to neuronal or
muscular factors can affect the micturition process and render the LUT unable to
accomplish its function. Bladder dysfunctions can be categorized into two groups based
on the pathophysiological changes observed in the DSM. The first category includes
bladder dysfunctions in which the DSM contractility is abnormally increased. Within this
category, the most important pathophysiological condition is known as overactive
bladder (OAB). The second category of bladder dysfunctions includes conditions in
which the DSM contractility is decreased causing the LUT to retain urine for an
abnormally long period of time. This condition is termed underactive bladder.
Overactive bladder is a pathophysiological condition which affects ~17% of the
American population (147). Although, the disease affects people of all ages, studies
report that the majority of OAB patients are 65 years old or more. OAB has a tremendous
impact on patients’ quality of life by affecting their sleep, work, and sexual activity.
Patients affected with the disease, experience greater spontaneous phasic DSM
contractions during the filling phase of the micturition process (16, 120) as well as
nocturia, frequent urination, urgency, incontinence, and involuntary contractions of the
DSM (147).
Underactive bladder is a less common pathophysiological condition which is defined as a
contraction of reduced strength and/or duration resulting in prolonged or incomplete
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emptying of the bladder (159). The disease has multiple origins including neuronal and
muscular. Aging which causes decay in DSM activity is also seen as a contributing factor
to this condition (159).
1.4 ION CHANNELS
Ions channels are protein structures anchored in the cell membrane to facilitate the flow
of inorganic ions such as Na+, K+, Ca2+, and Cl- down their electrochemical gradients
(129). Ion channels are not only pores regulating the flux of ions through the cell
membrane; they also play critical roles in numerous physiological processes including
nerve and muscle excitation, action potential generation, muscle contraction, blood
pressure regulation, cell proliferation, hormone secretion, learning and memory (129). In
the human genome, more than 340 genes coding for ion channels have been identified
and more than 60 ion channel targeting drugs are currently on the market to attest the
importance of these proteins (129). Ion channels have two major functional propertiesselectivity and gating.
Selectivity is the functional property which allows the channel to discriminate between
ions by acting like a filter. With the exception of nonselective cation channels, most ion
channels allow migration of a specific ion across the cell membrane (129).
Gating is the functional property that allows the channel to remain either in an open or
closed state (129). When ion channel’s gating is regulated by changes in the
transmembrane voltage, they are termed voltage-gated ion channels (129). On the other
hand, ion channels are named ligand-gated ion channels when the channel’s gating is
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regulated by a small molecule (ligand) which interact directly with the channel or with a
receptor linked to the channel (129).
Classification and nomenclature of ion channels are based on the nature of their most
important permeant ion. There are four major classes of ion channels- Na+, K+, Cl-, and
Ca2+ channels (129).
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1.5 K+ CHANNELS
K+ channels are by far the largest and the most diverse group of ion channels. They are
expressed in almost every cell type in which they play various physiological roles (129).
Between 70 and 80 genes are known to code for K+ channel proteins (129). In the DSM,
the physiological role of K+ channels is to regulate muscle contraction and relaxation
(130). This function is achieved by a precise regulation of intracellular Ca2+
concentration which is controlled by Ca2+ entry via voltage-gated Ca2+ (Cav) channels
(130). In general, K+ channels’ opening causes cell membrane hyperpolarization,
interruption of Ca2+ entry via Cav channels, and DSM relaxation (129, 130). By contrast,
K+ channels’ inhibition causes membrane depolarization, increase of Ca2+ entry via Cav,
and DSM contraction (129, 130). Structurally, all K+ channels form a pore-loop and can
have 2 to 8 transmembrane (TM) domains (Fig. 1.5.1). K+ channels are classified into
four major families including voltage-gated (Kv), Ca2+-activated (KCa), inward rectifying
ATP-sensitive (Kir), and two pore domain (K2P) K+ channels (129, 130).
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Figure 1.5.1. Illustration of the transmembrane architecture and subunit stoichiometry of the K + channel types
expressed in detrusor smooth muscle cells. Kir channels (represented by KATP channel) have the simplest K+ channel
structure, with two transmembrane segments (S) connected by a pore loop. Four such subunits form a functional
tetrameric channel pore. K2P channels form a tetrameric pore structure from two subunits each containing two pore
loops. Kv channel subunits have six transmembrane segments with a voltage sensor in the S4 transmembrane domain.
BK channels consist of four pore-forming α-subunits and the four regulatory β1 or β4 subunits. Abbreviations: BK
channels, large-conductance voltage-activated and Ca2+-activated K+ channels; K2P, two-pore-domain K+ channels;
KATP, channels, inward-rectifying ATP-sensitive K+ channels; Kir channels, inward-rectifying K+ channels; Kv
channels, voltage-gated K+ channels. Reprinted from Petkov (2012) with permission .
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Voltage-gated K+ (Kv) channels form the most diverse family of K+ channels and are
encoded by more than 40 genes (130). Kv channels are known to participate in the
repolarization phase of the action potential and in maintaining the cell’s resting
membrane potential (Fig. 1.5.2) (56, 60, 74, 77, 155). Kv channels are classified into 12
subfamilies (Kv1 – Kv12) based on the amino-acid sequence homology. Each Kv gene
encodes a pore-forming α-subunit protein which assembles into tetramer to form a
functional channel (130). While Kv1, Kv2, Kv3, Kv4, Kv7, Kv10, Kv11, and Kv12
channels can form their own homotetramers, Kv5, Kv6, Kv8, and Kv9 channels cannot
but rather form heterotetramers by assembling with the Kv2 channel α-subunit (130).
Despite, the significant number of Kv channel genes identified in the human genome,
only a small fraction of Kv channels has been studied in the DSM suggesting that more
work is needed to determine if these channels can potentially regulate DSM contraction
and relaxation.
Ca2+-activated K+ (KCa) channel family has five members (KCa1.1, KCa2.1 KCa2.2,
KCa2.3, and KCa3.1) which can be classified based on the single channel conductance
(130). The large conductance voltage-activated and Ca2+-activated K+ (KCa1.1 or BK)
channel is also known as big-K or maxi-K because of its high single channel conductance
(100 – 250 pS) (130). The BK channel can be activated by both Ca2+ and voltage and is
highly expressed in the DSM where it plays a role in maintaining the resting membrane
potential and securing the repolarization phase of the action potential (60, 61, 67, 75, 80,
130). The small conductance Ca2+-activated K+ (SK) channels have a single channel
conductance ranging from 5 to 20 pS (129, 130). There are 3 types of SK channels which
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include SK1 (KCa2.1), SK2 (KCa2.2), and SK3 (KCa2.3) channels (129, 130). SK channels
are voltage-insensitive and are regulated by Ca2+ and calmodulin (106). In the DSM, they
are suggested to contribute to the afterhyperpolarization phase of the action potential
(Fig. 1.5.2) (45, 56). The intermediate-conductance Ca2+-activated K+ (KCa3.1 or IK or
SK4) channel has a single channel conductance ranging from 20 to 80 pS (129, 130). IK
channels are activated by Ca2+ and insensitive to voltage changes (129, 130). Their role in
the DSM remains unclear since most studies suggest that pharmacological modulation of
these channels has no effects on DSM excitability and contractility (2, 127).
Inward-rectifying ATP-sensitive K+ (Kir) channels induce high amplitude of inward K+
currents during the hyperpolarization phase of the action potential (129, 130). In the
DSM, the Kir channels are represented by the Kir6 (KATP) channel which has a single
channel conductance ranging from 11 to 12 pS (86, 87). These channels are activated by
both low intracellular ATP and high ADP levels (129, 130). Whether KATP channels are
physiologically relevant in the DSM remains controversial as evidence of their
physiological role or not are conflicting (Fig. 1.5.2). Some studies argues in favor of
KATP channels’ ability to regulate DSM contractility and excitability (45, 58, 86, 87, 133,
141) while others suggest that activation of KATP channel with glibenclamide, a specific
KATP channel inhibitor has not effects on DSM contractility and excitability (37, 133,
141).
Two-pore-domain K+ (K2P) channels has 15 members including (K2P1 – K2P15) which are
mostly known for their role in stretch, oxygen, pH and temperature sensing (12, 129,
130). They play a role in maintaining the cell’s resting membrane potential (Fig. 1.5.2).
In the DSM, knowledge about K2P channels is still at its infancy. The few studies which
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investigated K2P channels subtypes (TASK-1 and TASK-2) in the DSM suggest that these
channels play an important role in stabilizing the DSM cell’s resting membrane potential
(12).

Figure 1.5.2. Schematic illustration of the detrusor smooth muscle action potential and the roles of various K +
channels in determining resting membrane potential and action potential. BK, Kv, K2P, and probably KATP
channels determine the resting membrane potential. BK and Kv channels contribute to the initial repolarization phase
of the action potential. SK and Kv channels contribute to the prolonged after-hyperpolarization phase of the action
potential. Abbreviations: BK channels, large-conductance voltage-activated and Ca2+-activated K+ channels; Cav,
voltage-gated Ca2+ channels; K2P, two-pore-domain K+ channels; KATP, channels, inward-rectifying ATP-sensitive K+
channels; Kv channels, voltage-gated K+ channels; SK channel, small conductance Ca2+-activated K+ channels;.
Reprinted from Petkov (2012) with permission.
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1.6 BETA3 ADRENERGIC RECEPTORS
Beta adrenergic receptors are receptor proteins which are expressed in a wide variety of
cell types. They include three subtypes which are beta1-, beta2-, and beta3- adrenergic
receptors. The molecular expression and functional role of beta-AR in the DSM varies
from species to species. While in the guinea pig, beta1-ARs seem to be the most
predominant and physiologically relevant (100); in rats, studies report that beta2- and
beta3-AR are the most important (7). In the human DSM, although all three beta-AR
have been identified (82, 83, 151, 168), qPCR data reveal that beta3-AR represent more
than 90% all of beta-AR (168). Furthermore, the use of selective beta1- and/or beta2-AR
on human DSM seems to have controversial effects (7). By contrast, pharmacological
activation of beta3-AR has been shown to significant cause relaxation of the DSM
contractions in humans (14, 27, 79, 81, 88, 90, 156). These studies suggest that beta3ARs are key regulators of human DSM contractility. The mechanism by which β-AR
activation causes relaxation of the DSM is thought to involve the cyclic cAMP (cAMP)
signaling pathway (22, 115). cAMP activates protein kinase-A (PKA), which in turn
phosphorylates various proteins involved in DSM excitation-contraction coupling and
stimulates the BK channels to promote DSM relaxation (22, 58, 115). Beta3-AR agonists
have been shown to increase the intracellular cAMP levels in native DSM tissues as well
as in heterologously expressed systems (46, 69, 88, 94, 139, 150). Because of the
preponderant role of beta3-AR in human DSM physiology, the FDA has approved
mirabegron, a beta3-AR agonist for the treatment of overactive bladder (21, 27, 50, 51,
157).
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CHAPTER 2
DISSERTATION OUTLINE

In the present chapter, I will describe the dissertation outline. I will first present the
central hypothesis of my thesis and present the rationale that motivated my research
during my PhD training. Next, I will described in details, the experimental approaches,
methods, and techniques that I used to test my hypothesis. I employed two principal
approaches in my research. The first approach consisted of identified the genetic markers
of K+ channels expression in the DSM. In this approach, I employed various techniques
including RT-PCR, qPCR, western blot and immunostaining. These techniques were
employed to identify the mRNA and the proteins expressions of specific K+ channels.
The second approach consisted of determining the functional role of the K+ channels
identified previously. The functional studies were performed using isometric DSM
tension recording techniques and various pharmacological modulators. The majority of
the data presented in this dissertation are based on these two principal approaches. In the
context of my study, I will also present data collected by other members of the Petkov’s
lab that have been published with me as co-author. These additional data will provide
further evidence for the role K+ channels in the DSM.
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2.1 CENTRAL HYPOTHESIS
Overactive bladder (OAB), a pathophysiological condition resulting from the urinary
bladder’s failure to achieve proper storage of urine which further lead to urgency, affects
about 17% of Americans. For many years, the pharmacological treatment of OAB relied
primarily on oral administration of antimuscarinic drugs which unfortunately have
limited efficacy and dose-related side effects. Recently, the FDA has approved
mirabegron, a beta3-ARs agonist, for the treatment of OAB. However, the ability of this
drug to treat all forms of OAB remains uncertain. Intravesical injection of botulinium
toxins has also been proposed but this approach is invasive, expensive, and
uncomfortable for patients. Therefore, alternative treatment options are urgently needed.
Numerous studies have demonstrated that various K+ channels including the largeconductance Ca2+-activated K+ (BK) channels, the small (SK) and intermediate (IK)
conductance Ca2+-activated K+ channels, and the voltage-dependent K+ (KV) channels are
important regulators of the DSM excitability and contractility (2, 26, 29, 60, 65, 75, 77,
80, 120, 126, 130, 134, 145). Also, it has been revealed that during the urinary bladder
filling phase, beta3-ARs are activated to induce DSM relaxation via the protein kinase A
pathway. Therefore, we suggest that K+ channels including KV channels, KCa channels as
well as beta3-AR could represent better pharmacological targets than antimuscarinics in
the treatment of OAB. The objective of our study was to elucidate the physiological role
and regulatory mechanisms of K+ channels and β3-ARs in the DSM. We hypothesized
that K+ channels and beta3-ARs play major roles in DSM excitability and
contractility and could represent promising pharmacological targets for the
treatment of various forms of OAB including neurogenic detrusor overactivity.
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2.2 EXPERIMENTAL APPROACHES, METHODS, AND TECHNIQUES
EXPERIMENTAL APPROACHES
To test our central hypothesis, we used various experimental approaches which allowed
us to investigate the molecular expression of K+ channels and beta3-ARs at the mRNA
and protein level, and further assess the functional role of these proteins. Channels
mRNA expression and relative quantity in DSM tissue was assessed using RT-PCR and
qPCR techniques. We also developed a novel experimental approach of DSM single-cell
enzymatic isolation to further determine mRNA messages in DSM cells. The single-cell
RT-PCR and qPCR techniques allowed us to establish whether mRNA messages for
various K+ channels or beta3-ARs were expressed in DSM cells and not in other cells
such as neurons, fibroblasts, interstitial cells which are also present in the DSM tissue. K+
channels protein expressions were investigated by western blot and immunostaining
techniques. Finally, the channels functional roles were addressed by using isometric
DSM tension recordings and K+ channels modulators.
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METHODS AND TECHNIQUES
Human DSM tissue collection

All human studies presented in this dissertation were conducted according to the
reviewed and approved institutional review board protocol HR#16918 of the Medical
University of South Carolina (MUSC). Control human samples were collected from
patients without a preoperative history of OAB symptoms. These control patients had an
American Urological Association (AUA) symptom score<8 and did not have a clinically
relevant neurological disease. NDO patients had overactive bladder (OAB) symptoms
and were characterized by an American AUA symptom score >7. Human tissue samples
were collected with patients’ consent during surgeries such as radical cystectomy for
bladder cancer and other open bladder surgeries for malignant or non-malignant
conditions of the lower urinary tract. Two types of DSM samples were collected from
each

patient.

The

first

sample

was

stored

in

ice-cold

Ca2+-free

N-2-

hydroxyethylpiperazine-N'-2-ethanesulphonic acid (HEPES)-buffered dissection solution
(§Solutions and Drugs) and was used to conduct functional studies on DSM contractility,
western blot, and immunostaining experiments. The second sample was kept in RNAlater (QIAGEN Sciences, Hilden, Germany) and was used for RT-PCR and qPCR
experiments. Both samples were transported to the laboratory immediately after surgery.

Animal studies and DSM tissue harvesting

All animal studies including rat and guinea pig studies were performed according to the
Animal Use Protocol #1747, reviewed and approved by the University of South Carolina
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Institutional Animal Care and Use Committee. Sprague-Dawley rats and Hartley-Albino
guinea pigs were euthanized by carbon dioxide inhalation followed by thoracotomy. The
animal whole bladder was then removed by transversal incision above the bladder neck.

DSM cells isolation and collection

DSM cells were isolated from humans and guinea pigs DSM tissue as follows (1, 2, 22,
29, 30, 74, 75, 77, 79, 80, 127, 131, 133, 134, 143, 145, 164, 166): The bladder tissue was
pinned on a sylgar-coated dish then the urothelium and the mucosa were removed under a
dissection microscope using micro scissors. The DSM was then cut into strips (5–8 mm
long, 2–4 mm wide), and 1–2 strips were placed in dissection solution (2 ml)
supplemented with 1 mg/ml bovine serum albumin (BSA), 1 mg/ml papain, 1 mg/ml DLdithiothreitol, and incubated for 25–30 min at 37 ºC. Next, the DSM strips were
transferred into a dissection solution (2 ml) containing 1 mg/ml BSA, 1 mg/ml
collagenase type II, and 100 µM CaCl2 and incubated for another 5-6 min at 37 ºC. DSM
strips were then washed with fresh BSA containing dissection solution. The individual
DSM cells were dispersed when the enzyme-treated tissue was passed through the tip of a
Pasteur pipette. Dispersed DSM cells were put in a glass chamber and allowed to settle at
the bottom for about 20 min. Next, DSM cells were washed out 4-5 times using a
perfusion system which removes the cells that do not adhere to the glass-bottom of the
chamber. DSM cells are characterized by their spindle-shape, bright and shiny
appearance under the Axiovert 40CFL microscope (Carl Zeiss®, Germany) as well as
their responsiveness to mechanical stimulation which indicates the presence of functional
contractile proteins and that they are physiologically active. DSM cells were collected
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individually

by

suction

into

a

glass

micropipette

using

an

MP-285/ROE

micromanipulator (Sutter Instruments, San Rafael, California). A poll of approximately
100 DSM cells was collected for RNA extraction and further single-cell RT-PCR and
qPCR experiments. The remaining DSM strips were kept in the dissection solution and
used for functional studies and “whole tissue” RT-PCR and qPCR, western blot, and
immunostaining.

RT-PCR and qPCR experiments

Using the RNeasy Mini Kit (Qiagen, Hilden, Germany), we extracted total RNA from
whole DSM tissue, brain tissue, and a poll of enzymatically isolated DSM cells of
humans and guinea pigs (1, 2, 74, 75). The extracted total RNA was reverse-transcribed
into cDNA using M-MLV Reverse transcriptase (Promega, Madison, WI) and oligo d(T)
primers. The amplification of the cDNA product was performed in the presence of GoTaq
Green Master Mix (Promega, Madison, WI) and PCR primers for various K+ channels
and beta3-ARs, respectively using a mastercycler gradient from Eppendorf (Hamburg,
Germany). Primers were designed based on the complete cDNA sequences of the K+
channels and beta3-AR investigated and synthesized by Integrated DNA Technologies
(IDT, Coralville, IA). PCR products were loaded onto a 2% agarose ethidium bromidestained gel and allowed to migrate via electrophoresis. The expected length of the
fragment for each K+ channels and beta3-ARs investigated was confirmed by using a 20
or 100 bp extended range DNA ladder from Lonza (Rockland, ME, USA). Guinea pig
and human brain tissue were always used as positive control. For the qPCR experiments,
we applied a two-step amplification followed by melting curve protocol using the IQTM5
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Thermo Cycler system (Bio-Rad, California, USA). 10 – 100 ng/µL of whole DSM tissue
or DSM isolated cells’ cDNA was mixed with IQ SYBR Green Supermix (Bio-Rad,
California, USA) and each individual K+ channels primers separately then loaded onto a
96-wells plate. GAPDH was chosen as an internal control gene to analyze K+ channel
isoforms mRNA relative expression and each sample was run in duplicate or triplicate.
All RT-PCR products from the whole DSM tissue, brain tissue, and DSM isolated cells of
humans and guinea pigs were purified using the GenElute™ PCR Clean-Up Kit (SigmaAldrich Co., St. Louis, MO) and sequenced at the University of South Carolina
Environmental Genomics Core Facility to confirm their identity.

Western blot

Approximatively 30 µg of total protein extracted from guinea pig whole DSM tissue was
loaded into a 10 % Tris-HEPES-SDS precast polyacrylamide mini gels (Thermo
scientific, Rockford, IL) and run at 150 V for 40 min using a PowerPac Universal power
supply from Bio-Rad (Hercules, CA). Proteins were then transferred from the gel onto an
immobilon-P PVDF membrane by semi-dry transfer technique using a Hoefer semi-dry
blotter TE70XP (Fisher scientific). Next, the membrane was blocked by 5% non-fat dry
milk in 0.5% TBST (0.5% Tween-20 in TBS) buffer for 1 h. Following the block, the
membrane was incubated with the affinity-purified antibodies specific for each K+
channel tested separately. Next, the membrane was washed with 0.5% TBST 4 times and
re-incubated with secondary antibody (diluted to 1:1,000) in the blocking buffer for 1 h at
room temperature. Bound antibodies were detected by the enhanced chemiluminescence
substrate kit (Amersham, Piscataway, NJ) according to the manufacturer's instructions.
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To confirm the specificity of the primary antibody, additional Western blot experiments
were conducted by incubating each primary antibody with its competing peptide.

Immunohistochemistry
Experiments were performed to determine whether K+ channels proteins were expressed
in DSM cells of humans and guinea pigs. DSM tissue was sliced into 2 X 2 mm and 6 µm
thick sections using a vibratome Model G tissue slicer (Oxford Laboratories, Foster City,
CA) and transferred in individual dishes for immunostaining. Tissue sections were
incubated with primary antibody for each K+ channel tested in 1% BSA/PBS at 37oC for
1 h. Tissue sections were then rinsed multiple times with 1% BSA/PBS, incubated for
one hour in 5% normal donkey serum in 1% BSA/PBS, then re-incubated with secondary
antibody (1:100) in the dark for another hour. Tissue sections were subsequently washed
with 1% BSA/PBS then PBS and then incubated with α smooth muscle actin (1:50) or
phalloidin (1:50) in PBS for 2 h in the dark. Then DSM tissue sections were rinsed three
more times with PBS, incubated with 4′,6-diamidino-2-phenylindole (DAPI) (1:5000) in
PBS for 15 min and then mounted with 1,4-diazabicyclo[2.2.2]octane (DABCO) (Sigma
Aldrich, St. Louis, MO, USA). The specificity of the primary antibody was confirmed by
incubating each K+ channel antibody tested with its competing peptide. Tissue sections
were visualized under a confocal microscope LSM 510 or 700 META (Carl Zeiss,
Germany) 63X objective.
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Isometric DSM tension recordings

Isometric DSM tension recordings experiments were performed as follows (1, 2, 22, 29,
74, 75, 77, 79, 80, 143, 145, 164, 166): DSM strips were clipped between a force
displacement transducer and a hook then submerged into a thermostatically controlled
(37oC) 10 ml bath filled with Ca2+-containing physiological saline solution (PSS) and
aired with 95% oxygen- 5% carbon dioxide (Fig. 2.2.1).

Figure 2.2.1. Isometric DSM tension recording setup used to study drug effect on DSM contractility in vitro.
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DSM strips were then stretched to 1 g of tension to elicit spontaneous phasic
contractions. Strips were washed out with fresh PSS every 15 min and allowed to
equilibrate for a period 45 min to 1 h. On DSM isolated strips that exhibited spontaneous
phasic contraction amplitude >0.1 g, tetrodotoxin (1 µM TTX), a neuronal Na+ channels
blocker was first added to the bath before a K+ channels or beta3-AR modulator was
applied. In DSM strips which exhibited spontaneous phasic contraction amplitude less
than 0.1 g, contractions were induced by electrical field stimulation (EFS) and TTX (1
µM) was not added since TTX effectively suppresses EFS-induced contractions. Using a
PHM-152I stimulator (Med Associates, Inc., Georgia, VT), we either applied stimulation
of 10 Hz EFS frequency at 1 min intervals or we applied increasing EFS frequencies (0.5,
2, 3.5, 5, 7.5, 10, 12.5, 15, 20, 30, 40, 50 Hz) at 3 min intervals. On the 10 Hz EFSinduced contractions, increasing concentrations of K+ channel or beta3-AR activators and
inhibitors were applied as described above. On the 0.5 – 50 Hz EFS-induced contractions,
a single concentration of K+ channel or beta3-AR modulator was applied. The EFS pulses
had the following parameters: pulse amplitude (20 V), pulse width (0.75 ms), stimulus
duration (3s), polarity was reversed for alternating pulses. The DSM response to EFS was
recorded using MyoMed software (Med Associates).

Solutions and drugs
The Ca2+-free dissection solution had the following composition (in mM): 80
monosodium glutamate; 55 NaCl; 6 KCl; 10 glucose; 10 N-2-hydroxyethylpiperazine-N'2-ethanesulphonic acid (HEPES); 2 MgCl2; and pH 7.3 adjusted with NaOH. The Ca2+containing PSS was prepared daily and contained (mM): 119 NaCl; 4.7 KCl; 24
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NaHCO3; 1.2 KH2PO4; 2.5 CaCl2; 1.2 MgSO4; 11 glucose; and aerated with 95%
oxygen/5% carbon dioxide to obtain pH 7.4.

Data analysis and statistics

mRNA relative expressions was analyzed using the comparative threshold (Ct) method
(ΔΔCt, delta-delta Ct) (101) after determining the Ct values for reference (GAPDH) and
target genes for each sample. Fold changes in target mRNA expression level were
calculated after normalization to GAPDH. We used MyoMed software (Med Associates,
Inc., Georgia, VT) to record isometric DSM spontaneous phasic and nerve-evoked
contractions. MiniAnalysis software (Synaptosoft, Inc., Decatur, GA) was used for data
analysis of DSM spontaneous phasic and nerve-evoked contractions amplitude, muscle
force (determined by integrating the area under the curve of the contractions), contraction
frequency, contraction duration (determined at half width), and muscle tone (determined
by contraction baseline curve).
For the spontaneous phasic contractions and the 10 Hz EFS-induced contractions, a 5 min
period prior to the first compound application was taken as a control (100%) and the
responses to subsequent compound application were normalized to that control. During
cumulative addition of compounds, the effect of each compound concentration on
contraction amplitude, muscle force, frequency, duration, and muscle tone was evaluated
by analyzing a 5 or 10 min period prior to the following respective concentration
application. For the 0.5–50 Hz EFS-induced DSM contractions, the contraction amplitude
at EFS frequency of 50 Hz prior to compound application (control conditions) was taken
to be 100% and the data were normalized. GraphPad Prism 4.03 software (GraphPad
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Software, Inc., La Jolla, CA) was used for statistical analysis and CorelDraw Graphic
Suite software (Corel Co, Ottawa, Ontario, Canada) was used for data illustration. In the
summary data, n represents the number of individual DSM isolated strips or cells, and N
is the number of guinea pigs, rats, or human subjects. Paired Student’s t-test was used to
analyze qPCR data, concentration-response, and frequency-response curves. All results
are expressed as mean ± SEM; p<0.05 was considered to be statistically significant.
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CHAPTER 3
CA2+ -ACTIVATED K+ CHANNELS IN THE DETRUSOR SMOOTH MUSCLE

Chapter 3 focuses on the physiological roles of Ca2+-activated K+ channels in the DSM.
These K+ channels comprise the large-conductance Ca2+-and voltage-activated K+ (BK)
channel, the intermediate-conductance Ca2+-activated K+ (IK) channel, and the smallconductance Ca2+-activated K+ (SK1-3) channels. I have investigated all these ion
channels individually and will present molecular and functional data collected in humans.
A first section (chapter 3.1) addresses the role of BK channels in the pathology of
neurogenic detrusor overactivity, a form of OAB. Data presented in this section have
been submitted for publication and are currently under review. The second section
(chapter 3.2) presents data pertaining to SK and IK channels expression and
physiological roles in human DSM. These data have already been published (2) and have
been slightly modified with authorization of the publisher to fit the format of this
dissertation.

31

3.1. NEUROGENIC DETRUSOR OVERACTIVITY IS ASSOCIATED WITH
DECREASED EXPRESSION AND FUNCTION OF THE LARGE
CONDUCTANCE CA2+-ACTIVATED K+ CHANNELS IN DETRUSOR SMOOTH
MUSCLE

Data presented in this section have been submitted for publication and are currently under
revision. The original manuscript has been modified to fit the format of this dissertation.
Human tissues were surgically obtained by Dr. Rovner’s team from the Medical
University of South Carolina. Dr. Rovner is a collaborator with the Petkov’s lab

ABSTRACT
Neurogenic detrusor overactivity (NDO) is a form of bladder dysfunction which can
affect patients suffering from various neurological diseases such as spinal cord injury,
Parkinson’s disease, and multiple sclerosis. Large-conductance Ca2+-activated K+ (BK)
channels are key regulators of the detrusor smooth muscle (DSM) excitability and
contractility. In the present study, we investigate the potential changes in BK channels
expression and function in patients suffering from NDO in comparison to control nonNDO patients. We first used quantitative polymerase chain reactions (qPCR) to
investigate BK channels mRNA relative expression in both control and NDO patients.
Then, using isometric DSM tension recordings, we tested the DSM isolated strips
physiological responses to pharmacological blockade of BK channels with iberiotoxin, a
selective BK channel antagonist. DSM tissues were obtained from patients undergoing
open bladder surgery for malignant or non-malignant conditions of the lower urinary
tract. The qPCR experiments revealed that DSM tissues from NDO patients have lower
BK channels mRNA expression in comparison to controls. The difference in BK channel
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mRNA expression was statistically significant for the pore forming BKα-subunits but not
for the accessory BKβ1 and BKβ4 subunits. Isometric DSM tension recordings
experiments demonstrated that iberiotoxin significantly increase myogenic contractions
in control DSM while DSM isolated strips from NDO patients were almost unresponsive
to iberiotoxin treatment.
Our study suggests that a decrease in DSM BK channel expression and function might be
the major reason for increased DSM contractility in NDO patients. BK channel
dysfunction therefore plays a key role in NDO.
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INTRODUCTION
Neurogenic detrusor overactivity (NDO) is a form of overactive bladder (OAB) which
often develops in patients suffering from various neurological diseases such as spinal
cord injury, Parkinson’s diseases, spina bifida, and multiple sclerosis (8). In comparison
to healthy patients, NDO patients experience greater spontaneous phasic detrusor smooth
muscle (DSM) contractions during the filling phase of the micturition process (16, 120).
Additionally, serious alteration in the DSM electrochemical properties of NDO patients is
reported leading to significant increase in DSM contractility and excitability (8). NDO
patients also experience the classic clinical symptoms which are associated with OAB
including nocturia, frequent urination, urgency, incontinence, and involuntary
contractions of the DSM (147). For many years, the mainstay of all forms of OAB
treatment has been antimuscarinic drugs which have limited effectiveness and doserelated side effects (8). Recently, two new therapeutic approaches have been authorized
by the FDA. These therapies include oral administration of mirabegron, a selective β3adrenoceptor agonist (50, 157) and intravesical injection of botulinium toxin (33, 95, 96).
Whether, these new therapies will be effective to treat OAB in a long term remains
uncertain.
K+ channels are known to be key regulators of the DSM contractility and excitability in
various species (130). Amongst these K+ channels, the large conductance voltage- and
Ca2+ activated K+ (BK) channel could be the most important because of its role in the
regulation of the DSM action potential, resting membrane potential, and contractility (22,
60, 61, 67, 75, 80, 109, 130, 131, 134, 145, 146, 164). Structurally, BK channels are
composed of four pore forming α-subunits and four regulatory β1, β2, β3, or β4 subunits
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(130). The structural integrity of the BK channels are extremely important for their
function since studies have demonstrated that loss of BKα subunits or BKβ1 subunits
functions significantly increases DSM contractility and urination frequency causing
detrusor overactivity (DO) in mouse (22, 109, 131, 154). It has also been shown that in a
rat model of partial urethral obstruction, BKα subunit mRNA and protein expression
were significantly reduced in comparison to sham-operated rats plus BK channel whole
cell current was attenuated (9). A recent study by Petkov’s laboratory has provided the
first direct molecular evidence for BK channels expression and function in native human
DSM (75). The aforementioned study demonstrated mRNA and protein expression for
the pore forming BKα-subunit as well as the accessory BKβ1 and BKβ4 subunits in
human DSM (75). Iberiotoxin, a selective BK channel blocker, inhibited the majority of
the whole cell outward K+ current, depolarized the DSM cell resting membrane potential,
and increased the contractility of human DSM isolated strips (75). In the contrary,
pharmacological activation of BK channels with NS1619, a BK channel agonist
suppressed human DSM excitability and contractility (80). Other studies also
demonstrated a direct involvement of BK channels in the etiology of OAB in patients
with benign prostatic hyperplasia (BPH), DO, and NDO (26, 120). All of the above cited
studies demonstrate the critical physiological role of BK channels in human DSM
excitability and contractility, and further suggest that BK channels could be promising
drug targets for OAB treatment (26, 32, 75, 80, 98, 107, 108, 120, 134, 145). In the
present study, we investigated the changes in BK channels subunits expression and
function in NDO patients using qPCR and isometric DSM tension recordings on native
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human DSM isolated strips. The overall goal of the study was to determine whether NDO
is linked to changes in the DSM BK channel expression and function.
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MATERIALS AND METHODS
Human DSM tissue collection
Human DSM tissue was collected as described in chapter 2.2. For these studies, DSM
specimens were isolated from 10 patients (7 controls and 3 NDO patients, 49-76 years
old).
Quantification of BK channel subunits mRNA message by qPCR
Specific primers for BKα, BKβ1, BKβ4 subunits, and GAPDH were designed based on
the cDNA complete sequences of human genes in Genbank and synthesized by Integrated
DNA Technologies (IDT, Coralville, Iowa, USA) (Table 3.1.1). qPCR experiments were
carried out on human DSM tissue cDNA (0.5 µg/µL) using IQ SYBR Green Supermix
(Bio-Rad, California, USA). GAPDH was chosen as an internal control gene to analyze
BKα, BKβ1, and BKβ4 subunits mRNA relative expression and each sample was run in
triplicate. The parameters of the qPCR experiments were as follows: Cycle 1, 95oC for 3
min; cycle 2, 95oC for 10 s then 61oC for 30 s (repeated 40 times); cycle 3, 95oC for 1
min; cycle 4, 61oC for 1 min; cycle 5, 61oC for 10 s (repeated 81 times to generate a
melting curve).
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Sense

Anti-sense

Product
(bp)
400

Accession
Number
NG012270

BKα

TGCCTAAAGCATGATTTG

GCCGACATGCTAAATAAATTAG

BKβ1

TGCCACCTGATTGAGACC

TGCGGAGAAGCAGTAGAAG

258

NM004137

BKβ4

CATTTGTGGTGGGCTTTCT

ACATGTTCCGCAGGTGG

168

NM170782

GAPDH

GGATTTGGTCGTATTGGG

GGAAGATGGTGATGGGATT

205

NM002046

Table 3.1.1. qPCR primers for BKα, BKβ1, BKβ4 subunits and GAPDH. bp-base pair

Isometric DSM tension recordings

Experiments were conducted as described in chapter 2.2.

Solutions and Drugs
The Ca2+-free dissection solution and the Ca2+-containing PSS compositions are
described in chapter 2.2. Iberiotoxin and TTX were purchased from Sigma-Aldrich Co.

Data analysis and statistics

Analysis was conducted as described in section 2.2.
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RESULTS
The relative expression levels of BKα subunit mRNA is significantly decreased in
NDO DSM
Recently, we established that human DSM cells express BKα, BKβ1, and BKβ4 subunits
at both mRNA and protein levels (75). Here, we revealed that in patients with NDO, the
BKα, BKβ1, and BKβ4 subunit mRNA expression was lower compared to control
patients (Fig. 3.1.1). There was a 15.8-fold decrease in BKα subunit mRNA relative
expression in NDO DSM (N=3) compared to controls (N=7) (P<0.01; Fig. 3.1.1). The
changes in BKβ1 and BKβ4 subunits in NDO DSM compared to controls were minor and
were evaluated at 1.1-fold and 1.6-fold decrease, respectively, (P>0.05; Fig. 3.1.1).
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as an internal control
and did not vary between DSM samples from control and NDO patients. These data
suggest that in patients suffering from NDO, there is a statistically significant decrease in
BKα subunit expression but not in BKβ1, and BKβ4 subunits expression.
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Figure 3.1.1. Patients with NDO have decreased BKα, BKβ1, and BKβ4 subunit mRNA expression in DSM.
qPCR analyses showing a 15.8-fold, 1.1-fold, and 1.6-fold decrease in BKα (A), BKβ1 (B) and BKβ4 (C) mRNA
expression in NDO DSM tissue (N=3) compared to controls (N=7). Data are shown as relative mRNA expression
normalized to GAPDH.
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Pharmacological inhibition of the BK channels with iberiotoxin had a reduced effect
on the contractility of DSM strips isolated from patients with NDO
To restrain neuronal activity, tetrodotoxin (TTX, 1 µM), a selective voltage-gated Na+
channel blocker, was added to the bath in the beginning of all experiments. In DSM strips
isolated from control patients, iberiotoxin (200 nM) considerably increased the phasic
contraction amplitude, muscle force integral, and muscle tone by 81.9±38.7%,
96.9±37.7%, and 14.4±8.3%, respectively (n=12, N=7; P<0.05; Fig. 3.1.2A, C).
However, in DSM strips isolated from patients with NDO, iberiotoxin (200 nM) had no
significant effects on any of the parameters of DSM contractility including phasic
contraction amplitude, muscle force integral, and muscle tone (n=13, N=3; P>0.05; Fig.
3.1.2B, C). Collectively, these results suggest a decrease in BK channel activity in DSM
from patients with NDO, which contributes to the increase in the spontaneous phasic
contractions.
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Figure 3.1.2. Inhibition of BK channels with iberiotoxin caused a significant increase in spontaneous phasic and
tonic contractions in control DSM but not in NDO DSM isolated strips. Original DSM tension recording
illustrating iberiotoxin (200 nM) effects on spontaneous phasic contraction in control (A) and NDO (B) DSM isolated
strips, respectively. C. Summary data showing a statistically significant increase in spontaneous phasic contractions
amplitude, muscle force integral, and muscle tone of control DSM strips (n=12, N=7, P<0.05) and lack of significant
iberiotoxin effects in NDO DSM strips (n=13, N=3, p>0.05). #P<0.05 for control vs. iberiotoxin and *P<0.05 for
control vs. NDO.
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DISCUSSION
The present study establishes a clear correlation between BK channels expression and
function and the abnormally elevated DSM contractility observed in NDO patients. We
found that mRNA expression of the pore forming BKα subunit was significantly
decreased in NDO DSM compared to controls. We also found that spontaneous phasic
contractions were abnormally increased in NDO DSM compared to control DSM, and
that pharmacological blockade of BK channels with iberiotoxin did not increased DSM
contractility in NDO patients contrarily to controls.
The expression and physiological relevance of BK channels in human DSM has recently
been demonstrated (75). RT-PCR and western blot data confirmed that the pore forming
α-subunit as well as the regulatory β1 and β4 subunits are expressed at mRNA and
protein level, respectively, in human DSM (75). The pore-forming α subunits ensure the
movement of K+ ions across the cell membrane, while the β1 subunits regulate the
channel’s activity by modulating BK channel Ca2+ sensitivity(22, 109, 130, 131, 146).
The structural integrity of the BK channel confers to the channel its ability to determine
the resting membrane potential and to contribute to the initial repolarization of the action
potential (130). Any changes in BK channel subunits expression could significantly
hamper the channel’s ability to regulate DSM excitability and contractility. For instance,
it has been demonstrated that in mouse model in which the BKα subunit was genetically
deleted, DSM cells were depolarized and DSM contractility was abnormally increased,
mimicking symptoms of DO (22, 109, 146, 154). Another study also showed that genetic
deletion of the BKβ1 subunit causes an increase in DSM contractility in mice (131). One
human study performed in patients with BPH and associated DO reported that mRNA
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and protein expression for BKα and BKβ subunits were significantly reduced (26).
Similarly to what is observed in BPH/DO patients, our study reported that in comparison
to controls, NDO patients DSM also have significantly reduced BKα subunit mRNA
expression and a moderate decrease in BKβ1 and BKβ4 subunits mRNA expression (Fig.
3.1.1). These studies support the concept that the NDO phenotype is associated with
decreased BK channel expression in human DSM.
As we correlate the molecular findings with the functional data, we found that NDO
patients DSM have abnormally elevated contractility in comparison to controls (Fig.
3.1.2). Additionally, unlike control DSM, inhibition of the BK channel with iberiotoxin
did not significantly affect DSM contractility in NDO DSM isolated strips suggesting that
in NDO patients DSM, the BK channel function might be altered (Fig. 3.1.2). Our data
are in line with a previous report which demonstrates that in NDO patients,
pharmacological activation of BK channels with NS1619, a BK channel agonist, has no
effect on DSM phasic contractions (120).
Our data are further supported by recent findings which show that NS1619 significantly
decreased DSM excitability and contractility in controls non-NDO patients (80).
CONCLUSION
We demonstrated that in NDO patient, the DSM contractility is abnormally elevated in
comparison to controls and that this particular phenotype is most likely due to the
significant reduction in BKα subunit expression. Therefore, we suggest that targeting BK
channels by either pharmacological or genetic manipulation could be a promising
therapeutic strategy to treat OAB, and especially NDO.
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3.2 SK BUT NOT IK CHANNELS REGULATE HUMAN DETRUSOR SMOOTH
MUSCLE SPONTANEOUS AND NERVE-EVOKED CONTRACTIONS

Data presented in this section have already been published and the original paper has
been modified to fit the format of this dissertation with authorization of the publisher.
Human tissues were surgically obtained by Dr. Rovner’s team from the Medical
University of South Carolina. Dr. Rovner is a collaborator with the Petkov’s lab.

ABSTRACT
Animal studies suggest that the small (SK) and intermediate (IK) conductance Ca2+activated K+ channels may contribute to detrusor smooth muscle (DSM) excitability and
contractility. However, the ability of SK and IK channels to control DSM spontaneous
phasic and nerve-evoked contractions in human DSM remains unclear. We first
investigated SK and IK channels molecular expression in native human DSM and further
assessed their functional role using isometric DSM tension recordings and SK/IK
channels selective inhibitors. Quantitative PCR experiments revealed that SK3 channel
mRNA expression in isolated DSM single cells was ~12 to 44-fold higher than SK1,
SK2, and IK channels. RT-PCR studies at the single-cell level detected mRNA messages
for SK3 channels but not SK1, SK2, and IK channels. Western blot and
immunohistochemistry analysis further confirmed protein expression for the SK3 channel
and lack of detectable protein expression for IK channel in whole DSM tissue. Apamin (1
µM), a selective SK channel inhibitor, significantly increased the spontaneous phasic
contraction amplitude, muscle force integral, phasic contraction duration, and muscle
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tone of human DSM isolated strips. Apamin (1 µM) also increased the amplitude of
human DSM electrical field induced (EFS)-contractions. However, TRAM-34 (1 µM), a
selective IK channel inhibitor, had no effect on the spontaneous phasic and EFS-induced
DSM contractions suggesting a lack of IK channel functional role in human DSM. In
summary, our molecular and functional studies revealed that the SK, particularly the SK3
subtype, but not IK channels are expressed and regulate the spontaneous and nerveevoked contractions in human DSM.
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INTRODUCTION
Overactive bladder (OAB), occurring in approximately 17% of the American population,
is a pathophysiological condition that impairs quality of life (147). The current
pharmacological treatment of OAB is primarily based on antimuscarinic drugs, which are
not universally effective and have many unwanted side effects (5, 130). In order to
develop novel effective pharmacological treatments for OAB, it is crucial to improve our
understanding of the basic physiology, pathophysiology, and pharmacology of the
bladder function. Previous studies have already demonstrated that various K+ channels
including the large-conductance Ca2+-activated K+ (BK) channel (22, 26, 35, 60, 75, 79,
80, 131, 145), the voltage-gated K+ (KV) channels (29, 57, 60, 74, 77), and the ATPsensitive K+ (KATP) channels (35, 132) are essential contributors to urinary bladder
physiology. However, other important channels such as the small (SK) and intermediate
(IK) conductance Ca2+-activated K+ channels remain largely unexplored in human
detrusor smooth muscle (DSM) although some studies outline a potential role for these
channels in DSM phasic contractions (31, 35, 58, 67, 68, 117, 120, 163). The SK channel
family consists of three isoforms: SK1, SK2, and SK3 (129). IK channel, initially
classified as SK4, is the only member of its family (129, 130). SK1-3 channels are
selectively blocked by apamin, a peptide isolated from Apis mellifera (129, 153), whereas
the IK channels are selectively blocked by TRAM-34 (163). In guinea pig DSM isolated
strips, apamin significantly increased the amplitude and duration but decreased the
frequency of the spontaneous phasic contraction (66). In pig DSM, which has similar
characteristics to that of human DSM (34), apamin increased both amplitude and
frequency of the DSM spontaneous contractions (23). In mice, genetic ablation of the
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SK3 channels caused an increase in the spontaneous phasic contraction in vitro and nonvoiding contractions in vivo (68).
Notably, it has been demonstrated that activation of SK and IK channels has the
opposite effect in the DSM of various species. NS4591, a non-selective SK and IK
channel opener, inhibited electrical field stimulation (EFS)-induced and carbacholinduced phasic contractions in rat, pig, and human DSM (117). In rats, an increase in
bladder capacity and micturition volume as well as a reduction in bladder overactivity
was observed after application of NS309, an activator of SK/IK channels (125).
Similarly, in rats and cats, NS4591 (30 mg/kg) inhibited bladder overactivity induced by
capsaicin and acetic acid in vivo (73). Furthermore, SKA-31, the most potent SK/IK
channel activator known to date (137) has been shown to decrease excitability and
contractility in guinea pig DSM via selective SK channel activation (127). Collectively,
these data suggest an important role played by SK and IK channels in DSM contractility
in non-human tissues. Indeed, the majority of the current knowledge about the functional
role of SK and IK channels comes principally from animals and is likely not directly
translatable to humans due to species differences in DSM ion channel expression, action
potential shape, and pattern of contractility. Furthermore, the limited number of
functional studies performed on human DSM specimens have not addressed the role of
SK and IK channels under normal physiological conditions of spontaneous activity but
rather after addition of depolarizing agents such as KCl or carbachol (35, 117, 120). An
investigation of human DSM strips exhibiting spontaneous phasic contractions would
provide a more physiologically relevant condition for the determination of the role of SK
and IK channels.
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The aim of this study was two-fold: 1) to investigate the molecular expression of SK and
IK channels in human DSM using RT-PCR, quantitative PCR (qPCR), Western blot, and
immunohistochemistry and, 2) to evaluate the functional role of SK and IK channels in
spontaneous and nerve-evoked contractions using isometric DSM tension recordings and
the selective SK and IK channels inhibitors, apamin and TRAM-34, respectively.
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MATERIALS AND METHODS
Human DSM tissue collection
Human tissue collection experiment is described in chapter 2.2. In total, we used DSM
tissue samples from 36 (25 males and 11 females) patients (28-85 years old; average age
61.9±2.2) including 29 Caucasians and 7 African-Americans without a history of OAB.

Detection and quantification of mRNA message by RT-PCR and qPCR

Experiments were conducted as described in chapter 2.2. Specific primers for SK1-4
channels and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (Table 3.2.1) were
designed based on the cDNA complete sequences of human genes in Genbank. The
parameters of the qPCR experiments were as follows: Cycle 1, 95 oC for 3 min; cycle 2,
95 oC for 10 s then 55 oC for 30 s (repeated 40 times); cycle 3, 95 oC for 1 min; cycle 4,
55 oC for 1 min; cycle 5, 55 oC for 10 s (repeated 81 times to generate a melting curve).
The parameter for the RT-PCR experiments were as follows: cDNA was heated for 3 min
at 94oC then amplified by 35 cycles (94 oC for 30 s, 60.1 oC for 30 s, 72 oC for 15 s)
followed by 5 min of extension at 72 oC. Total RNA extracted from human brain was
purchased from Clontech (Mountain view, CA, USA) and used as a positive control.
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Channel

Sense

Anti-sense

Product
(bp)

Accession
Number

SK1

TCAAATGCCTCATCAGCCTCTCCA

GCGCGTGTTGAAGGTGATCTTGTT

389

NM002248

SK2

TGGTGGACAATGGAGCAGATGACT

AACCAAGAGTACAGTTCCTGGGCA

359

NM170775

SK3

CTGCCTGTGGGAAATTGAATGGCA

AGGAGCACCATTCTTGGGACATGA

470

NM170782

IK

CTCATCGTGGCCTTTCATGCCAAA

CATGTAAAGCTTGGCCACGAACCA

378

NM002250

205

NM002046

GAPDH GGATTTGGTCGTATTGGG
GGAAGATGGTGATGGGATT
Table 3.2.1. RT-PCR and qPCR primers for SK and IK channels identification. bp- base pair
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Detection and localization of SK and IK channel proteins by Western blot and
immunohistochemistry

Western blot and immunohistochemistry experiments are described in chapter 2.2. We
used the following primary antibodies: affinity-purified rabbit polyclonal antibodies antiKCa2.3 (SK3) (1:200) and anti-KCa3.1 (IK) (1:300) (Alomone Labs, Jerusalem, Israel).
Goat anti-rabbit IgG conjugated with horseradish peroxidase (diluted to 1:1,500) was
used as a secondary antibody.

Human heart protein medley was purchased from

Clontech Laboratories (Mountain View, CA) and used as a positive control.

Isometric DSM tension recordings

Experiments were performed as described in chapter 2.2.

Solutions and drugs
The Ca2+-free dissection solution and the Ca2+-containing PSS composition are described
in chapter 2.2. Apamin, TRAM-34, and TTX were purchased from Sigma-Aldrich Co.
(St. Louis, MO, USA).

Data analysis and statistics

Analysis was performed as described in chapter 2.2. Fold changes in target mRNA
expression level were calculated after normalization to GAPDH and the SK3 channel
expression level was arbitrarily chosen as the calibrator.
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RESULTS

Detection and relative expression level of mRNA messages for SK1, SK2, SK3, and
IK channels in human DSM

First, qPCR experiments were performed in order to evaluate the mRNA relative
expression for all SK1-3 and IK channels. In human whole DSM tissue, we found that
SK1 and SK3 channel mRNA expressions were higher compared to SK2 and IK channels
(Fig. 3.2.1A). SK3 channel mRNA expression was 3-fold and 7-fold higher than SK2 and
IK channel mRNA expression, respectively (n=14, N=7, p<0.001; Fig. 3.2.1A).
However, SK1 and SK3 channel mRNA expression was comparatively similar in whole
DSM tissue (n=14, N=7, p<0.05; Fig. 3.2.1A). Next, we conducted qPCR experiments on
human DSM freshly isolated single cells to confirm that the mRNA messages detected in
the whole DSM tissue originated directly from DSM cells but not from other non-DSM
cell types such as neurons, fibroblasts, vascular, and endothelial cells present within the
DSM layers (29, 30, 74, 75). The single-cell qPCR experiments confirmed a significantly
higher SK3 channel mRNA relative expression compared to other SK and IK channels.
SK3 channel mRNA expression was 12-fold, 41-fold, and 44-fold higher than SK1, SK2,
and IK channels, respectively (n=16, N=8, p<0.001; Fig. 3.2.1B). These results
demonstrate that in human DSM cells, the SK3 channel expression is predominant among
SK and IK channels at the mRNA level.
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Figure 3.2.1. qPCR analyses for SK1, SK2, SK3, and IK channel mRNA expression in (A) human whole DSM tissue
(n=14, N=7); and (B) human DSM isolated single cells (n=16, N=8). Data were normalized to GAPDH and SK3
mRNA message was arbitrarily chosen as the calibrator. Ct values are expressed as mean ± SE. SK and IK channel
mRNA levels which are statistically different from SK3 channel mRNA level are indicated by (***) for p<0.005.
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Next, we investigated SK1, SK2, SK3, and IK channel mRNA message expression using
RT-PCR experiments on both human whole DSM tissue and freshly isolated DSM single
cells. In human whole DSM tissue, our RT-PCR experiments demonstrated detectable
expression of all SK and IK channel subtype mRNA messages (n=6-14, N=3-7; Fig.
3.2.2). At the DSM single-cell level, only the SK3 channel mRNA message was detected.
There was no detection of SK1, SK2, or IK channels which is consistent with our qPCR
data in human isolated DSM single cells (n=8-12, N=4; Fig. 3.2.2). RT-PCR experiments
were conducted on human DSM cDNAs equivalent to 100 ng of starting mRNA.
Negative control experiments performed in the absence of the reverse transcriptase (-RT)
demonstrated an absence of genomic DNA contamination. These data suggest that the
SK3 channel is highly expressed at the mRNA level, whereas SK1, SK2, and IK channel
mRNA is expressed at very low, perhaps non-physiological, levels in human DSM cells.
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Figure 3.2.2. RT-PCR detection of SK1 (A), SK2 (B), SK3 (C), and IK (D) channel mRNA messages in human whole
DSM tissue (n=6-14, N=3-7) and isolated DSM single cells (n=8-12, N=4). No product was observed in the negative
controls (-RT) in which reverse transcriptase was not added to the reaction.
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Native human whole DSM tissue expresses SK3 but not IK channel protein

To further investigate the expression of SK/IK channel protein in native human DSM
tissue, we performed Western blot experiments using specific antibodies against the SK3
or IK channels. The data showed that human whole DSM tissue expresses SK3 channel
protein (Fig. 3.2.3A) but not IK channel protein (Fig. 3.2.4A). These data verified our
RT-PCR results which showed an SK3 but not an IK channel mRNA message in human
DSM single cells. Further immunohistochemical analysis also confirmed the expression
of SK3 channel protein (Fig. 3.2.3B) and ruled out the expression of IK channel protein
(Fig. 3.2.4B) in human whole DSM tissue. Western blot and immunohistochemistry
control experiments were further conducted by pre-absorption of the primary antibody
with its antigenic competing peptide to verify the specificity of the antibodies for their
intended epitope.
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Figure 3.2.3. Western blot and immunohistochemical detection of SK3 channel protein expression in native
human whole DSM tissues. A) Protein expression for SK3 channels was detected by Western blot in native human
whole DSM tissue. The immunoreactive band was eliminated by a competing peptide (+CP). Experiments were
conducted in 3 separate Western blot reactions using protein isolated from 3 patients. B) Immunohistochemical
detection of SK3 channels in mucosa-free human whole DSM tissue using SK3 channel specific antibody. Cells’ nuclei
are shown in blue (B1); F-actin is shown in green (B2). Red staining indicates detection of the SK3 channels (B3). The
merged images of the nuclei, F-actin, and the expected SK3 channels are illustrated in B4. Images were captured with a
Carl Zeiss LSM 510 META confocal microscope. Experiments were conducted on tissue samples isolated from 4
different patients.
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Figure 3.2.4. Western blot and immunohistochemical detection of IK channel showing the lack of IK channel protein
expression in native human whole DSM tissues. A) Protein expression for IK channels was detected by Western blot in
human heart protein medley (positive control) but not in native human whole DSM tissue. The immunoreactive band in
human heart protein medley was eliminated by a competing peptide (+CP). Experiments were conducted in 3 separate
Western blot reactions using protein isolated from 4 patients. B) IK channel protein was not detected in mucosa-free
human whole DSM tissue following immunohistochemical reaction using IK channel specific antibody. Cells’ nuclei
are shown in blue (B1); F-actin is shown in green (B2). Lack of red staining in panel B3 indicates no expression of IK
channel. The merged images of the nuclei and F-actin are illustrated in B4. Images were captured with a Carl Zeiss
LSM 510 META confocal microscope. Experiments were conducted on tissue samples isolated from 4 different
patients.
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Role of SK and IK channels in spontaneous (myogenic) phasic and tonic DSM
contractions Here, we sought to evaluate the roles of SK and IK channels in human
DSM spontaneous contractions by using the SK and IK channel specific inhibitors,
apamin and TRAM-34, respectively. Apamin (1 µM) increased the DSM spontaneous
phasic and tonic contractions and had a biphasic effect on DSM spontaneous contraction
(Fig. 3.2.5A). Within the first 10 min, apamin (1 µM) increased the DSM spontaneous
phasic contraction amplitude by 162.1 ± 41.7%, muscle force integral by 171.8 ± 45.5%,
and muscle tone by 11.7 ± 1.8% (n=28, N=13, p<0.005), without any significant effect on
the spontaneous phasic contraction frequency and duration (Fig. 3.2.5B). We also
evaluated the changes in the spontaneous phasic contractions, 30-40 min after apamin
addition. During this second time period, the spontaneous phasic contraction amplitude
was increased by 116.4 ± 39.2%, muscle force integral by 136.5 ± 50.7%, and phasic
contraction duration by 13.8 ± 3.9% (n=28, N=13, p<0.005); no significant effect was
observed on the phasic contraction frequency and muscle tone (Fig. 3.2.5C). On the other
hand, TRAM-34 (1 µM) did not have any significant effect on the spontaneous phasic
and tonic contractions in the first 10 min or 30-40 min after addition (n=4, N=4, p>0.05;
Fig. 3.2.6). Collectively, these results suggest that SK channels but not IK channels
regulate human DSM myogenic activity.
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Figure 3.2.5. Apamin increases the spontaneous phasic contraction amplitude, muscle force integral, phasic
contraction duration, and muscle tone in human DSM isolated strips. A) Original DSM tension recordings
illustrating apamin (1 µM) effect on human DSM isolated strips. B) Summary data showing significant increase in
human DSM spontaneous phasic contractions amplitude, muscle force integral, and muscle tone within 10 min
following apamin (1 µM) addition. C) Summary data showing a significant increase in human DSM spontaneous
phasic contractions amplitude, muscle force integral, and phasic contraction duration 30-40 min following apamin (1
µM) addition. The 10-min control period prior to apamin addition was taken to be 100 % and data were normalized.
Values are means ± SE (n=28, N=13; **p<0.01, ***p<0.005). TTX (1 µM) was present throughout the experiments.
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Figure 3.2.6. TRAM-34 does not affect the spontaneous phasic and tonic contractions in human DSM isolated
strips. A) Original DSM tension recordings illustrating the lack of TRAM-34 (1 µM) effect on human DSM isolated
strips. B) Summary data showing that TRAM-34 (1 µM) has no effect on any of the spontaneous phasic and tonic
contractions parameters. TRAM-34 effect was evaluated within 10 min following TRAM-34 addition. The 10-min
control period prior to TRAM-34 addition was taken to be 100 % and data were normalized. Values are means ± SE
(n=4, N=4; p>0.05). TTX (1 µM) was present throughout the experiments.
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Role of SK and IK channels in nerve-evoked contractions
In this experimental series, we investigated the effects of apamin (1 µM) and TRAM-34
(1 µM or 30 µM) on nerve-evoked contractions of human DSM isolated strips (Fig.
3.2.7-8). Nerve-evoked contractions were generated by EFS and characterized in
response to increasing EFS frequencies (0.5–50 Hz) in the presence or absence of apamin
or TRAM-34, respectively. Increasing EFS frequencies (0.5, 2.0, 3.5, 5, 7.5, 10, 12.5, 15,
20, 30, 40, 50 Hz) were first applied to each human DSM strip as a control. Then, apamin
(1 µM) or TRAM-34 (1 µM or 30 µM) was added to the bath for 30 min. Next, the same
EFS protocol (0.5-50 Hz) was applied to evaluate how these SK and IK channel
inhibitors modulate EFS-induced contractions. The frequency-response curves showed
that apamin (1 µM) significantly increased the amplitude of the EFS-induced contractions
at stimulation frequencies ranging from 3.5 to 50 Hz (n=23, N=9, p<0.01; Fig. 3.2.7B).
At the maximal stimulation frequency of 50 Hz, apamin increased the EFS-induced
contraction amplitude by 23.5 ± 6.1% (n=23, N=9, p<0.01). However, TRAM-34 (1 µM)
did not have any significant effect on EFS-induced contraction at all stimulation
frequencies (0.5-50 Hz) (n=7, N=2, p>0.05). This lack of effect was also observed at
TRAM-34 concentration as high as 30 µM (n=21, N=7, p>0.05; Fig. 3.2.8B) suggesting
that IK channels do not play a role in the nerve-evoked contractions.
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Figure 3.2.7. Apamin increases the amplitude of the electrical field stimulation (EFS)-induced contractions in
human DSM isolated strips. A) Original recordings illustrating apamin (1 µM) effect on EFS-induced (0.5-50 Hz)
contractions. As shown, apamin (1 µM) also induced myogenic contractions, consistent with data illustrated in Fig. 4.
B) Frequency-response curves showing a significant increase in the amplitude of the EFS-induced contractions
following application of apamin (1 µM). The maximal EFS-contraction amplitude at a stimulation frequency of 50 Hz
under control conditions was taken to be 100 % and the contractions were normalized. Values are means ± SE (n=23,
N=9; **p<0.01, ***p<0.005).
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Figure 3.2.8. TRAM-34 has no effect on the amplitude of the electrical field stimulation (EFS)-induced
contractions in human DSM isolated strips. A) Original recordings illustrating the lack of TRAM-34 (30 µM) effect
on EFS-induced (0.5-50 Hz) contractions. B) Frequency-response curves showing no significant change in the
amplitude of the EFS-induced contractions following application of TRAM-34 (30 µM). The maximal EFS-contraction
amplitude at a stimulation frequency of 50 Hz under control conditions was taken to be 100 % and the contractions
were normalized. Values are means ± SE (n=21, N=7; p>0.05).
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DISCUSSION
In the present study, we used combined molecular (RT-PCR, qPCR, Western blot, and
immunohistochemistry),

functional

(isometric

DSM

tension

recordings),

and

pharmacological (SK and IK channel inhibitors) approaches to investigate the molecular
expression of all SK and IK channels in freshly isolated human DSM cells and further
evaluated their functional role in human DSM contractility. Single-cell RT-PCR
experiments confirmed the expression of only the SK3 channel subtype at the mRNA
level. qPCR experiments indicated that the SK3 channel is the most predominant subtype
in native human DSM single cells at mRNA level. Western blot and immunostaining
further confirmed SK3 channel protein expression. Functional studies using apamin and
TRAM-34 suggest that the SK channels but not the IK channels have an important role in
human DSM contractility.
SK and IK channels mRNA expression in human DSM cells
In human whole DSM tissue, RT-PCR showed that all SK and IK channels were
expressed. Furthermore, the qPCR experiments not only confirmed mRNA expression for
all SK and IK channel subtypes in whole DSM but also indicated that SK1 and SK3
channels are the most predominant. However, at the DSM single-cell level, only the SK3
channels were detected by RT-PCR, in all patients tested. Moreover, qPCR data from
isolated DSM single cells indicate a much higher expression level for the SK3 channel.
The difference in mRNA relative expression between whole DSM tissue and isolated
DSM single cells could be explained by the fact that the detection of mRNA messages in
isolated DSM single cells is a more accurate approach. The unique advantage of using

66

freshly isolated DSM single cells in RT-PCR and qPCR is that this approach eliminates
any possible contamination by other non-DSM cell types including neurons, fibroblasts,
endothelial cells, and vascular cells present within the DSM layers (29, 30, 74, 75). It is
possible that the detected SK1 channel mRNA in whole DSM originated from neuronal
cells present in the DSM layers consistent with the findings from Chen et al. (31). The
aforementioned study using qPCR experiments, revealed that the SK3 channel is the most
predominant SK channel subtype in human whole bladder tissue and that the SK1
channel is highly expressed in human neuronal tissues (brain) (31). This observation was
confirmed by our RT-PCR, Western blot, and immunohistochemistry data showing
mRNA message and protein expression for SK3 channel in native human DSM single
cells and whole DSM tissue, respectively (Figs. 3.2.1-3). The presence of the SK3
channel protein in human whole DSM tissue confirms that SK3 channels play a critical
physiological role in human bladder physiology, similar to rodent models (68). Studies
have shown that selective suppression of SK3 channel expression increased the phasic
contractions of mouse isolated DSM strips and increased non-voiding contractions in vivo
(68). Suppression of SK3 channel expression by genetic manipulations further elevated
micturition pressure compared to control mice. Transgenic mice overexpressing the SK3
channels had greatly elevated bladder capacities and urine output compared to wild-type
mice (68). In the present study, we detected high levels of SK3 channel mRNA message
in human DSM single cells and further confirmed the SK3 channel protein expression in
whole DSM tissue. Therefore, it is likely that SK3 channels play an important functional
role in human DSM contractility.

67

SK channels regulate human DSM spontaneous phasic contractions
Using channel specific inhibitors, apamin and TRAM-34, we determined the SK and IK
channel functional roles in human DSM spontaneous phasic contractions. Our data show
that apamin but not TRAM-34 significantly increased the phasic contraction amplitude,
muscle force integral, phasic contraction duration and muscle tone of the DSM
spontaneous contraction suggesting that SK channels but not IK channels are effective
modulators of human DSM contractility. Consistent with our human data, studies in
guinea pig DSM have shown that apamin but not TRAM-34 increases DSM spontaneous
contractions (127). Furthermore, apamin but not TRAM-34 blocked guinea pig DSM
relaxation induced by SKA-31, a novel and potent SK channel opener, suggesting that IK
channels have no functional role in guinea pig DSM physiology as compared to SK
channels (127). A previous study has established a correlation between spontaneous
contractile activity and electrical activity in guinea pig DSM (58). The study showed that
the inhibition of SK channels with apamin increased spontaneous phasic contraction
amplitude and duration, reduced phasic contraction frequency while converting the
electrical activity from individual action potentials into bursts without changing either the
action potential shape or afterhyperpolarization (58). Apamin also increased guinea pig
and mouse DSM action potential frequency suggesting that SK channels are important
regulators of DSM excitability (45, 60). These animal data are consistent with our human
data since apamin increased spontaneous phasic contraction amplitude and duration
without affecting the phasic contraction frequency of human DSM isolated strips. We
propose that the initial burst in action potentials could explain the initial jump observed in
spontaneous contraction observed immediately after apamin was added into the baths
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(Fig. 3.2.5A). Earlier studies further showed that apamin increased human DSM phasic
contractions induced by 10 mM KCl, suggesting the involvement of SK channels in KClinduced contractions (35). Studies by others also reported that apamin can partially
reverse the relaxation caused by the selective SK channel opener, NS4591, in rat, pig and
human DSM strips stimulated by 1 µM carbachol (117). The major advantage of our
work compared to those conducted previously on human DSM is that herein we
evaluated the SK and IK channels functional role on human DSM strips exhibiting
spontaneous phasic contractions. The unique advantage of using these spontaneously
contracting DSM strips is their direct physiological relevance compared to those in which
contractions are artificially induced by depolarizing agents such as KCl or carbachol (35,
117).
SK channel role in human DSM nerve-evoked contractions
During micturition, parasympathetic nerves release ATP and acetylcholine which activate
purinergic P2X receptors and muscarinic receptors to cause DSM contraction. Using
EFS, we activated the cholinergic and purinergic nerves present in the human DSM strips
to induce contractions and then evaluated if apamin or TRAM-34 could modulate EFSinduced contractions. Our data show that apamin but not TRAM-34 significantly
increased the amplitude of the EFS-induced contraction at all stimulation frequencies
between 3.5 and 50 Hz suggesting that SK channels but not IK channels modulate human
DSM nerve-evoked contraction. Our data on human DSM are consistent with previous
studies on mouse and guinea pig DSM isolated strips (65, 127). In mouse and guinea pig,
blocking SK channels with apamin resulted in an increase in the amplitude of nerveevoked contractions (65, 127). However, in guinea pig DSM, inhibition of IK channels
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with TRAM-34 had no effect on nerve-evoked contractions suggesting the lack of a
functional role for IK channels (127). Our findings suggest that SK channels participate
in a negative feedback loop which limits the DSM excitability and contractility in
response to nerve stimulation consistent with previous mouse and guinea pig DSM
studies (65, 66, 68, 127).
In summary, the SK3 channels are the only SK channel subtype expressed in human
DSM single cells at the mRNA level. SK3 channel protein expression was also confirmed
in whole DSM tissue. DSM contractility studies using apamin and TRAM-34 showed
that the SK channels but not the IK channels have a critical role in human DSM function.
Taken together, we suggest that the SK channels, the SK3 subtype in particular, are
important modulators of human DSM contractility. SK3 channels could therefore
represent novel therapeutic targets for the pharmacological treatment of OAB.
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CHAPTER 4
FUNCTIONAL LINK BETWEEN BK CHANNELS AND BETA3 ADRENERGIC RECEPTORS
DURING NERVE-EVOKED CONTRACTIONS

Chapter 4 addresses the functional link between BK channels and beta3-AR during
nerve-evoked contractions. Because human material is limited, we first designed
strategies to test our hypothesis by using laboratory animals. We investigated the role of
beta3-AR in guinea pigs (chapter 4.1) and rats (chapter 4.2), two commonly used
laboratory animals. We found that contrarily to guinea pigs, beta3-AR played a more
physiologically-relevant role in rat DSM nerve-evoked contractions and that rats are
better animal models than guinea pig to study beta3-AR functions in the DSM. We
further found that there is a functional link between BK channels and beta3-AR during
nerve-evoked contractions in rat DSM (chapter 4.2). The data in rat DSM served as a
basis to further investigate the mechanism in humans (chapter 4.3).
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4.1 DO ΒETA3-ADRENERGIC RECEPTORS PLAY A ROLE IN GUINEA PIG
DETRUSOR SMOOTH MUSCLE EXCITABILITY AND CONTRACTILITY?

Data presented in this section have already been published and the original paper has
been modified to fit the format of this dissertation with authorization of the publisher.
Electrophysiological data were collected by Dr. Hristov, a post-doctoral fellow in Dr.
Petkov’s lab.

ABSTRACT

In many species, beta3-ARs have been reported to play a primary role in
pharmacologically-induced detrusor smooth muscle (DSM) relaxation. However, their
role in Guinea pig DSM remains controversial. The aim of this study was to investigate if
beta3-ARs are expressed in Guinea pig DSM and to evaluate how BRL37344 and L755,507, two selective beta3-AR agonists, modulate Guinea pig DSM excitability and
contractility. We used a combined experimental approach including RT-PCR, patchclamp electrophysiology, and isometric DSM tension recordings. Beta3-AR mRNA
message was detected in freshly isolated Guinea pig DSM single cells. BRL37344 but not
L-755,507 caused a slight decrease in DSM spontaneous phasic contraction amplitude
and frequency in a concentration-dependent manner. In the presence of atropine (1 µM),
only the spontaneous phasic contractions frequency was inhibited by BRL37344 at higher
concentrations. Both BRL37344 and L-755,507 significantly decreased DSM carbacholinduced phasic and tonic contractions in a concentration-dependent manner. However,
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only BRL37344 inhibitory effect was partially antagonized by SR59230A (10 µM), a
beta3-AR antagonist. In the presence of atropine, BRL37344 and L-755,507 had no
inhibitory effect on electrical field stimulation-induced contractions. Patch-clamp
experiments showed that BRL37344 (100 µM) did not affect the DSM cell resting
membrane potential and K+ conductance. Although beta3-ARs are expressed at the
mRNA level, they play a minor to no role in Guinea pig DSM spontaneous contractility
without affecting cell excitability. However, BRL37344 and L-755,507 have pronounced
inhibitory effects on Guinea pig DSM carbachol-induced contractions. The study outlines
important DSM beta3-ARs species differences.
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INTRODUCTION

For many years, pharmacological treatment of OAB and associated urinary incontinence
(UI) has relied exclusively on antimuscarinic drugs (5, 114, 170). However, beta-ARs)
could represent alternative targets for OAB because pharmacological stimulation of βARs causes DSM relaxation (22, 79). Among all beta-ARs subtypes (beta1, beta2, and
beta3), the beta3-ARs may be the most promising new pharmacological targets for OAB
treatment because they represent 97% of all beta-ARs expressed in human DSM (168).
Such predominant expression in DSM suggests that drugs targeting beta3-ARs will
potentially have fewer side effects compared to antimuscarinic drugs, which can cause
dry mouth, constipation, headaches, blurred vision, etc. (5, 14, 170). The activation of
beta-ARs stimulates adenylyl cyclase which converts ATP into cAMP. Increased
intracellular cAMP activates protein kinase A (PKA), which then can phosphorylate
various proteins and relax DSM (111, 134). In mouse and Guinea pig, stimulation of
beta-ARs by isoproterenol, a non-selective beta-AR agonist, relaxes DSM by activation
of the large-conductance calcium-activated potassium (BK) channels (22, 134). Similarly
in rat, stimulation of beta3-AR by the selective beta3-AR agonist, BRL37344, relaxes
DSM by activation of the ryanodine receptors (RyRs) and BK channels (79). The
increase in RyRs activity in rat DSM by BRL37344 and in Guinea pig DSM by
isoproterenol leads to an increase in transient BK currents (TBKCs) frequency, which
causes membrane hyperpolarization and thus relaxation (79, 134). Furthermore, in DSM
of BK channel knockout mice, beta-AR-mediated relaxation is significantly compromised
(22). However, to our knowledge, beta3-AR mRNA or protein expression has not yet
been confirmed in Guinea pig DSM, and the functional role of beta3-ARs in Guinea pig
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DSM remains controversial (100, 169). Clarification of this role is important because the
Guinea pig is a widely used animal model to study DSM function.

Our goal was to provide molecular evidence for beta3-AR mRNA message expression in
Guinea pig DSM using RT-PCR and establish whether beta3-ARs have a functional role
in Guinea pig DSM excitability and contractility. Our molecular studies indicate the
presence of the beta3-AR mRNA message in Guinea pig DSM cells, and that the
selective beta3-AR agonists, BRL37344 and L-755,507 substantially inhibit carbacholinduced contractions. The compounds have a negligible inhibitory effect on spontaneous
contractions, and no inhibitory effect on the nerve-evoked contractions of Guinea pig
DSM in the presence of atropine. Finally, with the patch-clamp technique, we established
that BRL37344 had no effect on Guinea pig resting membrane potential, voltage-step
induced steady-state K+ currents, and TBKCs.
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METHODS

Animal studies and DSM tissue harvesting

DSM tissue harvesting was conducted as described in chapter 2.2. We used 76 adult (63
males, and 13 females) Hartley-Albino guinea pigs, weighing on average 366.6 ± 21.1 g.

DSM single-cell isolation and individual collection

DSM single cells collection for electrophysiology and RT-PCR experiments were
collected as described in chapter 2.2.

RNA Extraction/RT-PCR/Sequencing

Specific primers sequences for beta3-AR were obtained from a previous publication (70)
and synthesized by Integrated DNA Technologies (IDT, Coralville, IA). The sense and
antisense

primers

were

5′-GTGGGAGGCAACCTGCTGGT-3′

and

5′-

CGCCACCACTGGCTCAT-3′, respectively. RT-PCR experiments were conducted as
described in chapter 2.2. cDNA was heated for 15 min at 95 oC then amplified by 35
cycles (95 oC for 30 s, 60 oC for 30 s, 72 oC for 30 s) followed by a 5-min extension at 72
o

C. The expected length of the fragment was 387 bp.

Isometric DSM tension recordings

Isometric tension recordings experiments are described in section 2.2. Increasing
BRL37344 or L-755,507 concentrations (1 nM–100 µM) were applied at 10-min
intervals directly into the bath in the absence or presence of SR59230A (10 µM), a
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selective β3-AR antagonist (22, 39, 71, 138). On a separate set of strips, BRL37344 (100
µM) was added into the tissue baths containing DSM strips exhibiting spontaneous
phasic contractions in the presence or absence of atropine (1 µM), a muscarinic receptor
antagonist. For the EFS experimental series, we separated the cholinergic component of
the EFS-induced contractions from the purinergic component by blocking purinergic
receptors with α,β-methylene-ATP and suramin. DSM isolated strips were pre-incubated
with suramin (10 µM) and α,β-methylene-ATP (10 µM) for 15 min prior to the EFScontrol protocol. The purinergic component of the EFS-induced contractions was
assessed by addition of 1 µM atropine to block the cholinergic component. This
experimental series was also performed in the presence or absence of SR59230A (10
µM).

Electrophysiological (patch-clamp) experiments
These experiments were performed by Dr. Hristov, a post-doctoral fellow in Dr. Petkov’s
laboratory. To preserve the physiological environment of the DSM cells, amphotericinperforated whole-cell mode of the patch-clamp technique was applied in all
electrophysiological experiments (54, 72). Whole-cell currents and membrane potential
were recorded as previously described (22, 75, 79, 91). Briefly, freshly isolated single
DSM cells were placed onto an experimental chamber for 20 min to allow them to adhere
to the glass bottom, and were then washed with extracellular solution. The ionic currents
and resting membrane potential were recorded using Axopatch 200 B amplifier;
pCLAMP version 10.2 software; Digidata 1322A and Digidata 1440A (Molecular
Devices, Union City, CA). The signals were filtered using an eight-pole Bessel filter
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(model 900CT/9L8L; Frequency Devices, Ottawa, IL). Patch-clamp pipettes were pulled
from borosilicate glass (Sutter Instruments, Novato, CA) using a Narishige PP-830
vertical puller, coated with sticky dental wax to reduce capacitance, and then polished
with a Micro Forge MF-830 fire polisher (Narishige Group, East Meadow, NY) to give a
final tip resistance of 4–6 MΩ. Leak currents were not subtracted. TBKCs were recorded
at a holding potential of -40 mV or -20 mV (corrected for junction potential) for at least a
10-min period in the absence (control), and then in the presence of BRL37344 (100 µM).
Voltage-step protocols were used to elicit steady-state K+ outward current. Resting
membrane potentials of DSM cells were recorded using the current clamp mode of the
perforated patch-clamp technique. To determine the mean amplitude and frequency of
TBKCs, analysis was performed off-line using Clampfit of the pCLAMP version 10.2
and MiniAnalysis software (Synaptosoft, Inc., Decatur, GA). All patch-clamp
experiments were conducted at room temperature (22–23 °C).

Solutions and drugs
The Ca2+-free dissection solution and the Ca2+-containing PSS compositions are
described in chapter 2.2. The extracellular (bath) solution used for electrophysiological
recordings, and the patch pipette solution were prepared daily and had the same
composition as previously described (22, 79, 91). BSA and amphotericin-B were
purchased from Fisher Scientific (Pittsburgh, PA). Papain was obtained from
Worthington Biochemical Co. (Lakewood, NJ). L-755,507 was purchased from Tocris
Bioscience (Ellisville, MO). The rest of the drugs were purchased from Sigma-Aldrich
Co. (St. Louis, MO). BRL37344 stock solution was prepared daily in double distilled
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H2O and was heated to 60 oC to fully dissolve the drug according to the manufacturer’s
instructions. L-755,507 was also prepared daily and dissolved in dimethyl sulfoxide
(DMSO) at a final DMSO concentration not greater than 0.1%.

Data analysis and statistics

Analyses for isometric DSM tension recordings were analyzed as previously described in
chapter 2.2. Paired Student’s t-test was used to analyze electrophysiology data.
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RESULTS
Detection of mRNA message for β3-AR in Guinea pig DSM
RT-PCR experiments detected a β3-AR mRNA message in whole DSM and isolated
DSM single cells (Fig. 4.1.1). Using isolated DSM single cells is advantageous,
eliminating possible contamination from other cell types such as neurons, fibroblasts,
vascular myocytes, and other interstitial cells present within the DSM layers (29, 30, 91).
These results demonstrate that Guinea pig isolated DSM cells express β3-AR mRNA
message. Negative controls performed in the absence of reverse transcriptase (-RT)
demonstrated an absence of genomic DNA contamination. Next, we sought to evaluate
the β3-AR functional role in Guinea pig DSM contractility.
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Figure 4.1.1. RT-PCR detection of β3-AR mRNA in DSM whole tissue and isolated DSM single cells. The
expected size of the product was 387 bp. RT (+): reverse transcription, RT (-): no reverse transcription. Guinea pig ileal
tissue was used as a positive control. Illustrated gel image is a selected representation of at least 5 independent RT-PCR
experiments based on RNA extracted from 4 animals
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BRL37344 but not L-755,507 has a minor inhibitory effect on the spontaneous
phasic and tonic contractions in Guinea pig DSM isolated strips

Under control conditions before drug (BRL37344, L-755,507, or SR59230A) application
(taken to be 100%), Guinea pig DSM spontaneous phasic contractions average amplitude
was 0.4 ± 0.1 g, force was 1.4 ± 0.5 g/s, frequency was 3.0 ± 0.01 contractions/min,
duration was 8.0 ± 0.9 s/contraction, and tone was 0.2 ± 0.03 g (n=41 , N=23). In the
absence of SR59230A, BRL37344 (1 nM-100 µM) slightly inhibited the spontaneous
phasic contraction amplitude and frequency without statistically significant effects on
muscle force integral, phasic contraction duration, and muscle tone (Fig. 4.1.2A). At the
maximal concentration of 100 μM, BRL37344 significantly reduced the phasic
contractions amplitude by 17.6 ± 9.7%, and frequency by 20.7 ± 8.5% (n=7, N=7,
p<0.05; Fig. 4.1.2C and E). In the presence of SR59230A (10 µM), the BRL37344 (100
µM) inhibitory effect on the spontaneous phasic contraction frequency was antagonized
(n=8, N=4, p<0.05; Fig. 4.1.2E) but no antagonistic effect on the spontaneous phasic
contraction amplitude was observed (n=8, N=4, p>0.05; Fig. 4.1.2C). SR59230A alone
increased the amplitude and muscle force integral of the spontaneous phasic contractions.
SR59230A increased the spontaneous phasic contraction amplitude by 196.0 ± 20.7%
(n=8, N=4; p<0.005) and muscle force integral by 166.0 ± 57.6% (n=8, N=4; p<0.01)
with no significant effect on the phasic contraction frequency, duration, or muscle tone
(n=8, N=4; Fig. 4.1.2B). Unlike BRL37344, the other selective β3-AR agonist, L755,507 (1 nM-100 µM) had no significant effects on any of the five parameters of the
spontaneous contractions (n=12, N=6, p>0.05; Fig. 4.1.2C-G).
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Figure 4.1.2. Effects of BRL37344 and L-755,507 on the spontaneous phasic and tonic contractions of Guinea pig
DSM isolated strips. A-B. Original recordings of DSM spontaneous phasic contractions illustrating BRL37344
inhibitory effect (1 nM–100 µM) in the absence (A) or presence (B) of SR59230A (10 µM). C-G. Concentrationresponse curves for BRL37344 (1 nM-100 µM) inhibitory effects on the spontaneous phasic contraction amplitude (C),
muscle force integral (D), phasic contraction frequency (E), phasic contraction duration (F), and muscle tone (G), in the
presence or absence of SR59230A (10 µM). Concentration-response curves for L-755,507 (1 nM–100 µM) showed no
inhibitory effect on the spontaneous phasic and tonic contractions of DSM isolated strips (C-G). Spontaneous
contractions were taken to be 100% (n=7, N=7 for BRL37344; n=12, N=6 for L-755,507; and n=8, N=4 for SR59230A
+ BRL37344; *P<0.05 for the SR59230A effect). TTX (1 µM) was present throughout the experiments.
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To prove that the BRL37344 inhibitory effect on spontaneous contractions in the
concentration-response experiments was not due to a run-down of the preparation or a
desensitization of the β3-AR, we further examined the effect of a single supramaximal
BRL37344 concentration (100 µM) on spontaneous contractions. BRL37344 (100 µM)
significantly decreased spontaneous phasic contraction amplitude, muscle force integral,
phasic contraction frequency, but not phasic contraction duration or muscle tone. The
amplitude of the spontaneous phasic contractions decreased by 31.0 ± 9.1%, muscle force
integral by 33.2 ± 10.0%, and phasic contraction frequency by 16.6 ± 5.5% (n=14, N=5,
p<0.05; Fig. 4.1.3A and B). BRL37344 has been reported to have some antimuscarinic
effects in addition to its β3-AR agonist properties (79, 93). To separate these two effects,
we used the cholinergic antagonist atropine. In the presence of 1 µM atropine, BRL37344
(100 µM) significantly inhibited only the DSM spontaneous contraction frequency by
21.2 ± 3.8% without any significant effect on phasic contraction amplitude, muscle force
integral, phasic contraction duration, and muscle tone (n=9, N=5, p<0.05; Fig. 4.1.3C
and D). These results suggest that BRL37344 but not L-755,507 has a minor inhibitory
effect on the spontaneous contractions of guinea pig DSM isolated strips. This
BRL37344 inhibitory effect is partially blocked by atropine (Fig. 4.1.3).
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Figure 4.1.3. Application of a single concentration of BRL37344 (100 µM) decreased the Guinea pig DSM
spontaneous phasic contraction amplitude, muscle force integral, and phasic contraction frequency in the
absence of atropine. A, C. Original recording of DSM contractions illustrating BRL37344 inhibitory effect in the
absence (A) or presence of 1 µM atropine (C). B, D. Summary data showing BRL37344 (100 µM) inhibitory effect in
the absence (B) (n=14, N=5, ***P<0.005) or presence of 1 µM atropine (D) (n=9, N=5, ***P<0.005). Spontaneous
contractions were taken to be 100%. TTX (1 µM) was present throughout the experiments.
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Both BRL37344 and L-755,507 inhibit carbachol-induced contractions in Guinea
pig DSM isolated strips

Under control conditions (taken to be 100%), Guinea pig DSM carbachol-induced phasic
contraction average amplitude was 1.4 ± 0.3 g, force was 6.8 ± 1.3 g/s, frequency was 3.0
± 0.01 contractions/min, duration was 11.0 ± 0.6 s, and tone was 0.4 ± 0.06 g (n=59,
N=21). BRL37344 (1 nM–100 µM) completely inhibited all five parameters of the
carbachol-induced contractions (Fig. 4.1.4A and 4.1.5). L-755,507 (1 nM-100 µM)
caused a less dramatic—but still statistically significant—decrease in all five parameters
of the carbachol-induced contractions (Fig. 4.1.4B). However, only at concentrations
higher than 10 µM L-755,507 did significantly inhibit DSM carbachol-induced
contractions. At a concentration of 100 µM, L-755,507 decreased the phasic contraction
amplitude by 26.4 ± 4.8%, muscle force integral by 53.6 ± 4.0%, phasic contraction
frequency by 16.1 ± 6.6%, phasic contraction duration by 27.4 ± 3.8%, and muscle tone
by 20.3 ± 7.0% (n=12, N=3, p<0.05; Fig. 4.1.5).

In the presence of SR59230A (10 µM), BRL37344 still inhibited DSM carbacholinduced contractions; however, its inhibitory effect was partially antagonized (Fig.
4.1.4C and Fig. 4.1.5). BRL37344 (100 µM) inhibitory effect was partially reduced as
follows: phasic contraction amplitude was reduced by only 47.1 ± 3.1% (Fig. 4.1.5A);
muscle force integral was reduced by 30.4 ± 2.2% (Fig. 4.1.5B); phasic contraction
frequency was reduced by 51.6 ± 6.7% (Fig. 4.1.5C); phasic contraction duration was
reduced by 57.1 ± 5.7% (Fig. 4.1.5D); muscle tone was reduced by 64.2 ± 6.2% (Fig.
4.1.5E); (n=14, N=6 for control and n=25, N=6, in presence of 10 μM SR59230A;
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p<0.01). There was no significant change in the inhibitory effect of L-755,507 (1 nM–
100 μM) on the carbachol-induced contractions in the presence of 10 µM SR59230A
(n=7, N=3, p>0.05; Fig. 4.1.5).

Figure 4.1.4. Original DSM contraction recordings illustrating BRL37344 (1 nM–100 µM) and L-755,507 (1 nM-100
µM) concentration-dependent inhibitory effects on carbachol-induced phasic and tonic contractions of DSM isolated
strips in the absence (A, B) or presence (C, D) of SR59230A (10 µM). TTX (1 µM) was present throughout the
experiments.
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Figure 4.1.5. Concentration-response curves for BRL37344 (1 nM–100 µM) and L-755,507 (1 nM–100 µM) inhibitory
effects on carbachol-induced phasic contraction amplitude (A), muscle force integral (B), phasic contraction frequency
(C), phasic contraction duration (D), and muscle tone (E) in the presence or absence of SR59230A (10 µM).
Carbachol-induced contractions were taken to be 100% (n=14, N=6 for BRL37344; n=25, N=6 for BRL37344 +
SR59230A; **p<0.01, ***p<0.005 for the SR59230A effect) and (n=12, N=3 for L-755,507; n=7, N=3 for L-755,507
+ SR59230A; p>0.05 for the SR59230A effect). TTX (1 µM) was present throughout the experiments
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We further examined the effect of a single supramaximal concentration of L-755,507
(100 µM) on carbachol-induced contractions. L-755,507 (100 µM) significantly
decreased the amplitude, muscle force integral, duration, and tone but not the frequency
of carbachol-induced contractions (Fig. 4.1.6A). The amplitude of carbachol-induced
phasic contractions decreased by 18.1 ± 6.2%, muscle force integral by 34.4 ± 5.2%,
phasic contraction duration by 18.0 ± 5.1%, and muscle tone by 12.2 ± 5.0% (n=12, N=3,
p<0.05; Fig. 4.1.6B). These data suggest that BRL37344 and L-755,507 can substantially
reduce carbachol-induced contractions. Next, we evaluated whether pharmacological
activation of β3-ARs can modulate nerve-evoked contractions of Guinea pig DSM
isolated strips.

89

Figure 4.1.6. L-755,507 (100 µM) significantly reduced carbachol-induced phasic and tonic contractions of DSM
isolated strips. A. Original DSM contraction recordings illustrating L-755,507 (100 µM) inhibitory effect in the
absence of SR59230A (10 µM). B. Summary data showing that L-755,507 (100 µM) significantly reduced the
amplitude, muscle force integral, phasic contraction duration, and muscle tone (n=12, N=3, *p<0.05, **p<0.01,
***p<0.005). TTX (1 µM) was present throughout the experiments.
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BRL37344 decreases the amplitude of the EFS-induced contractions in Guinea pig
DSM isolated strips

Under control conditions at 50 Hz (taken to be 100%), Guinea pig DSM EFS-induced
contractions average amplitude was 4.0 ± 0.3 g (n=36, N=12). In the absence of atropine,
BRL37344 (100 µM) significantly reduced the amplitude of the EFS-induced
contractions at all stimulation frequencies between 7.5 and 50 Hz (Fig. 4.1.7A). At 50
Hz, BRL37344 (100 µM) significantly reduced the amplitude of the EFS-induced
contraction by 22.5 ± 6.2% (n=10, N=4, p<0.005; Fig. 4.1.7B). In the presence of
SR59230A (10 µM), BRL37344 (100 µM) still decreased the amplitude of the EFSinduced contractions (Fig. 4.1.7C). At 50 Hz, in the presence of SR59230A (10 µM),
BRL37344 inhibited EFS-induced contractions by 29.3 ± 5.4% (n=11, N=5, p<0.005;
Fig. 4.1.7D). SR59230A (10 µM) alone had no effect on the EFS-induced contractions as
illustrated in Fig. 4.1.7E and F (n=9, N=6, p>0.05). These results suggest that
BRL37344 inhibitory effect on EFS-induced contractions is not mediated by β3-ARs but
it is most likely due to BRL37344 antimuscarinic effects.
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Figure 4.1.7. BRL37344 (100 µM) significantly decreases the amplitude of the EFS-induced contractions of
Guinea pig DSM isolated strips in the absence or presence of SR59230A (10 µM). Original recordings illustrating
EFS-induced (0.5–50 Hz) contractions of DSM isolated strips in response to 100 µM BRL37344 (A), 10 µM
SR59230A and 100 µM BRL37344 combined (C), 10 µM SR59230A (E). Frequency-response curves for the EFSinduced (0.5-50 Hz) contractions in response to 100 µM BRL37344 (B), 10 µM SR59230A and 100 µM BRL37344
combined (D), 10 µM SR59230A (F) (n=10, N=4 for B; n=11, N=5 for D; n=9, N=6, p>0.05 for F; *p<0.05, **P<0.01,
***P<0.005). EFS-induced contraction amplitude at 50 Hz under control conditions was taken to be 100%.
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In the presence of suramin (10 µM) and α,β-methylene-ATP (10 µM) which were used to
block the purinergic component of EFS-induced contraction, BRL37344 (100 µM) still
decreased the amplitude of the EFS-induced contractions as shown in Figure 4.1.8A. In
the presence of suramin and α,β-methylene-ATP, Guinea pig DSM EFS-induced
contraction average amplitude at 50 Hz was 2.4 ± 0.4 g and was taken to be 100% (n=20,
N=10). At the maximal stimulation frequency of 50 Hz, BRL37344 (100 µM)
significantly reduced the amplitude of the EFS-induced contractions by 36.9 ± 8.5%
(n=10, N=5, p<0.005; Fig. 4.1.8B). SR59230A (10 µM) again did not block the
BRL37344 inhibitory effect on contraction amplitude at EFS stimulation frequencies
between 10 and 50 Hz (Fig. 4.1.8C). At the maximal stimulation frequency of 50 Hz, in
the presence of SR59230A (10 µM), BRL37344 (100 µM) decreased the EFS-induced
contraction amplitude by 52.7 ± 5.0% (n=10, N=5, p<0.005; Fig. 4.1.8D).
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Figure 4.1.8. In the presence of suramin (10 µM) and α,β-methylene-ATP (10 µM), BRL37344 (100 µM)
decreased the amplitude of the EFS-induced (0.5-50 Hz) contractions in DSM isolated strips. A, C. Original EFSinduced contraction recordings showing BRL37344 (100 µM) inhibitory effect in the absence (A) or presence (C) of
SR59230A (10 µM). B, D. Frequency-response curves showing BRL37344 inhibitory effect on EFS-induced
contraction amplitude in the absence (n=10, N=5, **P<0.01, ***P<0.005) (B) or presence (D) of 10 µM SR59230A
(n=10, N=5, **P<0.01, ***P<0.005). EFS-induced contraction amplitude at 50 Hz under control conditions was taken
to be 100%.
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In the presence of atropine (1 µM), which was used to block the cholinergic component
of the EFS-induced contraction, BRL37344 (100 µM) had no effect on the EFS-induced
contractions in the absence (n=13, N=6, p>0.05) or presence of 10 μM SR59230A (n=12,
N=5, p>0.05; Fig. 4.1.9). In the presence of atropine, Guinea pig DSM EFS-induced
contraction average amplitude at 50 Hz was 2.3 ± 0.2 g and was taken to be 100% (n=25,
N=11). These data also show that BRL37344’s inhibitory effect on EFS-induced
contractions is not mediated by β3-AR but is rather due to BRL37344 antimuscarinic
properties. Next, we sought to evaluate L-755,507 effect on EFS-induced contractions.
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Figure 4.1.9. In the presence of atropine (1 µM), BRL37344 (100 µM) does not affect the amplitude of the EFSinduced (0.5-50 Hz) contractions of DSM isolated strips. A, C. Original recordings illustrating the lack of
BRL37344 (100 µM) effect on EFS-induced contractions in the absence (A) or presence (C) of SR59230A (10 µM). B,
D. Frequency-response curves showing the lack of BRL37344 effect on the EFS-induced contraction amplitude in the
absence (B) (n=13, N=6, p>0.05) or presence (D) of 10 µM SR59230A (n=12, N=5, p>0.05).
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L-755,507 has no effect on the EFS-induced contractions of Guinea pig DSM
isolated strips

In this experimental series we investigated the effect of L-755,507 on EFS-induced
contractions. We observed that L-755,507 (100 µM) did not significantly inhibit EFSinduced contractions at all stimulation frequencies (0.5-50 Hz) in the absence (n=9, N=4,
p>0.05) or presence of 1 μM atropine (n=6, N=4, p>0.05; Fig. 4.1.10).

Figure 4.1.10. L-755,507 (100 µM) does not affect the amplitude of the EFS-induced (0.5–50 Hz) contractions of
DSM isolated strips. A, C. Original recordings illustrating a lack of L-755,507 (100 µM) effect on EFS-induced
contractions in the absence (A) or presence (C) of atropine (1 µM). B, D. Frequency-response curves showing the lack
of inhibitory effect on EFS-induced contractions by L-755,507 in the absence (B) (n=9, N=4, p>0.05) or presence (D)
of 1 µM atropine, (n=6, N=4, p>0.05).
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Pharmacological activation of beta3-ARs with BRL37344 does not modulate cell
excitability in Guinea pig DSM freshly isolated cells

BRL37344 was preferred over L-755,507 due to its more pronounced effects on Guinea
pig DSM contractility. We previously reported that in rat DSM, BRL37344 (100 µM)
induces relaxation by activation of TBKCs and membrane hyperpolarization (79).

The average capacitance of Guinea pig DSM cells was 34.7 0.8 pF (n=123 cells, N=30).
In the first patch-clamp experimental series, we investigated BRL37344 (100 µM) effect
on Guinea pig DSM TBKCs amplitude and frequency. Our results showed no statistically
significant change in the mean amplitude and frequency of TBKCs after application of
100 µM BRL37344 (n=6-9, N=5-7, p>0.05; Table 4.1.1). Next, we examined whether
the application of BRL37344 (100 µM) activates the voltage step induced steady-state K+
current in single DSM cells. From a holding potential -70 mV, we applied a voltage-step
protocol from 0 mV to +80 mV in 20 mV increments and 200 ms duration. BRL37344
(100 µM) did not activate the depolarization-induced steady-state outward K+ currents
(n=4, N=2, p>0.05; Table 4.1.1). In current clamp mode, we tested the effect of
BRL37344 (100 µM) on the resting membrane potential of freshly isolated Guinea pig
DSM cells, and BRL37344 did not affect the resting membrane potential (n=8, N=4,
p>0.05; Table 4.1.1). These data suggest that activation of β3-ARs with BRL37344 in
Guinea pig DSM does not modulate basal cell excitability.
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Transient BK
currents
(TBKCs)

Voltage step
induced wholecell current

Amplitude
-40 mV
Amplitude
-20 mV
Frequency -40
mV
Frequency
-20 mV
0 mV

Control

BRL37344 (100 M)

Statistics

24.0 4.6 pA

26.3 6.5 pA

19.8 2.4 pA

18.16 1.1 pA

50.2 22.8
TBKCs/min
45.3 18.2
TBKCs/min

65.76 30.4 TBKCs/min

2.3±1.0 pA/pF

1.1±0.3 pA/pF

3.5±1.1 pA/pF

1.8±0.2 pA/pF

5.9±1.7 pA/pF

3.6±0.6 pA/pF

11.4±3.3 pA/pF

10.8±1.9 pA/pF

22.8±7.5 pA/pF

22.7±5.1 pA/pF

-22.8 3.5 mV

-21.6 4.0 mV

n=9; N=7
p>0.05
n=6; N=5
p>0.05
n=9; N=7
p>0.05
n=6; N=5
p>0.05
n=4; N=2
p>0.05
n=4; N=2
p>0.05
n=4; N=2
p>0.05
n=4; N=2
p>0.05
n=4; N=2
p>0.05
n=8; N=4
p>0.05

74.23 31.2 TBKCs/min

20 mV
40 mV
60 mV
80 mV

Resting membrane potential
recorded in current clamp mode

Table 4.1.1. Summarized data illustrating a lack of effect of BRL37344 (100 M) on cell membrane excitability
in Guinea pig DSM freshly isolated cells. Perforated whole-cell patch-clamp experiments revealed no effect of 100
M BRL37344 on TBKCs amplitude and frequency recorded at -40 and -20 mV. Whole-cell outward K+ current
amplitude was also unchanged after application of 100 M BRL37344. Current-clamp experiments revealed that 100
M BRL37344 did not significantly change the level of the resting membrane potential in Guinea pig DSM freshly
isolated cells. These data were collected by Dr. Hristov.
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DISCUSSION

In this study, we applied a multi-disciplinary approach including molecular, cellular, and
tissue studies to evaluate the expression and potential functional role of β3-ARs in
Guinea pig DSM. Because beta3-ARs are considered viable therapeutic targets for OAB,
it is crucial to understand beta3-ARs expression and function in the bladder of Guinea
pig, a commonly used animal research model. Our data suggest that beta3-ARs are
expressed at the mRNA level but are minor contributors (if at all) in Guinea pig DSM
function. Unlike earlier studies (169), the novelty of our study is that we systematically
spanned for all five parameters of the phasic contractions including amplitude, muscle
force integral, frequency, duration, and muscle tone in Guinea pig DSM isolated strips.

The physiological significance of our study derives from the fact that beta3-AR have
been shown to be important facilitators of bladder relaxation by controlling spontaneous
phasic and nerve-evoked contractions as well as TBKC that contribute to DSM
excitability (22, 79, 134). Previous studies have established a functional link between the
beta3-AR and the BK channel, which plays a key role in DSM function (22, 75, 79, 91).
These findings have lead researchers to suggest that beta3-ARs could be suitable targets
for the pharmacological treatment of OAB. As a consequence, there are now a number of
beta3-AR agonists, which are currently under investigation for the treatment of OAB. In
anesthetized mice, CL316,243, a selective beta3-AR agonist, given intravenously at doses
of 0.03 and 0.1 mg/kg, significantly increases bladder capacity and threshold pressure
without a significant change in bladder compliance (39). CL316,243 also induces a
significant decrease in the amplitude of both micturition and non-voiding contractions
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(39). In anesthetized rats, intravenous injection of selective beta3-AR agonists such as
BRL37344, TAK-677, and FK175 (0.1-500 µg/kg) have been proven to significantly
decrease voiding frequency, bladder pressure, and the amplitude of bladder contractions
(94).

Whether beta3-ARs are expressed in Guinea pig DSM has been debated: no reports
identify their presence at the single-DSM-cell level. Pharmacological studies on Guinea
pig DSM using various beta3-AR agonists and antagonists yielded controversial results
(49, 100, 169). Clarification of beta3-AR functional role has a strong physiological
significance because the Guinea pig is an established animal model to study DSM
function added to the fact that species differences could also be a determining factor.
Some authors suggest that the beta1-AR is the most predominant beta-AR in Guinea pig
DSM, and thus is mainly responsible for Guinea pig DSM relaxation (100, 111, 169).
Other studies show that the selective beta3-AR agonist BRL37344 (300 µM) reduced the
amplitude of phasic rises in intravesical pressure of Guinea pig isolated whole bladder,
suggesting a role of beta3-ARs in Guinea pig DSM relaxation (49). Our molecular data
support the latter publication that the beta3-AR mRNA message is expressed in isolated
single cells of Guinea pig DSM (Fig. 4.1.1). The advantage of using isolated single cells
for RT-PCR is that this approach eliminates any possible contamination by other cell
types present within the DSM (29, 30, 75, 79). Due to the lack of specific antibodies for
Guinea pig beta3-ARs (111), we performed no Western blot or immunohistochemistry
studies at this time to further prove beta3-AR protein expression. To our knowledge, this
is the first report in which molecular evidence for the presence of beta3-ARs in Guinea
pig DSM has been provided.
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The functional role of beta-ARs activation in DSM is to induce relaxation (22, 79, 91,
134, 169), which is suggested to be mediated via activation of the beta-AR/PKA pathway
(79, 111, 134). Our results indicate that at higher concentrations BRL37344 induced a
slight concentration-dependent reduction of the amplitude and frequency of the
spontaneous phasic contractions of Guinea pig DSM isolated strips (Fig. 4.1.2).
Furthermore, a single supramaximal concentration of BRL37344 (100 μM) also
decreased the amplitude, muscle force integral, and frequency of the spontaneous phasic
contractions of Guinea pig DSM isolated strips (Fig. 4.1.3). The use of this supramaximal
concentration of 100 μM is justified by the fact that BRL37344 concentrations less than
or equal to 30 μM seems insufficient to induce inhibition of spontaneous DSM
contractions (22, 49, 169). However, at these high concentrations BRL37344 may also
non-selectively activate beta1-ARs and/or beta2-ARs (150).

Studies on rat DSM have shown that BRL37744 also exhibit some antimuscarinic
properties (22, 93, 110). In our study, we addressed this issue by using the muscarinic
receptor antagonist atropine. In the presence of atropine, BRL37344 (100 µM) lost its
inhibitory effect on the DSM phasic contraction amplitude and muscle force integral
(Fig. 4.1.3), further supporting its antimuscarinic properties. Our data (consistent with
early findings) (169), indicate that in the Guinea pig, beta3-ARs have a limited effects on
DSM relaxation because their pharmacological activation with BRL37344 significantly
modulates only one (frequency) spontaneous phasic contraction parameter and only at
high concentrations (10-100 µM). At these high concentrations BRL37344 may also nonselectively activate beta1-ARs and/or beta2-ARs (150).
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In DSM, the beta adrenergic relaxation is primarily mediated by activation of the BK
channel (22, 79, 134). Our electrophysiological data supported the idea that beta3-ARs,
although expressed in Guinea pig DSM, do not regulate the DSM excitability. Perforated
patch-clamp experiments revealed no effect of BRL37344 on whole-cell steady-state K+
current, TBKCs amplitude and frequency, and the resting membrane potential (Table
4.1.1). These findings clearly suggest species differences. Our previous studies on rat
DSM showed that the activation of beta3-AR by BRL37344 increased TBKCs frequency,
and hyperpolarized the cell membrane (79). In rat DSM, a functional link between beta3ARs and BK channel is mediated by the RyRs of the sarcoplasmic reticulum (79). Our
study shows that in Guinea pig DSM, unlike rat and human DSM, beta3-ARs are not the
primary regulator of DSM function.

Since the relationship between length and force can be converted to volume and pressure
using the law of Laplace (7), the evaluation of muscle force integral provides information
on the increase in bladder volume and intravesical pressure during bladder filling and
voiding phases. It is known that the BK channels shape Guinea pig DSM spontaneous
action potentials that determine the spontaneous phasic contractions including contraction
amplitude, duration, frequency, muscle force integral, and tone (22, 58, 66, 76, 79, 132).
Pharmacological inhibition of DSM BK channels increases the action potential duration
and frequency, causes membrane potential depolarization (62, 76), and increases the
amplitude of phasic contractions (22, 66, 76, 132). The increase in the amplitude of a
phasic contraction is provoked by the increase in intracellular Ca2+ during the action
potential depolarization phase and activation of L-type voltage-gated Ca2+ channels,
whereas the duration of a phasic contraction depended on the duration of the single action
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potential or a whole burst of action potentials (58, 62). Thus, there is a clear association
between the action potential parameters, BK channel activity, and the related phasic
contraction parameters. However, our data on Guinea pig DSM show that BRL37344
does not affect BK channel activity (Table 4.1.1).
We also evaluated the effects of beta3-AR agonists during cholinergic stimulation using
carbachol, a stable pharmacological analogue of acetylcholine, as previously done by
others (49, 91). Under such conditions, BRL37344 and L-755,507 significantly decreased
all phasic and tonic contraction parameters in a concentration-dependent manner (Figs.
4.1.4-5). BRL37344 inhibitory effect could be explained by its pronounced
antimuscarinic properties since this inhibitory effect on spontaneous contractions was
partially blocked by atropine (Fig. 4.1.3). Consistent with our results, previous studies by
Klausner et al. (2009) showed that isoproterenol, a non-selective beta3-AR agonist,
decreased the contractions induced by low concentrations of carbachol in rabbit DSM
strips suggesting the involvement of beta-ARs (91). Using arecaidine, a muscarinic
receptor agonist, to induce contractions in Guinea pig isolated whole bladder, Gillespie
(2004) also showed that BRL37344 (300 µM) could significantly reduce the amplitude of
phasic rises in intravesical pressure of Guinea pig isolated whole bladder (49).
Furthermore, SR59230A did not antagonize L-755,507 inhibitory effect on the carbacholinduced contractions (Figs. 4.1.4-5) suggesting that L-755,507-induced relaxation of the
carbachol-induced contractions is not mediated through beta3-AR. Indeed, at higher
concentrations (10-100 µM), L-755,507 may also act on beta1-/ beta2-AR directly. L755, 507 EC50 values for beta3-, beta1-, and beta2-AR are 0.43 nM, 530 nM, and >10
µM, respectively (43, 128). Therefore, the inhibitory effect of L-755,507 observed at
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such high concentrations (10–100 µM) on carbachol-induced contractions could be due to
its direct effects on beta1-and/or beta2-ARs (128), which tend to corroborate previous
finding by others (100, 169). One explanation for BRL37344 inhibitory effects on
carbachol-induced contractions is that during cholinergic stimulation with carbachol,
muscarinic M2 receptors, which are linked to the cAMP/PKA inhibitory pathway, are
activated. M2 receptors and beta3-ARs have opposing effects at the cAMP/PKA level
which may account for the inhibitory effects of BRL37344 and L-755,507 on carbacholinduced contractions. We find that the relaxation of Guinea pig DSM isolated strips by
BR37344 and L-755,507 is predominant during cholinergic stimulation with carbachol
and minor during spontaneous contractions, consistent with previous studies (169).

Nerve stimulation also plays an important role in the micturition process during which
acetylcholine and ATP are released from parasympathetic nerve terminals and act on
DSM muscarinic (M2/M3) and purinergic (P2X) receptors to generate DSM contractions
(59, 65). The observed decrease of the EFS-induced contraction amplitude by BRL37344
can be misleading (Fig. 4.1.7). This BRL37344 inhibitory effect was suppressed by
atropine, suggesting that BRL37344 acted directly on muscarinic receptors rather than
β3-ARs during nerve stimulation (Fig. 4.1.9). In addition to DSM cells, muscarinic
receptors are also present in bladder nerves (89). It has been reported that presynaptic
muscarinic receptors on parasympathetic nerve terminals in DSM strips are involved in
an autofacilitatory mechanism that enhances acetylcholine release during continuous EFS
(15). BRL37344 may therefore block muscarinic receptors in both DSM cells and bladder
nerves. Furthermore, the beta3-AR agonist, L-755,507, at concentration as high as 100
µM has no effect on the EFS-induced contractions in the absence or presence of atropine
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suggesting that beta3-ARs do not play any role in the nerve-evoked contraction of Guinea
pig DSM (Fig. 4.1.10). This latter observation confirms the concept that the decrease in
EFS-induced contraction caused by BRL37344 was a direct antimuscarinic effect. An
alternative explanation is that the beta3-ARs in Guinea pig DSM have a distinct
pharmacological profile compared to beta3-ARs in other species or that beta3-ARs might
not be functionally expressed in Guinea pig DSM.

In summary, four key points can be drawn from our study: 1) beta3-ARs are expressed at
the mRNA level but play a negligible functional role, if any, in Guinea pig DSM
relaxation; 2) BRL37344 inhibitory effect on Guinea pig DSM spontaneous and nerveevoked contractions is primarily mediated through its antimuscarinic properties; 3)
BRL37344 and L-755,507 have significant inhibitory effects on Guinea pig carbacholinduced contractions; 4) BRL37344 does not modulate Guinea pig basal cell membrane
excitability. Collectively, our data suggest that unlike rat and human DSM (79, 140, 151,
168), in Guinea pig DSM beta3-ARs have a minor to no functional role in DSM
excitability and spontaneous contractility.

We recommend particular prudence when interpreting data generated with BRL37344
because of its pronounced antimuscarinic effects. We also suggest that, although the
Guinea pig DSM is widely used for experimental studies, future investigations on beta3ARs should not use this animal model. Our study does not rule out β3-ARs functional
role in Guinea pig urothelium and other non-DSM bladder cells (49, 168).
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4.2 FUNCTIONAL BK CHANNELS FACILITATE THE BETA3 ADRENERGIC
RECEPTOR AGONIST-MEDIATED RELAXATION OF NERVE-EVOKED
CONTRACTIONS IN RAT DETRUSOR SMOOTH MUSCLE ISOLATED
STRIPS

Data presented in this section have been submitted for publication and are currently under
revision. The original manuscript has been modified to fit the format of this dissertation.

ABSTRACT
The large-conductance voltage- and Ca2+-activated K+ (BK) channel is a major regulator
of detrusor smooth muscle (DSM) contractility. Recent findings suggest that activation of
beta3 adrenergic receptors causes relaxation of the DSM. However, it is unknown
whether the beta3 adrenergic receptor-mediated relaxation of DSM is BK channeldependent during nerve-evoked contractions. To test this hypothesis, we induced nerveevoked contractions in rat DSM isolated strips by using a tissue bath system equipped
with platinum electrodes for electrical field stimulation (EFS). BRL37344, a beta3
adrenergic receptor agonist, significantly decreased the amplitude and muscle force of the
20 Hz EFS-induced DSM contractions in a concentration-dependent manner. The
BRL37344 inhibitory effect was significantly antagonized by SR59230A, a selective
beta3 adrenergic receptor antagonist. We further isolated the cholinergic from the
purinergic component of the 0.5–50 Hz EFS-induced DSM contractions by using
selective inhibitors, atropine as well as suramin and α,β-methylene-ATP, respectively.
We found that BRL37344 inhibited both the purinergic and cholinergic components of
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the nerve-evoked contractions in rat DSM isolated strips. The pharmacological blockade
of the BK channels with iberiotoxin, a selective BK channel inhibitor, increased the
amplitude and muscle force of the 20 Hz EFS-induced contractions in rat DSM isolated
strips. In the presence of iberiotoxin, there was a significant reduction of the BRL37344induced maximal inhibition of the 20 Hz EFS-induced contractions in rat DSM isolated
strips. These latter findings suggest that BK channels play a critical role in the beta3
adrenergic receptor-mediated relaxation of rat DSM nerve-evoked contractions.
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INTRODUCTION
The ability of beta3 adrenergic receptor agonists such as BRL37344, mirabegron
(YM178), solabegron (GW427353), FK-175, TAK677, TRK-380, CL316243, and
CGP12177A to inhibit detrusor smooth muscle (DSM) myogenic contractions has been
well documented (14, 46, 69, 79, 88, 94, 99, 139, 150, 151, 156). These beta3 adrenergic
receptor agonists have been shown to increase the intracellular cAMP levels in native
DSM tissues as well as in heterologously expressed systems (46, 69, 88, 94, 139, 150).
Specifically, in rat DSM isolated strips, FK175 was shown to increase the intracellular
cAMP level by ~30% (46). The recent approval of mirabegron as the first beta3
adrenergic receptor agonist for the treatment of overactive bladder (OAB) further outlines
the importance of beta3 adrenergic receptors as pharmacological targets for OAB. Since
OAB has myogenic and neurogenic origins with diverse mechanisms and etiology, it is
still unknown whether this new therapeutic approach will be effective to treat all forms of
OAB. There has been significant effort aiming to investigate the mechanism by which
beta3 adrenergic receptor agonists induce relaxation of DSM, especially during
neurogenic contractions. However, the exact mechanism remains uncertain. Experiments
conducted on DSM myogenic contractions suggest that the mechanism underlining the
beta3 adrenergic receptor-mediated relaxation of the DSM involves the cAMP signaling
pathway and the large-conductance Ca2+-activated K+ (BK) channels (79, 111, 130, 134,
164, 166). Our group revealed a functional link between BK channels and beta3
adrenergic receptors during myogenic contractions, a mechanism which utilizes the
ryanodine receptors of the sarcoplasmic reticulum to induce DSM relaxation (79). The
pharmacological blockade of BK channels with iberiotoxin, a selective BK channel
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inhibitor, caused a rightward shift of the concentration-response curve of the BRL37344
relaxant effects on myogenic contractions of rat DSM isolated strips. The BRL37344induced hyperpolarization of freshly isolated DSM cells was eliminated by iberiotoxin or
ryanodine suggesting that activation of beta3 adrenergic receptors increases the BK
channel activity and ultimately leads to DSM relaxation (79). It has been demonstrated
that in mouse DSM isolated strips, selective inhibition of the BK channels and protein
kinase-A with iberiotoxin and H-89, respectively, reduced the relaxant effect of
isoproterenol, a non-selective beta adrenergic receptor agonist (22). The fundamental role
of the BK channels in the beta-adrenergic/protein kinase-A-mediated relaxation of DSM
is demonstrated by the observations that genetic ablation of BK channel in a transgenic
mouse model leads to development of a compensatory adaptive upregulation of the betaadrenergic/cAMP/protein kinase-A signal transduction pathway (22). However, these
novel mechanisms have yet to be investigated in nerve-evoked DSM contractions. The
present study utilizes tissue baths equipped with electrodes for electrical field stimulation
(EFS), DSM strips isolated from rat urinary bladder, and various pharmacological
modulators to assess beta3 adrenergic receptor and BK channel functional role in the
nerve-evoked contractions.
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METHODS
Isometric DSM tension recordings
Isometric DSM tension recording experiments were performed as described in chapter
2.2. In total, 41 male Sprague-Dawley rats (10-16 weeks old) weighing 361.7 ± 5.2 g on
average were used.

Solutions and Drugs
The Ca2+-free dissection solution and the Ca2+-containing PSS compositions are given in
chapter 2.2. Iberiotoxin, atropine, suramin, and α,β-methylene-ATP were purchased from
Sigma-Aldrich (St. Louis, MO). BRL37344 and SR59230A were purchased from Tocris
Bioscience (Bristol, UK). BRL37344 was prepared daily in double-distillated water and
heated at 60oC to be completely dissolved as suggested by the manufacturer.

Data analysis and statistics

The data analysis was performed as described in chapter 2.2.
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RESULTS
BRL37344 inhibitory effect on EFS-induced DSM contractions is antagonized by
SR59230A, a selective beta3 adrenergic receptor antagonist
We investigated how beta3 adrenergic receptor stimulation with BRL37344 affects
nerve-evoked contractions of rat DSM isolated strips. We found that BRL37344
decreased the amplitude and muscle force of the 20 Hz EFS-induced contractions of rat
DSM isolated strips in a concentration-dependent manner. BRL37344 (10 nM – 1 µM)
had no significant inhibitory effect, however, BRL37344 at concentrations of 10 µM and
100 µM statistically significantly decreased the amplitude of the 20 Hz EFS-induced
DSM contractions by 22.3±9.3% and 48.4±7.0%, respectively and the muscle force by
26.0±8.6% and 52.6±6.2%, (n=8, N=6, p<0.05; Fig. 4.2.1A, C, and D). Pre-incubation of
rat DSM strips with SR59230A (10 μM), a selective beta3 adrenergic antagonist,
significantly reduced the BRL37344 inhibitory effect on the 20 Hz EFS-induced
contractions (Fig. 4.2.1B-D). SR59230A attenuated the relaxant effect of BRL37344 at
10 µM and 100 µM on the contraction amplitude from 22.3±9.3% to 5.5±0.7%, and from
48.4±7.0% to 31.0±3.5%, respectively; and also on the contraction force from 26.0±8.6%
to 10.0±2.6%, and from 52.6.0±6.2% to 33.5±6.0%, respectively (n=11, N=6, p<0.05;
Fig. 4.2.1C, D). Time control experiments performed in the absence of BRL37344 and
SR59230A showed no statistically significant difference in the 20 Hz EFS-induced
contraction amplitude and force (n=6, N=6, p>0.05; data not illustrated). These findings
suggest that the inhibitory effects on EFS-induced contractions induced by the beta3
adrenergic receptor agonist, BRL37344, can be antagonized by SR59230A.
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Figure 4.2.1. Activation of beta3 adrenergic receptors with BRL37344 decreases the amplitude and muscle force
of the 20 Hz EFS-induced contractions in rat DSM isolated strips. A) Original DSM tension recordings illustrating
BRL37344 (10 nM – 100 µM) inhibitory effects on 20 Hz EFS-induced contractions. This particular original recording
shows a bit greater degree of inhibition than the average observed. B) Original DSM tension recordings illustrating the
attenuation of BRL37344 (10 nM – 100 µM) inhibitory effects on rat DSM 20 Hz EFS-induced contractions in the
presence of SR59230A (10 µM). C-D) Cumulative concentration-response curves illustrating SR59230A antagonistic
effects against BRL37344 inhibitory effects on EFS-induced contraction amplitude and force, respectively (n=11, N=6;
*p<0.05)
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We also investigated how BRL37344 modulates the two main components of the nerveevoked contractions, namely the cholinergic and the purinergic components, under a wide
range of stimulation frequencies (0.5 – 50 Hz). First, we evaluated the changes in the
amplitude of the rat DSM EFS-induced contractions following application of BRL37344
(100 µM). We found that BRL37344 significantly inhibited EFS-induced contractions at
frequencies ranging from 3.5 to 50 Hz (Fig. 4.2.2A, C). At the maximal stimulation
frequency of 50 Hz, BRL37344 caused a 30.3±6.0% decrease in the amplitude of the
EFS-induced DSM contractions (n=12, N=6, p<0.005; Fig. 4.2.2C). This BRL37344
inhibitory effect was significantly antagonized by SR59230A (10 µM) at low stimulation
frequencies (3.5 – 12.5 Hz) but not at high frequencies (15 – 50 Hz) (n=8, N=3, p<0.005;
Fig. 4.2.2B, D). SR59230A (10 µM) per se did not have any effect on the nerve-evoked
DSM contractions (n=8, N=3, p>0.05). These data suggest that stimulation of beta3
adrenergic receptors with BRL37344 decreases rat DSM nerve-evoked contractions.
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Figure 4.2.2. Stimulation of beta3 adrenergic receptors with BRL37344 reduces rat DSM EFS-induced
contractions generated by a wide range of stimulation frequencies (0.5 – 50 Hz). Original DSM tension recordings
illustrating BRL37344 (100 µM) inhibitory effects on rat DSM EFS-induced contractions in the absence (A) or
presence (B) of SR59230A (10 µM). C) Frequency-response curves for the 0.5 – 50 Hz EFS-induced DSM contractions
in response to 100 µM BRL37344 (n=12, N=6). D) EFS frequency-response curves for BRL37344 (100 µM) inhibitory
effects on 0.5 – 50 Hz EFS-induced DSM contractions in the presence of SR59230A (10 µM) (n=8, N=3; ***p<0.005).
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BRL37344 inhibitory effect on nerve-evoked contractions of rat DSM isolated
strips: Role of cholinergic and purinergic components
We further separated the cholinergic component from the purinergic component of the
nerve-evoked contractions by using inhibitors of these two components. In the presence
of atropine (1 µM), which was used to block the cholinergic component of the nerveevoked contraction, BRL37344 (100 µM) significantly decreased the amplitude of the
EFS-induced DSM contractions at EFS stimulation frequencies ranging from 3.5 Hz to
50 Hz (Fig. 4.2.3A). In the presence of atropine, at the maximal stimulation frequency of
50 Hz, BRL37344 (100 µM) caused a 25.4±6.6% decrease in the amplitude of the EFSinduced contractions (n=15, N=8, p<0.005; Fig. 4.2.3C). This BRL37344 inhibitory
effect was antagonized by SR59230A (10 µM) at all EFS stimulation frequencies (3.5 –
50 Hz) (n=13, N=5; p>0.05; Fig. 4.2.3B, D). These data suggest that stimulation of beta3
adrenergic receptors with BRL37344 relaxes the EFS-induced DSM contractions of rat
DSM isolated strips via inhibition of the purinergic component of the EFS-induced DSM
contractions.
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Figure 4.2.3. In the presence of atropine, BRL37344 significantly inhibited the amplitude of the 0.5 – 50 Hz EFSinduced contractions of rat DSM isolated strips. Original DSM tension recordings illustrating BRL37344 (100 µM)
inhibitory effects on rat DSM EFS-induced purinergic contractions in the absence (A) or presence (B) of SR59230A
(10 µM). C) EFS frequency-response curves showing the BRL37344 inhibitory effects on the nerve-evoked
contractions in the presence of 1 µM atropine (n=15, N=8; ***p<0.005). D) EFS frequency-response curves showing
that SR59230A blocks BRL37344 inhibitory effects on the EFS-induced contractions (n=13, N=5, p>0.05).
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In order to investigate the cholinergic component of the EFS-induced contractions, we
blocked the purinergic component of the EFS-induced contractions with suramin (10 μM)
and α,β-methylene-ATP (10 μM) (63, 64, 145, 154, 161). These two inhibitors have
different mechanism of action. While suramin inhibits the purinergic receptor directly, α,
β-methylene-ATP first activates the receptors (it also acts as a receptor agonist) but then
quickly desensitizes the receptor. Thus, the combined use of both drugs secures higher
degree of purinergic receptor inhibition. It has been shown that the combination of these
two purinergic inhibitors decreases the number of spontaneous global Ca2+ flashes and
also nearly abolished the local Ca2+ transients evoked by EFS suggesting that these two
compounds combined completely block the purinergic component of the nerve-evoked
contractions in DSM (63). In the presence of suramin (10 µM) and α,β-methylene-ATP
(10 µM), BRL37344 significantly decreased the amplitude of the EFS-induced
contractions in rat DSM isolated strips at a wide range of EFS stimulation frequencies
(3.5 – 50 Hz) suggesting that BRL37344 inhibited the cholinergic component of the EFSinduced contractions (Fig. 4.2.4A, C). BRL37344 (100 µM) inhibited EFS-induced
contraction amplitude by 42.3±4.5% at the maximal stimulation frequency of 50 Hz
(n=12, N=5, p<0.005; Fig. 4.2.4C). This BRL37344 inhibitory effect on the cholinergic
component was slightly reduced at low stimulation frequency (3.5 – 20 Hz) by
SR59230A (10 µM) (n=9, N=5; p<0.005; Fig. 4.2.4B, D).

118

Figure 4.2.4. BRL37344 effects on the amplitude of the 0.5 – 50 Hz EFS-induced contractions of rat DSM
isolated strips in the presence of suramin and α,β-methylene-ATP. Original DSM tension recordings of EFSinduced DSM cholinergic contractions illustrating BRL37344 (100 µM) inhibitory effects in the absence (A) or
presence (B) of SR59230A (10 µM). EFS frequency-response curves showing BRL37344 inhibitory effect on EFSinduced contraction amplitude in the absence (n=12, N=5) (C) or presence (D) of 10 µM SR59230A (n=9, N=5;
***p<0.005). Application of α,β-methylene-ATP, a purinergic receptor agonist caused a transient contraction (A and
B) of the DSM followed by desensitization of the receptor.
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BRL37344 inhibitory effect on EFS-induced contractions is antagonized by
iberiotoxin, a selective BK channel blocker
In this experimental series, we investigated whether the BK channel plays a role during
the beta3 adrenergic receptor-mediated relaxation of nerve-evoked contractions in rat
DSM. We pretreated rat DSM isolated strips with iberiotoxin (200 nM) prior to
BRL37344 (10 nM – 100 µM) application (Fig. 4.2.5A). We found that blocking BK
channels with iberiotoxin significantly antagonized BRL37344 inhibitory effects on the
amplitude and muscle force of the 20 Hz EFS-induced contractions (Fig. 4.2.5B-C). The
BRL37344 inhibitory effects on 20 Hz EFS-induced DSM contractions were significantly
reduced as illustrated by reduction in the maximal BRL37344 inhibitory effect on the
EFS-induced contraction amplitude and force (n=7, N=5, p<0.05; Fig. 4.2.5B-C). These
findings suggest that BK channels and beta3 adrenergic receptors work in synergy to
oppose EFS-induced contractions in rat DSM isolated strips.
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Figure 4.2.5. Blockade of BK channels with iberiotoxin reduces the BRL37344 inhibitory effects on 20 Hz EFSinduced contractions of rat DSM isolated strips. A) Original DSM tension recordings illustrating the reduction of
BRL37344 (10 nM – 100 µM) inhibitory effects on rat DSM 20 Hz EFS-induced contractions by BK channels
blockade with 200 nM iberiotoxin. Cumulative concentration-response curves showing that pretreatment of rat DSM
isolated strips with 200 nM iberiotoxin opposes BRL37344 inhibitory effects on DSM EFS-induced contraction
amplitude (B) and force (C) (n=7, N=5; *p<0.05)
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DISCUSSION
The present study provides evidence that the beta3 adrenergic receptor agonist
BRL37344-mediated relaxation of rat DSM nerve-evoked contraction is regulated by the
BK channels. This BRL37344-induced DSM relaxation involved inhibition of both
cholinergic and purinergic components of the nerve-evoked contractions.
Stimulation of beta3 adrenergic receptors with BRL37344 reduces nerve-evoked
contractions in rat DSM isolated strips: role of purinergic and cholinergic
components. During the voiding phase of the micturition process, the parasympathetic
nerves become activated and acetylcholine and ATP, the two main excitatory
neurotransmitters in the bladder are released (7). ATP activates purinergic P2X receptors
while acetylcholine activates M2/M3 muscarinic cholinergic receptors to induce DSM
contractions and facilitate voiding (7). In our study, bladder nerves were stimulated with
a wide range of EFS frequencies in order to activate these two neurogenic pathways. It
has been demonstrated that the activation of both purinergic and cholinergic pathways is
EFS frequency-dependent (64). At low stimulation frequencies (≤ 20 Hz), the purinergic
pathway is predominant, contrary to the cholinergic component which predominates at
high frequencies (≥ 20 Hz) (18, 64, 161).
In a previous report, we showed in guinea pig DSM isolated strips BRL37344's inhibitory
effect on EFS-induced contractions was not mediated by beta3 adrenergic receptors
suggesting important species differences (1). We further showed that L-755,507, a
selective beta3 adrenergic receptor agonist failed to inhibit the nerve-evoked contractions
in guinea pig DSM isolated strips suggesting that in this particular species beta3
adrenergic receptors play a minor to no role at all during nerve-evoked contractions in
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guinea pig DSM (1). Here, we found that contrarily to guinea pig DSM, stimulation of
beta3 adrenergic receptors with BRL37344 caused a significant decrease of the nerveevoked contraction amplitude and force in rat DSM isolated strips in the presence or
absence of atropine (Figs. 4.2.2-3). BRL37344 (10 and 100 μM) caused a ~26% and
~52% decrease in rat DSM nerve-evoked contractions force, respectively. The
BRL37344 inhibitory effect reported here is similar to that in previous reports on human
DSM (151). The aforementioned study showed that BRL37344 (pEC50=6.25) caused a
22% and a 47% inhibition of human DSM carbachol-induced tone when used at
concentrations of 10 μM and 100 μM, respectively (151). Similar to Takeda et al. study,
the BRL37344 inhibitory effects that we report here at 10 and 100 μM could also be
mediated via activation of beta2 adrenergic receptors as recently suggested by Baker et
al. (10). We further studied the purinergic and the cholinergic components separately by
using inhibitors of these two components. In the presence of atropine, which was used to
block the cholinergic component of the nerve-evoked contractions, we found that
BRL37344 decreased the amplitude of the nerve-evoked contractions at all stimulation
frequencies tested suggesting that BRL37344 inhibits the purinergic component of the
nerve-evoked contractions (Fig. 4.2.3A, C). This BRL37344 inhibitory effect was
completely blocked at all EFS stimulation frequencies by SR59230A, which suggests that
BRL37344 inhibits the purinergic component of the nerve-evoked contractions. Our data
also showed that in the presence of α,β-methylene-ATP and suramin which were used to
block the purinergic component of the nerve-evoked contractions, BRL37344 decreased
the amplitude of the EFS-induced contractions at all stimulation frequencies tested
suggesting that BRL37344 inhibits the cholinergic component of the nerve-evoked
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contractions. However, the BRL37344 inhibitory effect on the cholinergic component
was not completely antagonized by SR59230A suggesting that BRL37344 might exhibit
some non-selective effects by also activating the beta2 adrenergic receptors (10). Taken
together, these data suggest that BRL37344 inhibitory effects on rat DSM nerve-evoked
contractions were mediated via inhibition of both purinergic and cholinergic pathways.
Functional BK channels regulate beta3 adrenergic receptor-mediated relaxation of
rat DSM neurogenic contractions
Previous studies, both in human and rodents, have shown that the BK channel plays an
important regulatory role in DSM physiology (22, 67, 75, 80, 130, 131, 134, 145, 164,
166). Activation of BK channels hyperpolarizes the cell membrane and prevents Ca2+
entry through L-type voltage-gated Ca2+ channels, which ultimately causes DSM
relaxation (75, 79, 130, 134, 145). This BK channel-mediated relaxation of the DSM has
made BK channel-targeting compounds potential drug candidates for the treatment of
bladder dysfunction (26, 80, 98, 130, 145). Along with BK channels, beta3 adrenergic
receptors have also been demonstrated to be promising targets for the pharmacological
treatment of OAB (13, 22, 50, 99, 157). Our group has recently provided evidence that
there is a functional link between beta3 adrenergic receptors and BK channels (79). We
have previously demonstrated that the pharmacological blockage of BK channels with
iberiotoxin opposes beta3 adrenergic receptor-mediated relaxation of rat DSM myogenic
contractions (79). In the present study, the beta3 adrenergic receptor agonist, BRL37344,
attenuates the contraction amplitude and muscle force of the 20 Hz EFS-induced
contractions in a concentration-dependent manner (Fig. 4.2.5). We further observed that
pharmacological blockade of BK channels with iberiotoxin antagonized the beta3
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adrenergic receptor-mediated relaxation of rat DSM nerve-evoked contraction amplitude
and force (Fig. 4.2.5). Using immunohistochemical analysis, Dr. Mark Nelson’s group
has demonstrated that BK channels are expressed in DSM but not in the bladder nerves
that innervate DSM (161). These findings clearly suggest that all of the iberiotoxin
effects reported in our study were not mediated via activation of efferent nerve terminals
to increase neurotransmitter release but rather solely through direct inhibition of BK
channels which are highly expressed in DSM (75, 131). Collectively, our data suggest
that BK channel activity is critical for the beta3 adrenergic receptor-induced attenuation
of the nerve-evoked contractions.
CONCLUSION
The present study reveals that the beta3 adrenergic receptor agonist, BRL37344, inhibited
both the purinergic and cholinergic components of the nerve-evoked contractions in rat
DSM. We also found that functional BK channels play a critical role in the BRL37344induced inhibition of the nerve-evoked contractions in rat DSM.
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4.3 BRL37344, A ΒETA3-ADRENERGIC RECEPTOR AGONIST, DECREASES
NERVE-EVOKED CONTRACTIONS IN HUMAN DETRUSOR SMOOTH
MUSCLE ISOLATED STRIPS: ROLE OF BK CHANNELS

Data presented in this section have been submitted for publication and is currently under
revision. The original manuscript has been modified to fit the format of this dissertation.
Human tissues were surgically obtained by Dr. Rovner’s team from the Medical
University of South Carolina. Dr. Rovner is a collaborator with the Petkov’s lab

ABSTRACT

The goal of the study was to investigate the mechanism by which BRL37344, a beta3-AR
agonist, facilitate the inhibition of nerve-evoked contractions in human DSM isolated
strips and to identify a role for the large-conductance Ca2+-activated K+ (BK) channels in
this process.
Human DSM specimens were obtained from open bladder surgeries on patients without
preoperative history of OAB symptoms. Isometric DSM tension recordings were
conducted using force-displacement transducers and thermostatically controlled tissue
baths. Nerve-evoked contractions were generated by electrical field stimulation (EFS).
BRL37344, a beta3-AR agonist, significantly decreased the amplitude and muscle force
of the DSM contractions induced by 20 Hz EFS, in a concentration-dependent manner.
This BRL37344-mediated inhibition of the amplitude and muscle force of the nerveevoked DSM contraction was significantly reduced by iberiotoxin, a selective inhibitor of
the BK channel, revealing a role for BK channels in the beta3-AR-induced inhibition of
human DSM nerve-evoked contractions. We further used atropine, α,β-methylene-ATP,
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and suramin to separate the cholinergic and purinergic components of human DSM
nerve-evoked contractions. We found that the beta3-AR agonist, BRL37344, inhibited
both components of the EFS-induced (0.5–50 Hz) DSM contractions.
In conclusion, this study supports the concept that beta3-AR agonists inhibit nerveevoked contractions in human DSM. We have further revealed that BK channels play a
critical role in BRL37344-mediated relaxation of nerve-evoked contractions in human
DSM. The study suggests that in addition to beta3-ARs, BK channels could also be
promising pharmacological targets in the treatment of urinary bladder dysfunction.
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INTRODUCTION
Overactive bladder (OAB) is a symptom based condition characterized by frequent
urination, urinary urgency, with or without urinary incontinence. The current therapeutic
approaches for OAB treatment which rely primarily on behavioral therapies in
combination with antimuscarinic drugs and a number of surgical techniques, have
variable outcomes and numerous potential adverse effects. These drawbacks in treating
OAB have led researchers to investigate alternative therapeutic approaches with novel
mechanisms of action, better efficacy, and fewer unfavorable effects.
Beta3-ARs, and the beta3-AR in particular, have emerged as targets for the treatment of
OAB as pharmacological activation of these receptors results in detrusor smooth muscle
(DSM) relaxation (22, 79). Beta3-AR agonists including BRL37344 ([4-[2-[[2-(3Chlorophenyl)-2-hydroxyethyl]amino]propyl]phenoxy]acetic

acid

sodium

hydrate),

mirabegron (YM178), solabergon (GW427353), TRK-380, and ritobegron (KUC-7483)
have been demonstrated to induce relaxation of human and rodent DSM spontaneous,
nerve-evoked, and pharmacologically-induced phasic contractions (14, 27, 79, 81, 88, 90,
156). In human DSM isolated strips, BRL37344 has been shown to inhibit carbacholinduced tone in a concentration-dependent manner (pEC50=6.25)(151). In fact,
BRL37344 caused a 22% and 47% inhibition of human DSM carbachol-induced tone
when used at a concentration of 10 µM and 100 µM, respectively (151). Furthermore, in
phase 3 clinical studies on patients with OAB, mirabegron has demonstrated both
efficacy and safety (27, 90). Based on these aforementioned studies which demonstrate
the prominent role of beta3-ARs in human DSM relaxation both in vitro and in vivo,
mirabegron has been approved as the first beta3-AR agonist for OAB in the US (27, 90).
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The mechanism by which beta-AR activation causes relaxation of the DSM is thought to
involve the cyclic cAMP (cAMP) signaling pathway (22, 115). cAMP activates protein
kinase-A (PKA), which in turn phosphorylates various proteins involved in DSM
excitation-contraction coupling and stimulates the BK channels to promote DSM
relaxation (22, 58, 115). In animal species, the BK channel is one of the most important
physiologically relevant K+ channels that controls DSM function (22, 58, 66, 79, 130,
134). Recent studies have further revealed a critical role for the BK channel in regulating
human detrusor excitability and contractility (75, 80). Increases in intracellular cAMP
levels via phosphodiesterase inhibition also stimulate BK channel activity and leads to
DSM relaxation (164, 166). Collectively, studies have established that there is a clear
functional link between the beta-AR/cAMP/PKA signal transduction pathway and BK
channels during DSM relaxation (22, 79, 134).
However, the potential functional link between beta3-ARs and BK channels during
nerve-evoked contractions is not well defined. To investigate this mechanism, we used
thermostatically-controlled tissue baths equipped with platinum electrodes for electrical
field stimulation (EFS) to generate nerve-evoked contractions in human DSM isolated
strips. The relationship between the effects of BRL37344, a beta3-AR agonist, and
iberiotoxin, a selective BK channel inhibitor, were examined in order to elucidate the
underlying mechanisms involved in the beta3-AR agonist-induced relaxation of human
DSM.
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METHODS
Human DSM tissue collection
Human studies were conducted as described in chapter 2.2.
Isometric DSM tension recordings
Isometric DSM tension recordings were conducted as described in chapter 2.2.

Solutions and Drugs
The Ca2+-free dissection solution and the Ca2+-containing PSS compositions are
described in chapter 2.2. All drugs were purchased from Sigma-Aldrich Co. (St. Louis,
MO), unless specified otherwise. BRL37344 was prepared daily in double-distillated
water and heated at 60oC to be completely dissolved at the concentration of 10 mM as a
stock solution as recommended by the manufacturer.

Data analysis and statistics

Data analysis was performed as described in chapter 2.2.
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RESULTS
BRL37344 inhibits EFS-induced contractions of human DSM strips in a
concentration-dependent manner
We investigated the effect of BRL37344 on the amplitude and muscle force of EFSinduced DSM contractions generated by 20 Hz/min EFS in human DSM isolated strips.
BRL37344 (10 nM–100 µM) was very effective at inhibiting the amplitude and force of
the 20 Hz EFS-induced contractions of human DSM isolated strips. BRL37344 (10 nM,
100 nM, 1 µM, 10 µM, and 100 µM) reduced the amplitude of the EFS-induced
contractions by 11.6±3.9%, 22.9±8.2%, 33.3±10.3%, 45.5±10.4%, and 71.9±6.1%,
respectively (n=4, N=3; Fig. 4.3.1A, C). BRL37344 (10 nM, 100 nM, 1 µM, 10 µM, and
100 µM) also decreased the force of the EFS-induced contractions by 7.0±5.2%,
33.2±4.9%, 46.2±9.1%, 57.7±7.9%, and 78.4±4.4%, respectively (n=4, N=3; Fig. 4.3.1A,
D). These data suggest that BRL37344 effectively decreases nerve-evoked contractions
in human DSM isolated strips.
BRL37344 inhibitory effect on EFS-induced contractions is reduced by iberiotoxin,
a selective BK channel blocker
In this experimental series, we investigated the relationship between β3-ARs and BK
channels in nerve-evoked DSM contractions. We found that in the presence of iberiotoxin
(200 nM), BRL37344 (10 nM–100 µM) inhibitory effects on the 20 Hz EFS-induced
contractions amplitude and force of human DSM isolated strips were significantly
reduced (Fig. 4.3.1B, C, and D). The maximal antagonistic activity of iberiotoxin was
observed at 1 µM BRL37344 where the BRL37344 inhibitory effects on the EFS-induced
contraction amplitude and force were reduced from 32.4±10.3% to only 2.4±0.3% and
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from 46.2±9.1% to 7.4±4.2%, respectively (Fig. 4.3.1C and D). These findings suggest
that BK channels and β3-ARs work in synergy to oppose nerve-evoked contractions in
human DSM.

Figure 4.3.1. Iberiotoxin, a BK channel blocker, significantly reduced the BRL37344 inhibitory effects on 20 Hz
EFS-induced contractions in human DSM isolated strips. A) An original DSM tension recording illustrating
BRL37344 (10 nM-100 µM) inhibitory effects on 20 Hz EFS-induced contractions in a human DSM isolated strip. B)
An original DSM tension recording illustrating that iberiotoxin (200 nM) increased the 20 Hz EFS-induced
contractions in human DSM and that the BRL37344 (10 nM-100 µM) inhibitory effects on the EFS-induced
contraction amplitude and force were significantly attenuated in the presence of iberiotoxin (200 nM). C-D)
Cumulative concentration-response curves illustrating iberiotoxin (200 nM) antagonistic action on BRL37344
inhibitory effects on EFS-induced contraction amplitude (C) and force (D), respectively (n=4, N=3; *P<0.05,
**P<0.01, ***P<0.005).
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BRL37344 decreases the amplitude of the EFS-induced DSM contractions in a wide
range of stimulation frequencies
Here, we investigated how the β3-AR agonist, BRL37344, modulates DSM nerve-evoked
contractions in response to a wide range of EFS frequencies in human DSM isolated
strips. We first applied increasing EFS frequencies (0.5–50 Hz) as a control protocol,
followed by the addition of a single concentration of BRL37344 (10 µM). Then, a second
EFS protocol was applied to evaluate BRL37344 effects on the nerve-evoked
contractions. In human DSM isolated strips, BRL37344 (10 µM) significantly decreased
the amplitude of the EFS-induced contractions (Fig. 4.3.2A). At the maximum EFS
frequency of 50 Hz, BRL37344 (10 µM) decreased human DSM EFS-induced
contraction amplitude by 38.1±6.6% (n=8, N=4; Fig. 4.3.2B). We also applied a higher
concentration of BRL37344 (100 µM) which caused almost a complete inhibition of the
EFS-induced DSM contractions. At the maximum EFS frequency of 50 Hz, BRL37344
(100 µM) decreased human DSM EFS-induced contraction amplitude by 85.4±2.1%
(n=11, N=3; data not illustrated). These data suggest that BRL37344 reduces human
DSM nerve-evoked contractions induced by EFS at a wide range of stimulation
frequencies.
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Figure 4.3.2. BRL37344 decreases the amplitude of the EFS-induced contractions in human DSM isolated strips
in a wide range of stimulation frequencies. A) An original DSM tension recording illustrating the inhibitory effects
of 10 µM BRL37344 on 0.5–50 Hz EFS-induced contractions of human DSM. B) Frequency-response curves showing
0.5–50 Hz EFS-induced contractions in response to 10 µM BRL37344 (n=8, N=4; **P<0.01, ***P<0.005).
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BRL37344 attenuates both purinergic and cholinergic components of EFS-induced
contractions in human DSM isolated strips
In this experimental series, we applied an experimental approach that allowed us to
separate the cholinergic component from the purinergic component during EFS-induced
DSM contractions. The cholinergic component of the EFS-induced DSM contractions
was assessed by blocking purinergic receptors with α,β-methylene-ATP, a desensitizing
agonist; and suramin, a purinergic receptor antagonist. Human DSM isolated strips were
pre-incubated with suramin (10 µM) and α,β-methylene-ATP (10 µM) for 15 min prior to
applying a 0.5–50 Hz EFS control protocol. Next, BRL37344 was added in the bath for
30 min followed by a second EFS protocol. The purinergic component of the EFSinduced contractions, on the other hand, was assessed by pre-treating the DSM strips with
1 µM atropine for 15 min prior to applying a 0.5–50 Hz EFS control protocol in the
presence or absence of BRL37344. In human DSM isolated strips, BRL37344 (10 µM)
caused a significant decrease in the amplitude of the EFS-induced contraction in the
presence of atropine at frequencies ranging from 3.5 to 50 Hz (Fig. 4.3.3A, B). At the
maximal stimulation frequency of 50 Hz, BRL37344 (10 µM) caused a 35.6±9.6%
decrease in the amplitude of DSM EFS-induced purinergic contractions in human DSM
(n=4, N=3; Fig. 4.3.3B). BRL37344 (100 µM) had a more pronounced effect compared
to BRL37344 (10 µM), and reduced the EFS-induced purinergic contraction amplitude of
human DSM strips by 68.6±12.1% at 50 Hz-frequency (n=4, N=3; data not illustrated).
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Figure 4.3.3. BRL37344 significantly inhibited the purinergic component of the 0.5–50 Hz EFS-induced
contractions in human DSM isolated strips. A) An original DSM tension recording illustrating BRL37344 (10 µM)
inhibitory effects on EFS-induced contractions of human DSM isolated strips in the presence of atropine (1 µM). B)
EFS frequency-response curves showing 10 µM BRL37344 inhibitory effects on nerve-evoked contractions of human
DSM isolated strips (n=4, N=3; *P<0.05, **P<0.01).
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In the presence of suramin (10 µM) and α,β-methylene-ATP (10 µM), BRL37344 also
significantly decreased the amplitude of the EFS-induced cholinergic contractions in
human DSM isolated strips at a wide range of EFS frequencies (3.5–50 Hz) (Fig. 4.3.4A
and B). At the maximal frequency of 50 Hz, BRL37344 (10 µM and 100 µM) decreased
the EFS-induced cholinergic contraction amplitude of human DSM strips by 26.5±9.7%
(n=8, N=5, P<0.05; Fig. 4.3.4B) and 91.0±5.3% (n=4, N=3; data not illustrated),
respectively. These data suggest that BRL37344 inhibits both the cholinergic and the
purinergic components of the EFS-induced contractions in human DSM.
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Figure 4.3.4. BRL37344 reduced the cholinergic component of the 0.5–50 Hz EFS-induced contractions of the
human DSM. A) An original DSM tension recording illustrating BRL37344 (10 µM) inhibitory effects on human
DSM EFS-induced contractions in the presence of suramin (10 µM) and α,β-methylene-ATP (10 µM). B) Frequencyresponse curves illustrating BRL37344 (10 µM) inhibitory effects on EFS-induced contraction amplitude of human
DSM isolated strips in the presence of suramin and α,β-methylene-ATP (n=8, N=5; *P<0.05, **P<0.01, ***P<0.005).
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DISCUSSION
The present study demonstrates that beta3-AR agonist, BRL37344, effectively inhibits
both the purinergic and cholinergic components of human DSM nerve-evoked
contractions. This BRL37344 inhibitory effect was significantly reduced by iberiotoxin, a
BK channel selective inhibitor suggesting that functional BK channels play a critical role
in the beta3-AR mediated relaxation of human DSM nerve-evoked contractions.
In mouse, rat, guinea pig, and human DSM, it has been shown that physiological DSM
nerve-evoked contractions are due to the combined action of two main excitatory
neurotransmitters, acetylcholine and ATP, released from the parasympathetic nerves(59,
64, 119, 142, 161). ATP activates P2X receptors while acetylcholine stimulates M2/M3
muscarinic receptors to induce DSM contractions(24, 59, 64, 105, 119, 142, 160, 161).
Acetylcholine activation of M2 muscarinic receptors causes inhibition of adenylyl
cyclase activity while activation of M3 receptors triggers the inositol 1,4,5-trisphosphate
pathway (55, 104). This dual muscarinic receptor action ultimately leads to DSM
contraction. We found that low concentrations of BRL37344 (10 nM–1 µM) decreased
the amplitude of nerve-evoked contractions in human DSM consistent with previous
studies demonstrating that BRL37344 could inhibit human DSM carbachol-induced tone
(151). Our study suggests that beta3-ARs play an important role in opposing human DSM
nerve-evoked contractions. Our data are also consistent with previous findings showing
that KUC-7322 and GW427353, two other selective beta3-AR agonists, also decreased
carbachol-induced and nerve-evoked contractions in human DSM (14, 81, 156). Unlike
the current study, these latter studies did not address the potential involvement of BK
channels in this process. Previously, we showed that BRL37344 effectively inhibits
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spontaneous phasic contractions of rat DSM isolated strips (79). This BRL37344
inhibitory effect was further demonstrated to be antagonized by SR59230A, a selective
beta3-AR antagonist, and H89, a PKA inhibitor, suggesting that the beta3-AR-mediated
relaxation of the DSM tone utilized the cAMP/PKA pathway(79).
Recently, our laboratory and others have demonstrated the critical role played by BK
channels in regulating DSM spontaneous phasic contractions (22, 66, 75, 79, 80, 130,
164, 166). BK channels, which are activated by Ca2+ sparks released from the
sarcoplasmic reticulum through the ryanodine receptors, regulate DSM function by
opposing the phasic contractions induced by Ca2+ entry through L-type voltage-gated
Ca2+ channels (79, 130, 134). Our group was the first to provide evidence for a functional
link between β3-ARs and BK channels (79). In guinea pig, isoproterenol, a non-selective
beta-AR agonist, activates cAMP/PKA pathway, increases Ca2+ spark activity which
activates BK channels and induces relaxation of the DSM (134). Iberiotoxin shifts the
concentration-response curves for the BRL37344 inhibitory effects on the spontaneous
phasic contraction amplitude, muscle force integral, and muscle tone, to the right
suggesting that the pharmacological blockage of BK channels opposes beta3-ARmediated relaxation of rat DSM myogenic contractions (79). However, until now this
mechanism has never been investigated in DSM nerve-evoked contractions. Here, we
reveal for the first time the role of BK channels in the beta3-AR-induced relaxation of
human DSM nerve-evoked contractions. BRL37344 decreased human DSM nerveevoked contractions in a concentration-dependent manner (Fig. 4.3.1). At concentrations
ranging between 10 nM and 10 µM, the BRL37344 inhibitory effect was significantly
antagonized by iberiotoxin suggesting that functional BK channels play an important role
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in the beta3-AR mediated relaxation of human DSM nerve-evoked contractions (Fig.
4.3.1B, C and D). It has been suggested that at concentrations equal or higher than 10
μM, BRL37344 may also activate beta2-ARs(10). Regardless of the potential BRL37344
effect on beta2-ARs, one would anticipate that the majority of the BRL37344 effect was
mediated via activation of the beta3-ARs since beta3-ARs represent ~97% of all beta-AR
mRNA expressed in the human bladder(167).
Using selective inhibitors, we further separated the purinergic and cholinergic pathways
which both contribute to DSM nerve-evoked contractions. Previous studies have
established that at low stimulation frequencies (≤ 20 Hz), the purinergic pathway plays a
greater role whilst at high stimulation frequencies (≥ 20 Hz), the cholinergic component
predominates (64, 161). In the presence of atropine, which was used to block the
cholinergic component of the nerve-evoked contractions, we found that beta3-AR
activation decreased the amplitude of the nerve-evoked contractions in human DSM in a
wide range of stimulation frequencies (Fig. 4.3.3). In the presence of suramin and α,β
methylene-ATP which were used to block the purinergic component, BRL37344 also
significantly decreased the amplitude of the nerve-evoked contractions in human DSM
(Fig. 4.3.4). Taken together, these data suggest that BRL37344 inhibits both cholinergic
and purinergic contractions of human DSM.

CONCLUSION

The present study reveals that beta3-AR agonist, BRL37344, is very effective at low
concentrations in reducing human DSM nerve-evoked contractions. We reveal for the
first time that the beta3-AR-agonist-mediated relaxation of human DSM nerve-evoked
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contractions is BK channel-dependent, emphasizing the critical role of BK channels in
human DSM physiology. Future studies using DSM tissue from patients with OAB and
detrusor overactivity are anticipated to demonstrate a similar functional relationship
between beta3-ARs and the BK channel, which would provide further impetus for
studying potential pharmacologic targets in this area for the treatment of OAB.
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CHAPTER 5
VOLTAGE-GATED K+ (KV) CHANNELS IN THE DETRUSOR SMOOTH MUSCLE

Chapter 5 discusses the expression pattern and functional roles of several Kv channels in
the DSM. We focused on two Kv channel families including Kv2 and Kv7 channels. The
study of Kv2 channels were performed in human DSM (chapter 5.1) as a follow up study
of the role of these channels in guinea pig. The data presented here have already been
published with me as a co-author and the original article has been modified to fit the
format of this dissertation after obtaining authorization from the publisher. In chapter 5.2,
we investigated Kv7 channels in guinea pig, a commonly used laboratory animal, to
assess how pharmacological modulation of these channels affects DSM contractility
(chapter 5.2). Based on the guinea pig data, we confidently initiated the investigation of
Kv7 channels roles in human DSM (chapter 5.3). The preliminary data presented in
chapter 5.3 need further investigation to clearly demonstrate the regulatory role of Kv7
channels in human DSM.
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5.1 EXPRESSION AND FUNCTION OF KV2-CONTAINING CHANNELS IN
HUMAN DETRUSOR SMOOTH MUSCLE

Data presented in this section have already been published with me as a co-author and the
original paper has been modified to fit the format of this dissertation after obtaining
authorization from the publisher. Molecular biology data were collected by Dr. Muyan
Chen, a former post-doctoral fellow in Dr. Petkov’s lab. Electrophysiological data were
collected by Dr. Kiril Hristov, a post-doctoral fellow in Dr. Petkov’s lab. All isometric
DSM tension recordings experiments were performed by me. Ca2+-imaging data were
obtained by Qiuping Chen, a former researcher associate in Dr. Petkov’s lab. Human
tissue harvesting was achieved by Dr. Eric Rovner’s urology team at the Medical
University of South Carolina. Dr. Eric Rovner is a collaborator with the Petkov’s lab.

ABSTRACT
The functional role of the voltage-gated K+ (KV) channels in human detrusor smooth
muscle (DSM) is largely unexplored. Here, we provide molecular, electrophysiological,
and functional evidence for the expression of KV2.1, KV2.2, and the electrically silent
KV9.3 subunits in human DSM. Stromatoxin-1 (ScTx1), a selective inhibitor of KV2.1,
KV2.2, and KV4.2 homotetrameric channels and of KV2.1/9.3 heterotetrameric channels,
was used to examine the role of these channels in human DSM function. Human DSM
tissues were obtained during open bladder surgeries from patients without a history of
overactive bladder. Freshly isolated human DSM cells were studied using RT-PCR,
immunocytochemistry, live-cell Ca2+ imaging, and the perforated whole cell patch-clamp
technique. Isometric DSM tension recordings of human DSM isolated strips were
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conducted using tissue baths. RT-PCR experiments showed mRNA expression of KV2.1,
KV2.2, and KV9.3 (but not KV4.2) channel subunits in human isolated DSM cells. KV2.1
and KV2.2 protein expression was confirmed by Western blot analysis and
immunocytochemistry. Perforated whole cell patch-clamp experiments revealed that
ScTx1 (100 nM) inhibited the amplitude of the voltage step-induced KV current in freshly
isolated human DSM cells. ScTx1 (100 nM) significantly increased the intracellular Ca2+
level in DSM cells. In human DSM isolated strips, ScTx1 (100 nM) increased the
spontaneous phasic contraction amplitude and muscle force, and enhanced the amplitude
of the electrical field stimulation-induced contractions within the range of 3.5–30 Hz
stimulation frequencies. These findings reveal that ScTx1-sensitive KV2-containing
channels are key regulators of human DSM excitability and contractility and may
represent new targets for pharmacological or genetic intervention for bladder dysfunction.
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INTRODUCTION
Increased detrusor smooth muscle (DSM) contractions are often associated with
overactive bladder (OAB), a pathophysiological condition that affects millions of
individuals by disturbing their sleep, work, quality of life, and social interactions (7, 8).
The exact mechanism that underlies human DSM contractility still remains unclear.
Potassium (K+) channels play a critical role in controlling DSM electrical activity, and
therefore contractility (7, 22, 75, 77, 126, 130, 131, 134, 145, 155). Inhibition of certain
types of K+ channels leads to membrane depolarization, activation of the L-type voltagegated Ca2+ (CaV) channels, and DSM contraction. Activation of K+ channels leads to
hyperpolarization of the cell membrane, inhibition of CaV-channels, a decrease in
intracellular Ca2+ concentration, and DSM relaxation (130).
Among K+ channels that control cell excitability and contractility, the KV channel
superfamily is the most diverse, but the least investigated in human DSM (130). In the
human genome the KV channel superfamily is represented by more than 40 genes
encoding the pore-forming α-subunits (52, 53, 130). KV channels are classified into 12
subfamilies based on their amino acid sequence homology. Each functional KV channel is
composed of four α-subunits. The members of KV1–4, KV7, and KV10–12 channel
subfamilies can form functional homotetrameric channels, whereas the members of KV5,
KV6, KV8, and KV9 channel subfamilies do not form their own homotetramers, but rather
form heterotetrameric channels with KV2 channel subunits (130). KV channels that
contain KV2 (KV2.1 or KV2.2) subunits are referred to as “KV2-containing channels.”
KV2-containing channels could form their own homotetramers or heterotetramers with
electrically silent KV (KV5, KV6, KV8, and KV9) subunits.
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At least several KV channels are expressed in DSM of mammals (29, 36, 47, 77, 122,
155). Expression of KV2.1, KV5.1, KV6.1, KV6.2, and KV6.3 channel subunits has been
shown in mouse DSM (155). The expression of KV2.1 and KV2.2 channels has been
shown in rat DSM (29), and the expression of KV2.1 and electrically silent KV channel
subunits has been detected in guinea pig DSM (77). However, it is questionable whether
these findings in animal models could be directly translated to humans, since species
differences in human and rodent DSM function are well documented (1, 7, 17, 29, 57, 77,
130).
Knowledge about KV channels in human DSM is limited and only the molecular
expression of some KV1 channels has been proven (36). There is a lack of information
about expression, function, and regulation of each individual KV channel in human DSM.
Microelectrode studies have shown that the nonselective KV channel inhibitor 4aminopyridine (4-AP) affects the after-hyperpolarization phase of the action potential and
increases the frequency of the action potentials in human DSM (57). However, because of
the nonselectivity of 4-AP, these experiments do not provide any information about the
physiological role of individual members of the KV channel family in human DSM. The
lack of KV channel subtype selective inhibitors with high affinity and selectivity has
hampered the study of these channels not only in human DSM but also in other tissues.
Recently, highly specific KV channel inhibitors have emerged enabling researchers to
examine individual KV channel subtypes and determine their functional roles in DSM
(130).
Stromatoxin-1 (ScTx1), a peptide isolated from African tarantulas, has been shown to
selectively inhibit KV2.1, KV2.2, and KV4.2 homotetramers, as well as KV2.1/6.3 and
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KV2.1/9.3 heterotetrameric channels (40, 41, 113). Recently, we showed that ScTx1 is a
useful pharmacological tool to study the function of KV channels in DSM of animal
species (29, 77). We demonstrated that KV2-containing channels sensitive to ScTx1
regulate rat and guinea pig DSM excitability and contractility (29, 77). However, the
expression and function of the KV2 channels have never been studied in human DSM. Dr.
Alison Brading, a world-renowned expert in ion channel DSM research, has emphasized
that “It would seem particularly important for those studying the ion channels in a
particular species to extend their studies to correlate channel properties with function, and
there are still far too few basic studies on human material” (17). A recent review article
further outlines the urgent need of studies on native human DSM (130).
The aim of this study was to examine the expression of ScTx1-sensitive KV2-containing
channels in human DSM, and to reveal their functional role in human DSM excitability
and contractility. To achieve this aim, we applied a multidisciplinary approach using
molecular biology techniques, live-cell Ca2+ imaging, patch-clamp electrophysiology, and
isometric DSM tension recordings of human DSM isolated strips. Because human is the
target species of interest for therapeutic intervention, the present study on native human
DSM is critical to validate animal models reflecting human bladder function in the
development of novel therapeutic strategies for the treatment of bladder pathologies.
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MATERIALS AND METHODS

Human DSM tissue collection
All human studies were performed as previously described in chapter 2.2. In this study
we used tissues from 27 patients (21 Caucasians and 6 African-Americans), of which
there were 16 males and 11 females aged 24 to 85 (average age 59.6 ± 3.2 yr). The
clinical diagnoses of the patients were as follows: 22 patients had urothelial carcinoma, 1
had urethral adenocarcinoma, 1 had enterovesical fistula, and 3 patients had
reconstructive lower urinary tract surgeries.

Fresh human DSM single cell isolation for RT-PCR, immunocytochemistry, live-cell
Ca2+ imaging, and patch-clamp experiments

Fresh human DSM single cells were isolated as previously described in chapter 2.2.

RNA extraction/RT-PCR/sequencing

RT-PCR experiments were conducted as described in chapter 2.2 and performed by Dr.
Muyan Chen, a former post-doctoral fellow in Dr. Petkov’s lab. All primers specific for
KV2.1, KV2.2, KV4.2, and KV9.3 were designed on the basis of the cDNA complete
sequences of human in GenBank. Specific primer pair sequences are listed in Table 5.1.1.
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Channel

Sense

Anti-sense

Product (bp)

KV2.1

ATGCGAAGTATGTCAAGCA

CATGGTACATCCCTAGAACG

334

KV2.2

ATGACCACTGTTGGCTATG

GTTTGGGTGAGAATGAGG

537

KV4.2

ATAGATACGGTAAGAGCCA

TGTGATATTAGTCCCAGTCA

417

KV9.3

GCACTCGGTAGGACTTCG

AGGATCGCTCACCACAAT

481

Table 5.1.1. RT-PCR primers for the subunits of the KV channels sensitive to ScTx1 and the silent KV9.3 channel
subunit. bp-base pair. RT-PCR primers were designed by Dr. Muyan Chen.
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Western blot analysis
These experiments were performed by Dr. Muyan Chen. Western blotting analysis was
conducted as described in chapter 2.2. Blots were incubated with the affinity-purified
rabbit polyclonal primary antibodies: anti-KV2.1 (DRK1 1:400), anti-KV2.2 (CDRK
1:2,000), anti-KV4.2 (Kcnd2 1:200) (Alomone Labs, Jerusalem, Israel) and anti-KV9.3
[KV9.3(K-12) 1:200] (Santa Cruz Biotechnology, Santa Cruz, CA) or anti-KV9.3 (KCNS3
1:200) (Abcam) overnight at 4°C. Goat anti-rabbit IgG conjugated with horseradish
peroxidase was used as secondary antibody.

Immunocytochemistry on human DSM isolated cells

These experiments were performed by Dr. Muyan Chen. Human DSM cells were
enzymatically isolated from fresh human DSM tissue, and dropped on a glass coverslip to
settle at room temperature, then processed for the following steps. Cells were fixed with
prewarmed 4% paraformaldehyde for exactly 10 min. Cells were then washed twice in
PBS, blocked, and permeabilized in PBS containing 10% normal donkey serum and 0.1%
Triton X-100 for 30 min. Once again, cells were washed in PBS and incubated with
rabbit polyclonal primary antibodies: anti-KV2.1, anti-KV2.2, and anti-KV4.2 (DRK1,
CDRK and Kcnd2, 1:100, Alomone Labs) at 37°C for 1 h. After that, cells were washed
two times with PBS and labeled with secondary antibodies Cy3-conjugated anti-rabbit
IgG, at 1:200, PBS-3% normal donkey serum-0.01% Triton X-100 (Jackson
ImmunoResearch, West Grove, PA) for 1 h in the dark. After labeling, cells were washed
with PBS and incubated with phalloidin for 2 h in the dark. Cells were then washed two
more times and incubated with 4′,6-diamidino-2-phenylindole for 15 min and washed
again, then mounted onto slides with DABCO. Control treatments were carried out as
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follows: 1) omission of the primary antibody for confirming the specificity of the
secondary antibody, and 2) absorption of the primary antibody by a competing peptide for
confirming the specificity of the primary antibody. Confocal images were acquired with
an LSM 510 META confocal microscope (Carl Zeiss).

Electrophysiological (patch-clamp) recording

Patch-clamp experiments were performed and by Dr. Kiril Hristov, a post-doctoral fellow
in Dr. Petkov’s lab. The amphotericin-B perforated patch-clamp technique was applied in
all electrophysiological experiments to preserve the native physiological environment of
the human DSM cells. Several drops ( 0.5 ml) of the DS containing the isolated single
cells were placed in an experimental chamber. Cells were allowed to adhere to the glass
bottom of the chamber for

20 min and after that were washed with extracellular

solution. Most cells were elongated and had a bright, shiny appearance when examined
with a phase-contrast microscope. Cells were used for patch-clamp recordings within 24
h after isolation. Axopatch 200B amplifier, Digidata 1440 A, and pCLAMP 10.2 software
(Molecular Devices) were used for electrophysiological recordings of the ionic currents.
The signal was filtered with eight-pole Bessel filter 900CT/9L8L (Frequency Devises,
Ottawa, IL). The glass pipettes used for patch-clamp experiments were made from
Borosilicate glass (Sutter Instruments, Novato, CA) and pulled using a Narishige PP-830
vertical puller (Narishige Group, Tokyo, Japan) to give a final tip resistance of 4–6 MΩ.
The pipettes were polished with a Micro Forge MF-830 fire polisher (Narishige Group).
All patch-clamp experiments were performed in voltage-clamp mode, in the presence of
the large-conductance Ca2+-activated K+ (BK) channel selective inhibitor iberiotoxin (200
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nM). The leak current was not subtracted during or after the experiments. The average
value of the current amplitude during the last 50 ms of the 250-ms depolarization step
was taken to evaluate the steady-state KV current. For the control current, at least five
pulses within 10 min were recorded and averaged. Only cells with stable control currents
for at least 10 min were used to examine the effect of ScTx1. All patch-clamp
experiments were carried out at room temperature.
Ca2+ imaging experiments

These experiments were performed by Qiuping Cheng, a research associate in Dr.
Petkov’s lab. For intracellular Ca2+ imaging experiments, 250 μl poly-l-lysine was added
to each 35 mm diameter glass-bottom dish, incubated at 37°C for 1 h, then dishes were
aspirated and washed with 2 ml sterile water three times. DSM cell suspension was added
into the dishes and kept for 30 min to allow cell adherence to the bottom of the dishes.
Fura-2 AM solution was diluted with bath solution to a final concentration of 2 μM.
Supernatant was then removed from the dishes, 250 μl fura-2 AM working solution was
added into the dishes, and samples were stored in a dark room for 30 min. Fura-2 AM
bath solution was then removed and cells were washed with bath solution three times.
Ca2+ imaging recordings were acquired with an OLYMPUS IX81 motorized inverted
research microscope, with 40 × oil objective, equipped with the MetaFluor 7.7.2.0
software. All Ca2+ imaging experiments were carried out at room temperature.

Isometric human DSM tension recordings

Isometric tension recordings were performed as described in chapter 2.2.
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Solutions and drugs
The Ca2+-free DS and the Ca2+-containing PSS compositions are described in chapter 2.2.
The extracellular (bath) solution used in the electrophysiological and Ca2+-imaging
experiments contained (in mM) 134 NaCl, 6 KCl, 1 MgCl2, 2 CaCl2, 10 glucose, and 10
HEPES, pH adjusted to 7.4 with NaOH. The pipette solution contained (in mM) 110
potassium aspartate, 30 KCl, 10 NaCl, 1 MgCl2, 10 HEPES, and 0.05 EGTA, pH adjusted
to 7.2 with NaOH and supplemented with freshly dissolved (every 1–2 h) 200 μg/ml
amphotericin-B. TTX was purchased from Sigma-Aldrich (St. Louis, MO). ScTx1 was
purchased from Alomone Labs. TTX was dissolved in citrate buffer and ScTx1 was
dissolved in distilled water.

Data analysis and statistics

Data analysis was performed as described in chapter 2.2.
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RESULTS

RT-PCR.
The expression of mRNA messages for KV2.1, KV2.2, KV4.2 and KV9.3 channel subunits
was detected in human DSM whole tissue (Fig. 5.1.1). Other cell types such as neurons,
fibroblasts, and vascular myocytes are also present within the DSM layer. Thus, it is
plausible that KV2.1, KV2.2, KV4.2, and KV9.3 channel detection may come from cell
types other than DSM cells. To eliminate the possible interference from non-DSM cell
types, we applied single-cell RT-PCR experiments on freshly isolated human DSM cells.
This experimental approach allows us to use selectively only the isolated DSM cells
while avoiding any contamination from non-DSM cells (1, 28, 30, 75, 77, 126). DSM
cells were characterized by their elongated, spindle shape, with a bright and shiny
contour. Single-cell RT-PCR experiments confirmed the mRNA expression of KV2.1,
KV2.2, and KV9.3 channel subunits in human DSM single cells (Fig. 5.1.1). mRNA
expression of the KV4.2 channel subunit was not confirmed in single DSM cells,
suggesting that this channel subunit is not expressed in human DSM cells. A lack of
genomic DNA contamination was also confirmed by performing negative control
experiments in the absence of the reverse transcriptase (−RT). All RT-PCR purified
products from the intact human DSM tissue and isolated human DSM cells were
sequenced to confirm their identity. PCR products were purified using the GenElute PCR
Clean-Up Kit (Sigma-Aldrich) and sequenced at the University of South Carolina
Environmental Genomics Core Facility to confirm their identity. Results were verified in
at least 30 different preparations obtained from 10 patients.
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Figure 5.1.1. RT-PCR detection of mRNA messages for voltage-gated K+ channel subunits KV2.1, KV2.2, KV4.2, and
KV9.3 in human detrusor smooth muscle (DSM) whole tissue (A) and freshly isolated single cells (B and C). KV2.1,
334 bp; KV2.2, 537 bp; KV4.2, 417 bp; and KV9.3, 481 bp. No products were observed in the negative controls (−RT)
in which reverse transcriptase was left out of the reaction. Data collected by Dr. Muyan Chen.
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Western blot analysis

To confirm the expression of these KV2-containing channels at the protein level in human
DSM tissue, we applied Western blot analysis. The presence of the KV2.1 and KV2.2
proteins in human DSM tissue was confirmed by using channel subunit-specific
antibodies (Fig. 5.1.2). Consistent with our single cell RT-PCR data, no KV4.2 protein
was detected in whole human DSM tissue. The specific antibodies for KV9.3 channel did
not show any signal in whole human DSM (data not illustrated). Preabsorption of the
primary antibody with its antigenic competing peptide indicated the specificity of the
antibodies for their intended epitope (Fig. 5.1.2). The results were verified in three
separate Western blot reactions using proteins isolated from three patients.

Figure 5.1.2. Western blot detection of KV2.1 and KV2.2 channel protein expression in human DSM whole tissue. A:
KV2.1 channel. B: KV2.2 channel. The immunoreactive band was eliminated by a competing peptide (+CP) . Data
collected by Dr. Muyan Chen.

157

Immunocytochemistry

Immunocytochemical labeling was further applied to confirm the specific expression of
KV2.1, and KV2.2 proteins at the level of single DSM cells and to demonstrate that the
KV2 proteins were localized to the cell membrane (Fig. 5.1.3). The results were carefully
controlled for specificity using the omission of the primary antibody or absorption of the
primary antibody by a competing peptide (Fig. 5.1.3). The data were verified in 12 single
DSM cells freshly isolated from three patients.
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Figure 5.1.3. Immunocytochemical detection of KV2.1 (A) and KV2.2 (B) channel in freshly isolated single human
DSM cells using KV2.1 and KV2.2 channel-specific antibody. Red staining (bottom left panels) indicates detection of
KV2.1 channel (Aa) and KV2.2 channel (Ba); after absorption of the primary antibody with a competing peptide (Ab
and Bb); and after the primary antibody was omitted and cells were incubated with the secondary antibody only
(2°Control) (Ac). Cell nuclei are shown in blue (top left panels); F-actin is shown in green (top right panels). The
merged images (bottom right) illustrate the overlap of all 3 images. Images were obtained via confocal microscope at
×63 and clearly demonstrate that the KV2 channel proteins were localized to the cell membrane. Data collected by Dr.
Muyan Chen.
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ScTx1-sensitivity of the whole cell KV current in human DSM cells
Our recent study revealed that KV2.1 and electrically silent KV channels sensitive to
ScTx1 are likely important regulators of guinea pig DSM excitability (77). Here, we went
one step further to evaluate the contribution of the KV2 channels sensitive to ScTx1 in
human DSM excitability. Whole cell voltage-clamp experiments were performed in the
presence of 200 nM iberiotoxin to eliminate the contribution of the BK current to the
total whole cell current. The average capacitance of the human DSM cells was 26.5 ± 6.1
pF (n = 4, N = 4). The cells were held at −70 mV, and then a 250-ms-long series of
potentials between −70 mV and +30 mV were applied in 10-mV increments, and then the
cells were repolarized back to −40 mV for another 250 ms. With increasing
depolarization of the membrane potential, the human DSM cells responded with gradual
increases of the whole cell current amplitude. Tail currents were recorded upon
repolarization back to −40 mV (Fig. 5.1.4). Under these experimental conditions, ScTx1
(100 nM) was applied to study the contribution of the ScTx1-sensitive current to the total
KV current in human DSM. The results showed that ScTx1 (100 nM) caused significant
inhibition of the whole cell current amplitude at positive voltages from +10 mV to +30
mV (n = 4, N = 4; P < 0.05; Fig. 5.1.4). The remaining whole cell current, after
application of the ScTx1, was probably determined by other types of KV channels.
Current-voltage relationships of the control current and ScTx1-insensitive current are
illustrated in Fig. 5.1.4B. Figure 5.1.4C represents the current-voltage relationship of the
ScTx1-sensitive current (n = 4, N = 4).
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Figure 5.1.4. Stromatoxin-1 (ScTx1) sensitivity of voltage-dependent whole cell KV current in freshly isolated
human DSM cells. A: representative recordings of whole cell outward KV currents elicited by a depolarizing voltage
step protocol (−70 mV to +30 mV in 10-mV increments) depicting the effect of ScTx1. ScTx1 (100 nM) significantly
decreased the voltage step-induced outward current in human DSM cells. ScTx1-sensitive current was obtained after
subtraction of the remaining ScTx1-insensitive current from the control current. B: current-voltage relationship in the
presence or absence of 100 nM ScTx1. ScTx1 (100 nM) significantly decreased the whole cell outward K V current in
human DSM cells (n = 4, N = 4; *P < 0.05). C: current-voltage relationship of the subtracted ScTx1-sensitive current in
human DSM cells (n = 4, N = 4). Values are means ± SE. All experiments were performed in the presence of the largeconductance Ca2+ activated K+ (BK) channel selective inhibitor iberiotoxin (200 nM). Data collected by Dr. Kiril
Hristov.
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Inhibition of ScTx1-sensitive KV2-containing channels increases intracellular Ca2+
levels

To determine the role of ScTx1-sensitive KV2-containing channels on the intracellular
Ca2+ levels, live-cell real-time Ca2+ imaging was carried out with fura-2. As shown in
Fig. 5.1.5, the intracellular Ca2+ level was significantly increased following application of
100 nM ScTx1 (Fig. 5.1.5A). Under control conditions, the fluorescence ratio (340/380
nM) was 0.84 ± 0.01 (n = 31, N = 7), and in the presence of 100 nM ScTx1, the
fluorescence ratio increased to 0.92 ± 0.01 (n = 31, N = 7; Fig. 5.1.5B). Intracellular Ca2+
level reached a plateau within 20 min following 100 nM ScTx1 application (Fig. 5.1.5A).
Thus, inhibition of ScTx1-sensitive KV2-containing channels increases intracellular Ca2+
levels in freshly isolated human DSM cells.
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Figure 5.1.5. ScTx1 increases the intracellular free Ca2+ level in freshly isolated human DSM cells. A: original trace
illustrating the increase in the intracellular free Ca2+ level following the application of 100 nM ScTx1. B: summary data
showing a significant increase in the intracellular free Ca2+ level after application of 100 nM ScTx1. This increase in
Ca2+ levels reached a plateau within the first 20 min following ScTx1 application. Values are means ± SE (n = 31, N =
7; *P < 0.05; **P < 0.01). Data collected by Mr. Qiuping Cheng.
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Role of ScTx1-sensitive KV2-containing channels in myogenic human DSM
contractions

ScTx1 was employed to investigate the potential functional role of KV2.1, KV2.2, and
KV2.1/9.3 channels in human DSM spontaneous phasic contractions. Blocking these KV
channels with ScTx1 (100 nM) significantly increased the DSM spontaneous phasic
contraction amplitude and force (Fig. 5.1.6). Within the first 10-min period after ScTx1
(100 nM) addition, the DSM spontaneous phasic contraction amplitude increased by 9.4
± 4.3% and muscle force integral increased by 19.8 ± 10.9% (n = 16, N = 11; P < 0.05;
Fig. 5.1.6). ScTx1 did not have any significant effects on the spontaneous phasic
contraction frequency, phasic contraction duration, and muscle tone (n = 16; N = 11; P >
0.05; Fig. 5.1.6).
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Figure 5.1.6. ScTx1 increases the amplitude and force of the spontaneous phasic contractions in human DSM
isolated strips. A: original DSM tension recordings illustrating the effect of ScTx1 (100 nM) on the spontaneous
phasic contractions of human DSM isolated strips. B: summary data showing significant increases in human DSM
spontaneous phasic contraction amplitude and force upon ScTx1 (100 nM) application. A 10-min period before ScTx1
application was taken as a control. The spontaneous contractions under control conditions were taken to be 100% and
data were normalized. The effect of ScTx1 was evaluated during the first 10 min following ScTx1 application. Values
are means ± SE (n = 16; N = 11; *P < 0.05). TTX (1 μM) was present throughout the experiments.
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Role of ScTx1-sensitive KV2 containing channels in nerve-evoked human DSM
contractions

In this experimental series, ScTx1 (100 nM) was employed to investigate the functional
implication of KV2.1, KV2.2, and KV2.1/9.3 channels inhibition on EFS-induced
contractions of human DSM strips (Fig. 5.1.7). ScTx1 (100 nM) significantly increased
the amplitude of the EFS-induced contractions at all stimulation frequencies ranging from
3.5 to 30 Hz (n = 24; N = 11; P < 0.05; Fig. 5.1.7). At 20 Hz EFS, ScTx1 (100 nM)
increased the amplitude of the EFS-induced contraction by 18.6 ± 4.7% (n = 24, N = 11;
P < 0.05; Fig. 5.1.7).
Collectively, these results suggest that KV2.1, KV2.2, and KV2.1/9.3 channels work to
oppose human DSM myogenic and nerve-evoked contractions.
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Figure 5.1.7. ScTx1 increases the amplitude of the electrical field stimulation (EFS)-induced contractions in
human DSM isolated strips. A: original traces of EFS-induced contractions (3.5–50 Hz) in the absence or presence of
100 nM ScTx1 illustrating an increase of the amplitude of the contractions following 100 nM ScTx1 application. As
illustrated, ScTx1 also induces spontaneous phasic contractions, consistent with the results illustrated in Fig. 6. B:
frequency-response curves showing a significant increase in the amplitude of the EFS-induced contractions following
application of ScTx1 (100 nM). The EFS-induced contraction amplitude at a stimulation frequency of 50 Hz under
control conditions was taken to be 100%. Values are means ± SE (n = 24, N = 11; *P < 0.05, **P < 0.01, ***P <
0.005).
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DISCUSSION
This study showed for the first time the expression and function of KV2-containing
channels sensitive to ScTx1 in native human DSM. Specifically, we used a
multidisciplinary experimental approach to demonstrate the expression of KV2.1 and
KV2.2 channel subunits and the electrically silent KV9.3 channel subunit as well as their
functional role in human DSM excitability and contractility.
Our RT-PCR experiments revealed mRNA expression of KV2.1, KV2.2, KV4.2, and KV9.3
channel subunits in whole human DSM tissue (Fig. 5.1.1). To avoid interference of
mRNA signals from other cell types such as neurons, fibroblasts, and interstitial cells, we
conducted single-cell RT-PCR experiments on freshly isolated human DSM cells. Unlike
RT-PCR experiments on whole human DSM tissue, single-cell RT-PCR experiments
revealed only the mRNA expression of KV2.1, KV2.2 and the electrically silent KV9.3
channel subunits (Fig. 5.1.1). These results indicated clearly that human DSM cells
express the KV2.1, KV2.2 and the silent KV9.3 channel subunits, but not KV4.2 channel
subunit. Furthermore, our Western blot experiments confirmed the expression of KV2.1
and KV2.2 channel subunits at the protein level (Fig. 5.1.2). Immunocytochemical
experiments also demonstrated the protein expression of KV2.1 and KV2.2 channel in
single human DSM cells and its cell membrane localization (Fig. 5.1.3). Although
expressed at mRNA level, detection of the electrically silent KV9.3 subunit protein was
not possible at this time because no selective KV9.3 antibody is commercially available to
further confirm KV9.3 protein expression. Thus, we conclude that human DSM expresses
KV2.1 and KV2.2 channel subunits, and at least mRNA of the electrically silent KV9.3
channel subunit.
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The next step was to investigate the role of KV2-containing channels in human DSM
excitability. Earlier studies conducted by conventional patch-clamp technique indicated
the presence of Ca2+ independent K+ current in human DSM cells, which was inhibited by
the nonselective KV channel blocker 3,4-diaminopyridine (36). Here, for the first time,
we provide electrophysiological data on KV2-containing channels in freshly isolated
human DSM cells, using the amphotericin-perforated patch-clamp technique in
physiological conditions with an intact intracellular environment. The main focus of our
patch-clamp experiments was to evaluate the contribution of KV2-containing channels
sensitive to ScTx1 in human DSM excitability. These experiments were performed
following inhibition of the BK channels with 200 nM iberiotoxin. Under such
experimental conditions the inhibitory effect of ScTx1 was significant at positive
voltages from +10 mV to +30 mV (Fig. 5.1.4B), corresponding to the peak of the action
potential in human DSM (57, 112). The results showed that ScTx1 significantly
decreased the amplitude of the whole cell KV current in human DSM cells (Fig. 5.1.4). At
more negative voltages, which correspond to the resting membrane potential in human
DSM, ScTx1 did not significantly inhibit the whole cell KV current. This observation
supports the concept that in human DSM cells KV2-containing channels most likely
contribute to the repolarization phase of the action potential, rather than the resting
membrane potential. The assumption that KV2 channels contribute to the repolarization
phase of the action potential is consistent with recent reports, which showed no effect of
ScTx1 on the resting membrane potential in guinea pig and mouse DSM (60, 77).
Collectively, the findings suggest that KV2-containing channels sensitive to ScTx1
contribute to human DSM excitability and are most likely involved in control of the

169

repolarization phase of the action potential in human DSM.
In human DSM, CaV-channels are responsible for the initiation of the action potential (57,
112). Here, we demonstrated that inhibition of the KV2-channels with ScTx1 significantly
increases the intracellular Ca2+ levels in freshly isolated human DSM cells (Fig. 5.1.5).
This increase of the intracellular Ca2+ is caused by inhibition of the ScTx1-sensitive KV2
channels and most likely subsequent activation of CaV channels in human DSM cells.
Our findings are supported by earlier studies showing that nonselective blockade of the
KV channel with 4-AP causes an inhibition of the slow after-hyperpolarization, and
increases the action potential frequency by activation of the CaV channels in human DSM
(57). These results indicate a functional role of KV2-containing channels in providing a
link between human DSM excitability, intracellular Ca2+ levels, and therefore
contractility in human DSM.
An increase in intracellular Ca2+ concentration is a key process required for activation of
DSM spontaneous contractions. Several studies have demonstrated the importance of
Ca2+ influx via CaV channels in the DSM contraction induced by muscarinic and
purinergic stimulation (7, 158, 162). DSM spontaneous phasic contractions are myogenic
in origin, and TTX (1 μM) does not affect these spontaneous phasic contractions (7, 60,
145). Our data were consistent with these previous reports. For the purpose of the current
study, we used TTX only as a precaution to block the transmission of the nerve impulses
within the autonomic nerves. Our studies on human DSM contractility reveal that ScTx1
significantly increased the spontaneous phasic contraction amplitude and force in human
DSM isolated strips, consistent with our previous findings in rat and guinea pig DSM (29,
77). However, ScTx1 did not cause any significant effect on spontaneous phasic

170

contraction frequency, phasic contraction duration, and muscle tone. In experimental
animals a burst of action potentials triggers a single phasic contraction (58). If a similar
mechanism operates in human DSM, one should expect that blocking of the K V2containing channel with ScTx1 would increase the frequency of the action potentials, and
therefore the amplitude of the phasic contraction without any effect on the phasic
contraction frequency.
Davies et al. (36) showed an increase in the amplitude of the spontaneous phasic
contractions of human DSM strips, without any effect on the phasic contraction
frequency or muscle tone following KV1 channel inhibition with correolide or agiotoxin2. Collectively, our data indicate that by decreasing membrane excitability, KV2containing channels also oppose human DSM spontaneous phasic contractions under
physiological conditions. Interestingly, ScTx1 had more profound effects on the
spontaneous phasic contractions in guinea pig as compared with human DSM (77). This
could be explained by the differential expression of the KV2-containing channels. Human
DSM expresses both KV2.1 and KV2.2 channels whereas guinea pig DSM expresses only
KV2.1 but not KV2.2 channels (77).
We studied the nerve-evoked contractions by stimulating the DSM nerves with EFS (Fig.
5.1.7). In both animal and human DSM, TTX (1 μM) completely eliminates the EFSinduced contractions (8, 29, 56, 60). The TTX-sensitivity confirms the neuronal origin
underlying the EFS-induced contractions. Our results also show that ScTx1 significantly
increases the amplitude of EFS-induced contractions over a range of stimulation
frequency from 3.5 to 30 Hz, indicating the functional role of these channels in human
DSM nerve-evoked contractions. This is consistent with our earlier animal studies (29,

171

77), and revealed that KV2-containing channels also work to oppose human DSM
contractility in response to excitatory neurotransmitters.
Phosphorylation of the KV2-containing channels is now recognized as a major means of
regulating their functional activity (84, 92). Our previous studies indicate a major role for
protein kinase A in DSM function (22, 79, 134). It is likely that phosphorylation of the
KV2-containing channels by protein kinase A also plays a role in regulating human DSM
function, but this topic requires further investigation.
The pathophysiology of OAB associated with detrusor overactivity is poorly understood,
and the current treatment is limited to antimuscarinics that have many adverse effects (8).
Therefore, a better understanding of the basic physiology of DSM is critical for
developing novel therapeutic approaches against OAB. Compelling lines of evidence by
our group and others have led us to now consider the KV2-containing channels as
promising pharmacological targets for some types of bladder dysfunctions. In rat and
guinea pig DSM, our laboratory has shown that pharmacological blockade of KV2containing channels with ScTx1 increased DSM contractility (29, 77). Other studies have
also shown that rat detrusor hyperreflexia was associated with a significant decrease in
KV2.1 channel mRNA levels (47). Therefore, mutations in KV2-containing channels
would be expected to cause bladder dysfunction.
The clinical significance of modulating the KV2-containing channels is twofold.
Targeting the KV2-containing channels with channel opening agents will reduce detrusor
overactivity and alleviate OAB. Alternatively, targeting KV2-containing channels with
selective inhibitors may have the potential for increasing DSM contractility, and thus
have clinical application for the treatment of some types of urinary retention due to
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detrusor underactivity. Moreover, increasing KV2 channels expression by genetic
manipulation can potentially reduce detrusor overactivity. To facilitate these novel
therapeutic approaches, we first need to better understand KV2-containing channel
expression, function, and regulation in human DSM. The present study has validated the
family of KV2-containing channels as important physiological regulators of human DSM
function. Importantly, such channels are potential pharmacological targets for the
treatment of some highly prevalent urological disorders such as OAB and/or some types
of urinary retention. Current pharmacological therapy for OAB consists of primarily
antimuscarinic therapy which has limited efficacy and is associated with considerable
side effects. Cholinergic agonists, the primary therapy for detrusor underactivity, have
almost no efficacy. The development of KV2-channel modulators would have potential
favorable effects on both of these conditions. However, development of such agents
would require some degree of selectivity for the lower urinary tract as KV2-containing
channel expression has been reported in some other smooth muscle tissues (3, 97, 135) as
well as some other human tissues such as pulmonary artery (42, 135), neurons (84), and
pancreatic delta cells (19). Thus, application of such agents for lower urinary tract
conditions may result in collateral effects elsewhere. Clinical trials of KV2-containing
channel modulators would need to be performed to validate such assumption and assess
the efficacy and therapeutic safety window.

CONCLUSION
In conclusion, ScTx1-sensitive KV2-containing channels are expressed in human DSM.
They control human DSM excitability, intracellular Ca2+ levels, and myogenic and nerve-
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evoked contractions. The KV2-containing channels may represent new targets for
pharmacological or genetic manipulation of human DSM. This study is a fundamental
basis for future investigation on human DSM tissues from patients with bladder
pathologies which may help reveal the role of KV2-containing channels in the etiology of
these bladder pathologies.

174

5.2 FUNCTIONAL IMPLICATIONS OF KV7 CHANNELS EXPRESSION IN
GUINEA PIG DETRUSOR SMOOTH MUSCLE CONTRACTILITY

ABSTRACT
There has been increasing interest in Kv7 channels targeting drugs for the treatment of
bladder dysfunctions since retigabine, a Kv7.2-7.5 channel activator normally prescribed
in the treatment of epilepsy was shown to also cause urinary retention. In the present
study, we examined the expression and functional roles of Kv7 channels in the detrusor
smooth muscle (DSM) of guinea pigs. Kv7 channels molecular expressions were
investigated using RT-PCR, qPCR, Western blot, and immunohistochemistry while their
functional roles were investigated using isometric DSM tension recordings and Kv7
channels modulators. In DSM isolated cells, we found that Kv7.1, Kv7.2, Kv7.3, and
Kv7.5 channels mRNA expression was relatively higher compared to the Kv7.4 channel
which was detected at non-physiological level. Immunohistochemical analysis revealed
protein expression for Kv7.1, Kv7.2, Kv7.3, and Kv7.5 channels but not the Kv7.4
channel in DSM cells. L-364373, a selective Kv7.1 channel activator and retigabine,
induced relaxation of spontaneous phasic contraction amplitude, muscle force, duration,
frequency, and muscle tone as well as the 10 Hz electrical field stimulation (EFS)induced contraction amplitude and muscle force of DSM isolated strips in a
concentration-dependent manner. Linopiridine and XE991, two Kv7 channel inhibitors,
increased the spontaneous phasic as well as the 10 Hz EFS-induced contractions
amplitude and muscle force of DSM isolated strips in a concentration-dependent manner.
On EFS-induced contractions generated by a wide range of stimulation frequency (0.5 –
50 Hz), we found that L-364373 (10 µM) and retigabine (10 µM) application decreased
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the contraction amplitude while XE991 (10 µM) application increased the contraction
amplitude. In summary, we revealed that among Kv7 channels, Kv7.1, Kv7.2, Kv7.3, and
Kv7.5 channels but not the Kv7.4 channel are expressed in guinea pig DSM cells and that
these channels regulate DSM spontaneous and nerve-evoked contractions.
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INTRODUCTION
The physiological roles of voltage-activated K+ (Kv) channels, one of the most diverse
K+ channel family, in the detrusor smooth muscle (DSM) of mammals is emerging. More
than 40 genes coding for Kv channels have been identified in the human genome (52,
53), however, information about the expression and the functional roles of Kv channels in
the DSM concerns only a fraction of these ion channels. In mouse and rat DSM,
molecular, electrophysiological, and functional studies have demonstrated the expression
and physiological roles of Kv2.1, Kv5.1, Kv6.1, Kv6.2, Kv6.3, Kv7.1, Kv7.4, and Kv7.5
channels (29, 36, 47, 122, 136, 148, 149, 155). In guinea pig DSM isolated cells, studies
suggest that Kv2.1, Kv6.2, Kv6.3, Kv8.2, Kv9.1, Kv9.2, and Kv9.3 channels are
expressed at the mRNA level and that only Kv2-containing channels are physiologically
active (74). Like in guinea pig DSM, the expression and physiological role of Kv
channels in humans DSM is only limited to Kv2-containing channels (74). In humans,
molecular evidence has confirmed the mRNA and protein expression of Kv2.1 and
Kv.2.2 channels only (74). Regardless of the type of Kv channel investigated in the DSM,
the general consensus suggest that activation of Kv channels hyperpolarizes the cell
membrane and diminishes DSM excitability and contractility while their inhibition causes
membrane depolarization and increase in DSM contractility via an elevation of
intracellular Ca2+ concentration (4, 29, 36, 47, 74, 118, 122, 136, 148, 149). In recent
years, retigabine, a third generation antiepileptic drug has become the focus of new
investigation for bladder dysfunction. Retigabine is a Kv7.2-7.5 channel activator which
is routinely prescribed to epileptic patients in order to restore physiological levels of
neuronal excitability which is abnormally elevated in those patients (51, 85, 123). In

177

addition to retigabine effects on the central nervous system, clinical studies have reported
that retigabine affects peripheral organs such as the urinary bladder by causing relaxation
of the DSM which in certain patients lead to urinary retention (21, 51, 85, 123). This
latter retigabine effect on the DSM has lead researchers to believe that Kv7 channels
targeting compounds such as retigabine could potentially be useful in the treatment of
overactive bladder (OAB), a pathophysiological condition which affects about 17% of the
American population (85, 147). The Kv7 channel is a subfamily of the Kv channel
family, and has five members or subtypes which are Kv7.1, Kv7.2, Kv7.3, Kv7.4, and
Kv7.5 channels. Structurally, Kv7 channels are composed of six transmembrane domains
and a pore loop forming one α-subunit that can assemble to form homo- or heterotetramer
channels (51-53). Unlike the Kv7.1 channel, Kv7.2, Kv7.3, Kv7.4, and Kv7.5 channels
possess a hydrophobic pocket outside the channel’s gate which allows allosteric binding
of their modulators (51). In the present study, we investigated the molecular (mRNA
messages and proteins) expression of all Kv7 channels subtypes (Kv7.1, Kv7.2, Kv7.3,
Kv7.4, and Kv7.5 channels) in the DSM of guinea pigs. We further used Kv7 channel
activators and blockers to determine whether the pharmacological modulation of Kv7
channels affects DSM spontaneous and nerve-evoked contractions. The overall objective
of this study was to investigate Kv7 channels expression and function in guinea pig DSM
and therefore assess whether Kv7 channels could be promising drug target for the
treatment of bladder dysfunctions.
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MATERIAL AND METHODS

Animal studies and DSM tissue harvesting

Animal experiments were conducted as described in chapter 2.2. For this study, we used
40 adult males Hartley-Albino guinea pigs, weighing on average 422.3±6.7 g.

DSM cells isolation and collection

Guinea pig DSM cells were isolated and collected as described in chapter 2.2.

RT-PCR and qPCR experiments

RT-PCR and qPCR experiments were conducted as previously described in chapter 2.2.
We used previously published guinea pig primers sequences for Kv7.1 – 7.5 channels
(116). The primers sequences and the size of the amplicon were as follows: Kv7.1- F: 5′ATTGTCCTGGTGGTGTTCTTTG-3′ and R: 5′-CCCCTGATGGCTGATGTGG-3′ (206
bp);

Kv7.2-

F:

5′-TCTACGCCACCAACCTGTC-3′

and

R:

5′-

TACATGGGCACCGTGACC-3′ (79 bp); Kv7.3- F: 5'-CTTGAAAACCGTCATCTGC3'

and

R:

5'-CAAGTTCACAGGGTCGTG-3'

(124

bp);

Kv7.4-

F:

5'-

CGATGTCATGCCTGCTGTG-3' and R: 5'-GGTGTCCTGCTGAATACTGC-3' (137
bp);

Kv7.5-

F:

5'-CGTCCGCACTCAGAAGTC-3'

TCCAATGTACCAGGCTGTG-3'

(137

bp);

and

GAPDH-

R:
F:

5'5′-

TACGACAAGTCCCTCAAGATTG-3′ and R: 5′-TCTGGGTGGCAGTGATGG-3′ (139
bp) (116). The parameters of the RT-PCR experiments were as follows: 5 min at 95 oC
then amplified by 35 cycles (95 oC for 30 s, 58 oC for 30 s, 72 oC for 30 s) followed by a
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5-min extension at 72 oC. The parameter of the qPCR experiments were as follows: Cycle
1, 95 oC for 3 min; cycle 2, 95 oC for 10 s then 58 oC for 30 s (repeated 40 times); cycle
3, 95 oC for 1 min; cycle 4, 58 oC for 1 min; cycle 5, 58 oC for 10 s with 0.5 oC increment
(repeated 81 times to generate a melting curve).

Western blot and immunohistochemistry

Our western blot and immunohistochemistry experiments were conducted as described in
chapter 2.2. We used the following primary antibodies: affinity-purified goat polyclonal
antibodies anti-KCNQ1 (Kv7.1) (1:100), anti-KCNQ2 (Kv7.2) (1:100), anti-KCNQ3
(Kv7.3) (1:100), anti-KCNQ4 (Kv7.4) (1:100), or anti-KCNQ5 (Kv7.5) (1:100) (Santa
Cruz Biotechnology, Inc., Santa Cruz, CA). For the western blot experiment, donkey
anti-goat IgG conjugated with horseradish peroxidase (diluted to 1:1,000) was used as a
secondary

antibody

while

Cy3-conjugated

anti-goat

IgG

(1:100)

(Jackson

ImmunoResearch, West Grove, PA) was the secondary antibody used in the
immunostaining experiments. Tissue sections were visualized under a confocal
microscope LSM 700 META (Carl Zeiss, Germany) 63X objective.

Isometric DSM tension recordings

Isometric DSM tension recordings experiments are described in chapter 2.2. We activated
Kv7 channels by applying increasing concentrations of L-364373 (100 nM – 100 μM), a
selective Kv7.1 channel agonist or retigabine (100 nM – 100 μM), a Kv7.2 – 7.5 channel
agonist at 10-min intervals. We also evaluated DSM spontaneous phasic contractions
responses to Kv7 channels blockade with XE991 (100 nM – 30 μM), a Kv7.1 – 7.5
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channel blocker; or linopiridine (100 nM – 30 μM), another Kv7.1 – 7.5 channel
antagonist. In DSM strips which exhibited spontaneous phasic contraction amplitude less
than 0.1 g, contractions were induced by electrical field stimulation (EFS) and TTX (1
µM) was not added since TTX effectively suppresses EFS-induced contractions. On the
10 Hz EFS-induced contractions, increasing concentrations (100 nM – 100 μM) of Kv7
channel activators and inhibitors were applied as described above. On the 0.5 – 50 Hz
EFS-induced contractions, a single concentration of Kv7 channel modulator was applied.

Solutions and drugs
The Ca2+-free dissection solution and the Ca2+-containing PSS composition are provided
in chapter 2.2. L-364373, retigabine, XE991, and linopiridine were purchased from
Tocris Bioscience (Bristol, UK). Stock solutions of L-364373, retigabine, and XE991
were prepared daily in dimethyl sulfoxide (DMSO). The final DMSO concentration in
the bath was not greater than 0.1%. Linopiridine was also prepared daily and dissolved in
double-distillated water.

Data analysis and statistics

Data analysis and statistics were performed as described in chapter 2.2.

181

RESULTS
Detection and relative expression level of mRNA messages for Kv7.1, Kv7.2, Kv7.3,
Kv7.4, and Kv7.5 channels in guinea pig DSM

We conducted RT-PCR and qPCR experiments on guinea pig DSM tissue and a poll of
isolated DSM cells to investigate Kv7 channels mRNA expressions. We used guinea pig
brain as a positive control since previous studies have established that all Kv7 channel
isoforms are expressed in guinea pig brain at the mRNA level (116). The RT-PCR
experiments revealed mRNA expression for all Kv7 channel isoforms in guinea pig
whole DSM tissue (N=4; Fig. 5.2.1A). Next, we conducted RT-PCR experiments on
guinea pig DSM freshly isolated single cells to confirm that the mRNA messages
detected in the whole DSM tissue originated from DSM cells but not from other nonDSM cell types such as neurons, fibroblasts, vascular, and endothelial cells present
within the DSM layers (1, 78, 127, 143, 165). Unlike whole DSM tissue, our RT-PCR
analysis on guinea pig DSM isolated single cells showed mRNA expression for all Kv7
channel isoforms except the Kv7.4 channel (N=4; Fig. 5.2.1A). RT-PCR experiments
were conducted on DSM cDNAs equivalent to 100 ng of starting mRNA. Negative
control experiments performed in the absence of the reverse transcriptase (-RT)
demonstrated an absence of genomic DNA contamination. Following the RT-PCR
experiments, we conducted qPCR analysis to determine the relative mRNA expression
level for each Kv7 channel isoform in guinea pig DSM whole tissue and isolated single
cells. In whole DSM tissue, we found that Kv7 channel isoforms relative mRNA level
was as follows: Kv7.1 ≈ Kv7.2 > Kv7.3 ≈ Kv7.5 > Kv7.4 (N=4; p<0.05; Fig. 5.2.1B).
When qPCR analysis was performed on a poll of isolated DSM cells, the relative mRNA
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level for Kv7 channel isoforms was as follows: Kv7.1 ≈ Kv7.2 > Kv7.5 > Kv7.3 ≈ Kv7.4
(N=4; p<0.05; Fig. 5.2.1B). These latter single-cell qPCR experiments confirmed the
previous RT-PCR data and further suggest that the Kv7.1, Kv7.2, Kv7.3, and Kv7.5 are
highly expressed at the mRNA level, whereas the Kv7.4 channel may not be
physiologically expressed in guinea pig DSM cells.

Figure 5.2.1. Kv7 channels mRNA expression in guinea pig DSM. A) Gel electrophoresis images illustrate RTPCR detection of all Kv7 channel subtypes including Kv7.1, Kv7.2, Kv7.3, Kv7.4, and Kv7.5 mRNA messages in
whole DSM tissue (N=4). At the DSM single cell level, unlike other Kv7 channel isoforms (Kv7.1, Kv7.2, Kv7.3, and
Kv7.5), the Kv7.4 channel mRNA message was not detected. Guinea pig brain was used as a positive control. No
product was observed in the negative controls (-RT) in which reverse transcriptase was not added to the reaction. B)
qPCR analysis show relatively low Kv7.4 channel mRNA expression in both DSM whole tissue (N=4) and DSM single
cells (N=4). Data were normalized to GAPDH using the ΔCt method. Ct values are expressed as mean ± SE.
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Guinea pig DSM cells express Kv7.1, Kv7.2, Kv7.3, and Kv7.5 but not Kv7.4
channel proteins

To assess whether the Kv7 channels previously found at the mRNA level using RT-PCR
experiments were also expressed at the protein level, we performed both Western blot
and immunostaining analysis on guinea pig whole DSM tissue. Western blot and
immunostaining analysis were performed using specific antibodies against each Kv7
channel isoform. Our Western blot data revealed that all Kv7 channel isoforms including
Kv7.1, Kv7.2, Kv7.3, Kv7.4, and Kv7.5 channels proteins are expressed in guinea pig
whole DSM tissue (N=3; Fig. 5.2.2) consistently with the RT-PCR data in guinea pig
whole DSM tissue (Fig. 5.2.1A).

Figure 5.2.2. Detection of Kv7.1, Kv7.2, Kv7.3, Kv7.4, and Kv7.5 channels protein expression in guinea pig
whole DSM tissues by the Western blot technique. The expected molecular weight (MW) for all Kv7 channels
isoforms including Kv7.1 (75 kDa), Kv7.2 (90 kDa), Kv7.3 (77 kDa), Kv7.4 (77 kDa), and Kv7.5 (99 kDa) channels
was confirmed by the use of a protein ladder. Experiments were conducted in 3 separate Western blot reactions using
protein isolated from 3 guinea pig whole DSM
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Immunohistochemical experiments were performed to determine whether these Kv7
channel proteins were localized in DSM cells. We used α smooth muscle actin antibody
(ab21027, Abcam) to specifically stain DSM cells as previously published (143). We
found protein expression for Kv7.1, Kv7.2, Kv7.3, and Kv7.5 channels in guinea DSM
(Fig. 5.2.3). However, we did not detect protein expression for Kv7.4 channel in guinea
pig DSM cells (Fig. 5.2.4) consistent with our single-cells RT-PCR data (N= 3; Fig.
5.2.1A). The specificity of every Kv7 channel isoform antibody was tested by incubating
the primary antibody with its competing peptide (Fig. 5.2.5).
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Figure 5.2.3. Confocal images illustrate Kv7.1 (A), Kv7.2 (B), Kv7.3 (C), and Kv7.5 (D) channels protein
expression in mucosa-free guinea pig whole DSM tissue.
Kv7 channels proteins were detected by
immunohistochemical reaction using channel’s specific antibodies. In all panels, α smooth muscle actin is shown in
green; cells’ nuclei are shown in blue; the specific Kv7 channel subtype protein expression is represented by the red
staining. The merged images of α smooth muscle actin, nuclei, and the Kv7 channel’s protein expression are illustrated
in quadrant labeled “Merge”. Images were captured with a Carl Zeiss LSM 700 META confocal microscope (63x
objective). Experiments were conducted on tissue samples isolated from 3 different guinea pigs.
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Figure 5.2.4. Confocal images illustrate the lack of Kv7.4 channel protein detection in guinea pig DSM tissue. α
smooth muscle actin is shown in green; Cells’ nuclei are shown in blue; the absence of red staining confirm that Kv7.4
was not detected. The merged images of α smooth muscle actin and nuclei are illustrated in quadrant labeled “Merge”.
Images were captured with a Carl Zeiss LSM 700 META confocal microscope (63x objective). Experiments were
conducted on tissue samples isolated from 3 different guinea pigs.
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Figure 5.2.5. Confocal images illustrate the lack of protein detection in the presence of competing peptides
confirming the specificity of the primary antibody for Kv7.1 (A), Kv7.2 (B), Kv7.3 (C), and Kv7.5 (D) channels
protein, respectively. In all panels, α smooth muscle actin is shown in green; Cells’ nuclei are shown in blue; the
absence of red staining confirm the successful block of the primary antibody by its competing peptide. The merged
images of α smooth muscle actin and nuclei are illustrated in quadrant labeled “Merge”. Images were captured with a
Carl Zeiss LSM 700 META confocal microscope (63x objective). Experiments were conducted on tissue samples
isolated from 3 different guinea pigs.
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Pharmacological activation of Kv7 channels causes relaxation of spontaneous phasic
and tonic contractions of guinea pig DSM isolated strips

We investigated the spontaneous phasic and tonic contractions responses to Kv7 channels
activation with L-364373, a selective Kv7.1 channel agonist, and retigabine, a Kv7.2-7.5
channel agonist in guinea pig DSM isolated strips. We found that L-364373 (100 nM –
100 μM) effectively decreased the spontaneous phasic and tonic contractions of guinea
pig DSM isolated strips (Fig. 5.2.6). Our data showed that L-364373 (100 nM – 100 μM)
attenuated the spontaneous phasic contractions amplitude, muscle force, frequency,
duration, and muscle tone of guinea pig DSM isolated strips in a concentration-dependent
manner (n=7, N=4; Fig. 5.2.6B and Table 5.2.1).

189

Figure 5.2.6. L-364373, a selective Kv7.1 channel activator causes relaxation of spontaneous phasic contraction
amplitude, muscle force, frequency, duration, and muscle tone in guinea pig DSM isolated strips. A) This original
DSM tension recording illustrates L-364373 (100 nM – 100 µM) relaxant effect on spontaneous phasic contractions of
DSM isolated strips in a concentration-dependent manner. B) Cumulative concentration-response curves showing
significant reduction in DSM spontaneous phasic contraction amplitude, muscle force, frequency, duration, and muscle
tone following L-364373 application. The 5-min control period prior to L-364373 addition was taken to be 100 % and
data were normalized (n=7, N=4). TTX (1 µM) was present throughout the experiments.
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Compound

Amplitude

Muscle Force

Frequency

Duration

Muscle tone

L-364373

4.8 (2.0 - 11.7)
µM
16.0 ± 6.8%

4.1 (1.2 - 13.9)
µM
13.2 ± 6.0%

N/A
46.4 ± 12.2%

N/A
46.8 ± 12.7%

N/A
54.4 ± 7.7%

Retigabine

2.3 (1.4 – 3.5) µM
0.7 ± 0.7%

XE991

4.5 (0.4 – 54.6)
µM
212.9 ± 42.2%

2.1 (1.3 – 3.4)
µM
0.2 ± 0.2%
2.3 (0.1 – 49.3)
µM
233.3 ± 66.2%

14.0 (4.3 – 46.1)
µM
11.2 ± 11.2%
No effect

8.7 (5.6 – 13.4)
µM
0.4 ± 0.4%
No effect

3.5 (0.1–17.3)
µM
76.4 ± 14.9%
No effect

Linopiridine

11.5 (1.0 – 127.0)
µM
415.1 ± 75.9%

10.7 (0.9 –
132.5) µM
415.1 ±
110.4%

No effect

No effect

No effect

Table 5.2.1. IC50 values and maximum effects of Kv7 channels modulators on spontaneous phasic and tonic
contractions of guinea pig isolated strips. IC50 values (in µM) are reported as means (95% confidence interval);
Maximum inhibition values for L-364373 and retigabine were determined at concentrations equal to 100 μM.
Maximum increase values for XE991 and linopiridine were determined at concentrations equal to 30 μM.
Values are reported as percentages of means ± SEM in comparison to control condition (taken to be 100%).
N/A = not applicable.
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In comparison to L-364373, retigabine had a more pronounced effect on DSM
spontaneous phasic and tonic contractions. Retigabine (100 nM – 100 μM) inhibited the
spontaneous phasic contraction amplitude, muscle force, frequency, duration, and muscle
tone of guinea pig DSM isolated strips in a concentration-dependent manner (Fig. 5.2.7).
At the maximal concentration of 100 μM, retigabine almost completely abolished the
phasic contractions amplitude, muscle force, frequency, and duration while the effect on
muscle tone was less pronounced (n=7, N=6, Fig. 5.2.7B and Table 5.2.1). Table 5.2.1
shows the different IC50 values for L-364373 and retigabine effects on guinea pig DSM
isolated strips spontaneous phasic contractions amplitude, muscle force, frequency,
duration, and muscle tone. These results suggest that Kv7 channels activation leads to
inhibition of the spontaneous phasic and tonic contractions in guinea pig DSM isolated
strips.
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Figure 5.2.7. Retigabine, a Kv7.2 – 7.5 channel activator causes relaxation of spontaneous phasic contraction
amplitude, muscle force, frequency, duration, and muscle tone in guinea pig DSM isolated strips. A) This original
DSM tension recording illustrates retigabine (100 nM – 100 µM) inhibitory effect on spontaneous phasic contractions
of DSM isolated strips in a concentration-dependent manner. B) Cumulative concentration-response curves showing
significant reduction in DSM spontaneous phasic contraction amplitude, muscle force, frequency, duration, and muscle
tone following retigabine application. The 5-min control period prior to retigabine addition was taken to be 100 % and
data were normalized (n=7, N=6). TTX (1 µM) was present throughout the experiments.
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Pharmacological blockade of Kv7 channels enhances spontaneous phasic and tonic
contractions of guinea pig DSM isolated strips

We investigated the effects of pharmacological inhibition of Kv7 channels on
spontaneous phasic and tonic contractions of DSM isolated strips. We used XE991 and
linopiridine, two Kv7.1-7.5 channel antagonists. We found that XE991 (100 nM – 30
μM) enhanced the spontaneous phasic contraction amplitude and muscle force of DSM
isolated strips in a concentration-dependent manner without statistically significant
effects on contraction frequency, duration, and muscle tone (Fig. 5.2.8A-B). At the
maximal concentration of 30 μM, XE991 effects on the spontaneous phasic contractions
amplitude and force compared to control were 212.9±42.2 % and 233.3±66.2%,
respectively (n=8, N=5, Fig. 5.2.8B and Table 5.2.1). We found that pharmacological
blockade of Kv7 channels with linopiridine (100 nM – 100 μM) also increased phasic
contraction amplitude and muscle force in a concentration-dependent manner (Fig.
5.2.8C-D). At the maximal concentration of 30 μM, linopiridine effects on the
spontaneous phasic contraction amplitude and muscle force compared to control were
415.1±75.9% and 415.0±110.4%, respectively (n=7, N=5, Fig. 5.2.8D and Table 5.2.1).
Table 5.2.1 shows the different IC50 values for XE991 and linopiridine effects on
spontaneous phasic contractions amplitude and muscle force of DSM isolated strips.
These data suggest that Kv7 channels blockade enhances the spontaneous phasic
contractions in guinea pig DSM isolated strips.
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Figure 5.2.8. XE991 and linopiridine, two Kv7.1 – 7.5 channel blockers increase spontaneous phasic contraction
amplitude and muscle force in guinea pig DSM isolated strips. Original DSM tension recordings illustrate that
XE991 (100 nM – 30 µM) (A) and linopiridine (100 nM – 30 µM) (C) application enhance spontaneous phasic
contractions in guinea DSM isolated strips in a concentration-dependent manner. Cumulative concentration-response
curves show significant increase in DSM spontaneous phasic contractions amplitude and muscle force following
XE991 (B; n=8, N=5) and linopiridine (D; n=7, N=5) application. The 5-min control period prior to XE991 or
linopiridine addition was taken to be 100 % and data were normalized. TTX (1 µM) was present throughout the
experiments.

195

Pharmacological activation of Kv7 channels inhibits EFS-induced contractions of
guinea pig DSM strips in a concentration-dependent manner

We investigated the effects of L-364373 and retigabine on the amplitude, muscle force,
duration, and muscle tone of EFS-induced DSM contractions generated by 10 Hz/min
EFS in DSM isolated strips. We found that L-364373 attenuated 10 Hz EFS-induced
contractions of DSM isolated strips in a concentration-dependent manner (Fig. 5.2.9AB). L-364373 (100 nM-100 µM) decreased the amplitude and muscle force of the 10 Hz
EFS-induced contractions without any significant effect on contraction duration and
muscle tone (n=6, N=4; Fig. 5.2.9B and Table 5.2.2). Similarly to L-364373 effect,
retigabine (100 nM–100 µM) also decreased the 10 Hz EFS-induced contraction
amplitude and muscle force in a concentration-dependent manner (Fig. 5.2.9C-D). At
higher concentrations, retigabine was more effective than L-364373 at reducing the
amplitude and muscle force of the 10 Hz EFS-induced contractions of DSM isolated
strips since retigabine (100 µM) completely inhibited the amplitude and muscle force of
the 10 Hz EFS-induced contractions (n=9, N=8; Fig. 5.2.9D and Table 5.2.2). These data
suggest that pharmacological activation of Kv7 channels attenuates nerve-evoked
contractions in guinea pig DSM isolated strips.
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Figure 5.2.9. Kv7 channels activation with L-364373 or retigabine reduces the 10 Hz EFS-induced contractions
in guinea pig DSM isolated strips. Original DSM tension recordings illustrate L-364373 (100 nM – 100 µM) (A) and
retigabine (100 nM – 100 µM) (C) inhibitory effects on DSM 10 Hz EFS-induced contractions, respectively.
Cumulative concentration-response curves show that L-364373 (B; n=6, N=4) and retigabine (D; n=9, N=8) attenuate
guinea pig DSM 10 Hz EFS-induced contraction amplitude and muscle force in a concentration dependent-manner.
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Compound

Amplitude

Muscle force

Duration

Muscle tone

L-364373

23.1 (8.7 – 61.2)
µM
28.0 ± 6.0%
9.7 (6.9 – 13.9)
µM
1.0 ± 0.7%
0.6 (0.1 – 5.6)
µM
155.3 ± 16.4%
N/A
144.0 ± 20.1%

24.9 (7.3 –
84.3) µM
37.2 ± 10.7%
10.1 (6.7 –
15.1) µM
0.3 ± 0.2%
1.4 (0.2 – 9.8)
µM
180.5 ± 24.2%
N/A
130.1 ± 13.1%

No effect

No effect

No effect

No effect

No effect

No effect

No effect

No effect

Retigabine

XE991

Linopiridine

Table 5.2.2. IC50 values and maximum effects of Kv7 channels modulators on 10 Hz EFS induced contractions
of guinea pig isolated strips. IC50 values (in µM) are reported as means (95% confidence interval); Maximum
inhibition values for L-364373 and retigabine were determined at concentrations equal to 100 μM. Maximum increase
values for XE991 and linopiridine were determined at concentrations equal to 30 μM. Values are reported as
percentages of means ± SEM in comparison to control condition (taken to be 100%). N/A = not applicable.
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Pharmacological blockade of Kv7 channels increases EFS-induced contractions of
guinea pig DSM strips in a concentration-dependent manner: We used XE991 and
linopiridine, two Kv7 channel blockers to assess the change in 10 Hz EFS-induced
contractions in guinea pig DSM isolated strips upon Kv7 channels blockade. The data
showed that XE991 (100 nM–30 µM) effectively enhanced the amplitude and muscle
force of the 10 Hz EFS-induced contractions of guinea pig DSM isolated strips in a
concentration-dependent manner (Fig. 5.2.10A-B). At the maximal concentration of 30
μM, XE991 effects on the 10 Hz EFS-induced contractions amplitude and muscle force
compared to control were 155.3±16.4% and 180.5±24.2%, respectively (n=9, N=7, Fig.
5.2.10B and Table 5.2.2). We also found that similarly to XE991, linopiridine (100 nM–
30 µM) also increased guinea pig DSM isolated strips 10 Hz EFS-induced contraction
amplitude and muscle force in a concentration-dependent manner (n=6, N=5; Fig.
5.2.10C-D and Table 5.2.2). At the maximal concentration of 30 μM, linopiridine effects
on the 10 Hz EFS-induced contraction amplitude, force, and muscle tone compared to
control were 144.0±20.1%, 130.1±13.1%, and 159.3±28.6%, respectively (n=6, N=5,
Fig. 5.2.10D and Table 5.2.2). These data suggest that pharmacological blockade of Kv7
channels enhances nerve-evoked contractions in guinea pig DSM isolated strips.
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Figure 5.2.10. Kv7.1 – 7.5 channels blockade with XE991 or linopiridine increases the 10 Hz EFS-induced
contractions in guinea pig DSM isolated strips. The original DSM tension recordings illustrate that XE991 (100 nM
– 30 µM) (A) and linopiridine (100 nM – 30 µM) (C) enhance guinea pig DSM 10 Hz EFS-induced contractions.
Cumulative concentration-response curves show that XE991 (B; n=9, N=7) and linopiridine (D; n=6, N=5) increases
DSM 10 Hz EFS-induced contraction amplitude and muscle force in a concentration dependent-manner.
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Activation of Kv7 channels with retigabine and L-364373 decreases the amplitude of
the EFS-induced DSM contractions in a wide range of stimulation frequencies
We addressed how activation of Kv7 channels modulates DSM nerve-evoked
contractions in response to a wide range of EFS frequencies in guinea pig DSM isolated
strips. We first applied increasing EFS frequencies (0.5–50 Hz) as a control protocol,
followed by the addition of a single concentration of L-364373 (10 µM) or retigabine (10
μM) (Fig. 5.2.11 A-B). Then, a second EFS protocol was applied to evaluate the
compound effects on the EFS-induced contractions. We found that in guinea pig DSM
isolated strips, L-364373 (10 µM) inhibited the 0.5 – 50 Hz EFS-induced contractions. L364373 (10 µM) significantly attenuated the amplitude of the EFS-induced contractions
at stimulation frequencies ranging between 7.5 and 50 Hz (n=7, N=4, p<0.05; Fig.
5.2.11A). At the maximum EFS frequency of 50 Hz, L-364373 (10 µM) reduced the
contraction amplitude to 67.3±4.8% in comparison to control (n=7, N=4; p<0.05; Fig.
5.2.11A). Retigabine (10 µM) significantly decreased the amplitude of the EFS-induced
contractions at stimulation frequencies ranging between 12.5 and 50 Hz (n=6, N=4,
p<0.05; Fig. 5.2.11B). At the maximum EFS frequency of 50 Hz, retigabine (10 µM)
reduced the contraction amplitude to 76.4±10.8% in comparison to control (taken to be
100%) (n=6, N=4; p<0.05; Fig. 5.2.11B). These data suggest that activation of Kv7
channels reduces guinea pig DSM nerve-evoked contractions induced by EFS at a wide
range of stimulation frequencies.
Kv7 channels inhibition with XE991 increases the amplitude of the 0.5 – 50 Hz EFSinduced DSM contractions: XE991, a Kv7.1-7.5 channel blocker was used to
investigate nerve-evoked contractions responses to Kv7 channel blockade. We employed
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the same experimental approach as described above for the Kv7 channel activators (Fig.
5.2.11A-B). The data showed that in DSM isolated strips, XE991 (10 µM) significantly
increased the amplitude of the EFS-induced contractions at stimulation frequencies
ranging between 5.0 and 20 Hz (n=8, N=5, p<0.05; Fig. 5.2.11C). The maximum
increase in the amplitude of the EFS-induced contraction was observed at 12.5 Hz
frequency where XE991 (10 µM) increased the contraction amplitude by ~20% (n=8,
N=5; p<0.05; Fig. 5.2.11C). These data suggest that inhibition of Kv7 channels enhances
guinea pig DSM nerve-evoked contractions induced by EFS at a wide range of
stimulation frequencies.

Figure 5.2.11. Effects of Kv7 channel modulators on the 0.5 – 50 Hz EFS-induced contractions in guinea pig
DSM isolated strips. Original DSM tension recordings and frequency-response curves illustrate L-364373 (A; n=7,
N=4) and retigabine (B; n=6, N=4) inhibitory effect on the 0.5 – 50 Hz EFS-induced contractions amplitude. C)
Original DSM tension recordings and frequency-response curves reveal that XE991 enhances the 0.5 – 50 Hz EFSinduced contraction amplitude (n=8, N=5). The maximal EFS-induced contraction amplitude at a stimulation frequency
of 50 Hz under control conditions was taken to be 100 % and the contractions were normalized (*p<0.05, **P<0.01,
***P<0.005).
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DISCUSSION
The present study reveals that Kv7.1, Kv7.2, Kv7.3, and Kv7.5 channels are expressed at
both mRNA and protein levels in guinea pig DSM cells. Additionally, we demonstrate
that these channels are functional as evidenced by the decrease in DSM contractility upon
channels activation with L-364373 and retigabine; and the increase in DSM contractility
when Kv7 channels were blocked by XE991 or linopiridine. The lack of Kv7.4 channel
expression in guinea pig DSM cells at both mRNA and protein level further suggest that
the observed changes in DSM contractility subsequent to various Kv7 channels
modulators application were mediated via the other Kv7 channel isoforms (Kv7.1, Kv7.2,
Kv7.3, and Kv7.5) but not the Kv7.4 channel.
Our RT-PCR experiments performed on a poll of enzymatically-isolated guinea pig DSM
cells demonstrate the mRNA expression of Kv7.1, Kv7.2, Kv7.3, and Kv7.5 channels but
not the Kv7.4 channel. Further qPCR experiments validated the RT-PCR findings since
the relative mRNA message expression of the Kv7.4 channel was extremely low
compared to the others Kv7 channel subtypes. These two experimental series combined
suggest that in the guinea pig DSM cells, only Kv7.1, Kv7.2, Kv7.3, and Kv7.5 channels
are expressed at the mRNA level. The Kv7 channels mRNA expression pattern that we
revealed in the present study is slightly different from previous studies in rat DSM where
only Kv7.4, Kv7.5, and arguably Kv7.1 channels are suggested to be expressed at the
mRNA level (121, 149). The protein expression of Kv7.1, Kv7.2, Kv7.3, and Kv7.5
channels in guinea pig DSM cells was further demonstrated via immunostaining. Using a
specific antibody against each Kv7 channel isoform, α smooth muscle marker, and a
confocal microscope, we demonstrated Kv7.1, Kv7.2, Kv7.3, and Kv7.5 channels protein
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expression in guinea pig DSM cells. Consistently with the single-cell RT-PCR and qPCR
data, we find no protein expression for the Kv7.4 channel in guinea pig DSM cell using
immunostaining approach suggesting that only the Kv7.1, Kv7.2, Kv7.3, and Kv7.5
channels are expressed in guinea pig DSM cells at the protein level. In absolute contrast
to the Kv7 channel protein expression pattern in guinea pig DSM cell, Svalo et al. have
found that in rat DSM, only the Kv7.4 channel protein was expressed, outlining important
species differences (149). Our findings represent the first molecular evidence for Kv7
channels expression in guinea pig DSM.
Next, we investigated the physiological roles of these Kv7 channels in the DSM of
guinea pigs. In most mammals including guinea pigs, the micturition process comprises a
filling and a voiding phase. During the filling phase, the DSM appears relaxed allowing
the bladder to store large amount of urine while during the voiding phase, the DSM
contracts forcefully to expel the stored urine (7, 15, 130). K+ channels have been
demonstrated to be involved in both phases of the micturition process. Studies suggest
that during the filling phase, K+ channels remain opened causing cell membrane
hyperpolarization and therefore limiting Ca2+ influx via L-type Cav channels (7, 15, 130).
The low intracellular Ca2+ level is responsible for keeping the DSM in a relaxed state.
However, during the voiding phase, K+ channels are closed causing cell membrane
depolarization; L-type Cav channels become activated and opened to allow influx of Ca2+.
The increase of intracellular Ca2+ concentration will further lead to DSM contraction (7,
15, 130). Our study reports that pharmacological activation of Kv7 channels with L364373 and retigabine relaxes guinea pig DSM spontaneous phasic and tonic
contractions. We also report that Kv7 channels blockade with XE991 or linopiridine
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increases DSM spontaneous phasic contractions. Therefore, our findings suggest that Kv7
channels are major regulators of guinea pig DSM contractility and that Kv7 channels are
involved in both phases of the micturition process. Our findings are in line with previous
reports which demonstrated that intravesical administration of retigabine increased
micturition volume and voiding intervals in freely moving conscious rats (148). In
conscious rats with capsaicin-induced irritated bladders, retigabine was shown to strongly
reduce bladder rings contractility, reduce bladder pressure, and delay voiding, plus the
retigabine effect on bladder rings was blocked by XE991 (149).
Kv7 channels regulatory roles on neurogenic contractions were also addressed in our
study. It is well-established that DSM contractions also have neurogenic origins. In
mouse, rat, guinea pig, and human, DSM contractions can be initiated by the combined
action of acetylcholine and ATP, two major excitatory neurotransmitters released from
the parasympathetic nerves (59, 64, 161). ATP activates P2X receptors while
acetylcholine stimulates M2/M3 muscarinic receptors to induce DSM contractions (24,
59, 64, 105, 119, 161). We found that Kv7 activation with L-364373 and retigabine
decreased the amplitude and muscle force of the guinea pig DSM EFS-induced
contractions in a concentration-dependent manner. Neurogenic contractions were
generated by EFS frequency of 10 Hz/min. We also found that pharmacological blockade
of Kv7 channels with XE991 or linopiridine enhanced DSM 10 Hz EFS-induced
contractions amplitude and muscle force in a concentration-dependent manner. Therefore
our data suggest that Kv7 channels play an important regulatory role in guinea pig DSM
neurogenic contractions. The retigabine effect on EFS-induced contractions reported in
our study is somehow similar to previous studies in rats DSM (136). The aforementioned
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study reported that retigabine (1 – 30 μM) inhibited EFS-induced contraction amplitude
generated by 20 Hz in a concentration-dependent manner (136). The authors also
reported that the retigabine relaxant effects on the EFS-induced contractions were
antagonized by 10 μM XE991 suggesting that Kv7 channels, more precisely Kv7.4 and
Kv7.5 channels, regulate rat DSM neurogenic contractions since only Kv7.4 and Kv7.5
but not Kv7.1, Kv7.2, and Kv7.3 channels were present at the mRNA level in rat bladder
(121, 136).
We also found that Kv7 channel regulate both the cholinergic and the purinergic
components of the guinea pig DSM EFS-induced contractions. Studies have
demonstrated that at EFS frequencies ≤ 20 Hz, the purinergic (ATP) pathway plays a
greater role whilst at EFS frequencies ≥ 20 Hz, the cholinergic (acetylcholine) component
predominates (64, 161). Our data showed that L-364373 (10 μM) and retigabine (10 μM)
inhibited the 0.5 – 50 Hz EFS-induced contraction amplitude while XE991 (10 μM)
application enhanced the 0.5 – 50 Hz EFS-induced contraction amplitude. The ability of
these Kv7 channels modulators to affect guinea pig DSM EFS-induced contractions (0.5
– 50 Hz) commands that Kv7 channels control the purinergic and the cholinergic
components of the neurogenic contractions in guinea pig DSM.
CONCLUSION
In summary, our study reveals that Kv7 channels are major regulators of guinea pig DSM
physiology as evidenced by their ability to control spontaneous phasic and EFS-induced
contractions. The changes in guinea pig DSM contractility observed after application of
various Kv7 channels modulators were mediated via Kv7.1, Kv7.2, Kv7.3, and Kv7.5
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channels but not Kv7.4 channel since our molecular data showed mRNA and protein
expression for Kv7.1, Kv7.2, Kv7.3, and Kv7.5 channels but not Kv7.4 channel in guinea
pig DSM cells. Kv7 channels could therefore represent promising drug targets for the
treatment of bladder dysfunctions.
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5.3. MOLECULAR AND FUNCTIONAL CHARACTERIZATION OF KV7
CHANNELS IN HUMAN DETRUSOR SMOOTH MUSCLE

OBJECTIVES
In the previous section (chapter 5.2), we examined the expression and functional roles of
Kv7 channels in the detrusor smooth muscle (DSM) of guinea pigs using RT-PCR,
qPCR, Western blot, immunohistochemistry and isometric DSM tension recordings
approaches. We found that among Kv7 channels, Kv7.1, Kv7.2, Kv7.3, and Kv7.5
channels but not the Kv7.4 channel were expressed at both mRNA and protein level in
guinea pig DSM cells. We also found that their pharmacological activation with L364373 and retigabine or their inhibition with XE991 and linopiridine affected DSM
spontaneous and nerve-evoked contractions suggesting that these channels play a key role
in guinea pig DSM contractility. We therefore proposed that Kv7 channels could
represent promising drug targets for the treatment of bladder dysfunctions. In the present
section, we went a step further by testing our hypothesis in humans. Given that human is
the ultimate subject of study and that animal findings cannot always been translated into
humans because of species differences, here, we investigated the expression and the
functional roles of all Kv7 channels in human DSM tissue. In the following paragraphs,
preliminary data on the expression and roles of Kv7 channels will be succinctly
presented.
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MATERIALS AND METHODS
Human DSM tissue collection
DSM tissue collection is described in chapter 2.2. In total, we used DSM tissue samples
from 11 (8 males and 3 females) patients (55-79 years old; average age 65.8±2.2) without
a history of OAB.

Detection and quantification of Kv7 channels mRNA message by RT-PCR and
qPCR

RT-PCR and qPCR experiments were conducted as previously described in chapter 2.2.
The primers sequences and the size of the amplicon were as follows: Kv7.1- F: 5′CTTGATGCGCACCATGAGGTTG-3′ and R: 5′- ACACCCATCACCCACATCTCAC3′ (180 bp); Kv7.2- F: 5′- CGAAGTACTCCACGCCAAACAC-3′ and R: 5′TTCCTCTACAACGTGCTGGAGC-3′

(190

bp);

Kv7.3-

F:

5'-

GAGACGTAGCATCACGCGAGAC-3' and R: 5'- TCCGTGTCTGTGTCCGTCTCAC3'

(195

bp);

Kv7.4-

F:

5'-

TGCTGGCTTCGCCTTACTGG-3'

TACCAGGTGGCTGTCAGGTAGG-3'

(201

bp);

and

Kv7.5-

R:

F:

5'5'-

ACGCGCTTAGCCCTACTATGC-3' and R: 5'- CAGATGCTTGATGGCTGGGAG-3'
(173

bp);

GAPDH-

F:

5′-

GGATTTGGTCGTATTGGG-3′

and

R:

5′-

GGAAGATGGTGATGGGATT-3′ (205 bp) . The parameters of the qPCR experiments
were as follows: Cycle 1, 95 oC for 3 min; cycle 2, 95 oC for 10 s then 58 oC for 30 s
(repeated 40 times); cycle 3, 95 oC for 1 min; cycle 4, 58 oC for 1 min; cycle 5, 58 oC for
10 s with 0.5 oC increment (cycle 5 was repeated 81 times to generate a melting curve).
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Isometric DSM tension recordings

These series of experiments were performed as previously described in chapter 2.2.

Solutions and drugs
The Ca2+-free dissection solution and the Ca2+-containing PSS had the same compositions
as previously described in chapter 2.2. Retigabine and XE991 were purchased from
Tocris Bioscience (Bristol, UK) and stock solutions were prepared daily in dimethyl
sulfoxide (DMSO). The final DMSO concentration in the bath was not greater than 0.1%.

Data analysis and statistics

Data analysis and statistical analysis were performed as previously described in chapter
2.2.
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RESULTS

Kv7.4 and Kv7.5 channels but not Kv7.1, Kv7.2, and Kv7.3 channels are expressed
in human DSM cells at the mRNA level

The RT-PCR experiments revealed that amongst Kv7 channels, only Kv7.1, Kv7.4, and
Kv7.5 channels was found in human whole DSM tissue while at the DSM single cells
level, Kv7.4 and Kv7.5 channels but not Kv7.1 channel was identified at the mRNA level
(N=4; Fig. 5.3.1A). The unique advantage of conducting RT-PCR experiments on freshly
isolated single cells is that this approach eliminates possible contamination from other
non-DSM cells such as neurons, fibroblasts, vascular, and endothelial cells present within
the DSM layers (2, 74, 75, 127, 143, 165). RT-PCR experiments were conducted on
DSM cDNAs equivalent to at least 50 ng of starting mRNA. Negative control
experiments performed in the absence of the reverse transcriptase (-RT) demonstrated an
absence of genomic DNA contamination. In whole DSM tissue, our qPCR data showed
that Kv7 channels relative mRNA level was as follows: Kv7.1 > Kv7.5 ≈ Kv7.4 (N=4;
Fig. 5.3.1B) while at the single cell level, Kv7.5 > Kv7.4 >> Kv7.1 (N=4; Fig. 5.3.1B).
Taken together these RT-PCR and qPCR data suggest that in human DSM cells, only
Kv7.4 and Kv7.5 are expressed at the mRNA level, and that the Kv7.5 channel could be
the most highly expressed.
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Figure 5.3.1. Kv7 channels mRNA expression in human DSM. A) Gel electrophoresis images illustrate RT-PCR
detection of Kv7.1, Kv7.4, and Kv7.5 mRNA messages in whole DSM tissue (N=4). At the DSM single cell level, only
Kv7.4 and Kv7.5 channels mRNA messages were detected. Human brain was used as a positive control. No product
was observed in the negative controls (-RT) in which reverse transcriptase was not added to the reaction. B) qPCR
analysis show relative expression of Kv7.1, Kv7.4, and Kv7.5 channel mRNA expression in both DSM whole tissue
(N=4) and DSM single cells (N=4). Data were normalized to GAPDH using the ΔCt method. Ct values are expressed
as mean ± SE.
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Role of Kv7 channels in spontaneous phasic and tonic DSM contractions in humans
We used retigabine, a Kv7.2-7.5 channel activator and XE991, a Kv7.1-7.5 channel
activator to investigate the roles of Kv7 channels in human DSM spontaneous
contractions. Previous studies in guinea pig DSM demonstrated that retigabine was very
effective at reducing the spontaneous phasic contraction at lower micromolar
concentrations. In the present study, we found that retigabine (10 µM) significantly
decreased the human DSM spontaneous phasic and tonic contractions (Fig. 5.3.2A).
Retigabine (10 μM) effects on the spontaneous phasic contraction amplitude, muscle
force, frequency, duration, and muscle tone compared to control were 19.6±9.9%,
17.5±8.7%, 37.8±22.4%, 48.1±24.7%, and 43.1±21.3%, respectively (n=6, N=4, p<0.05;
Fig. 5.3.2A).
On the other hand, pharmacological blockade of Kv7 channels with XE991 enhanced
DSM spontaneous contractions amplitude, muscle force, and muscle tone without any
significant effects on contraction duration and frequency (Fig. 5.3.2B). XE991 (10 µM)
effects DSM on spontaneous phasic contraction amplitude, force, and tone compared to
control were 197.6±44.9%, 237.0±72.8%, and 159.3±21.0%, respectively (n=5, N=3,
p<0.05; Fig. 5.3.2B). Collectively, these results suggest that Kv7 channels regulate
human DSM myogenic activity.
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Figure 5.3.2. Pharmacological modulation of Kv7 channels with retigabine (10 μM) or XE991 (10 μM) affects
human DSM spontaneous phasic and tonic contractions. A) Original DSM tension recordings and summary data
showing retigabine (10 µM) relaxant effects on human DSM isolated strips. Retigabine significantly decreased all 5
parameters of the DSM spontaneous phasic and tonic contractions including amplitude, muscle force, frequency,
duration, and muscle tone (n=6, N=4). B) Original DSM tension recordings and summary data showing that XE991 (10
µM) enhances human DSM spontaneous phasic and tonic contractions. XE991 effects were more pronounced on DSM
contraction amplitude and muscle tone and at a lesser extent on muscle force (n=5, N=3). The 10-min control period
prior to apamin addition was taken to be 100 % and data were normalized. TTX (1 µM) was present throughout the
experiments. *p<0.05, ***p<0.005
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Role of Kv channels in nerve-evoked contractions in humans
We further investigated the effects of retigabine (10 µM) and XE991 (10 µM) on nerveevoked contractions of human DSM isolated strips (Fig. 5.3.3-4). We first applied a wide
range of EFS frequencies (0.5 – 50 Hz) as a control followed by retigabine (10 µM) or
XE991 (10 µM) application for approximatively 30 min. Next, the same EFS protocol
(0.5 – 50 Hz) was applied to evaluate how these Kv channel modulators affect EFSinduced contractions. The frequency-response curves showed that retigabine (10 µM)
significantly attenuated the amplitude of the EFS-induced contractions at stimulation
frequencies ranging from 10 to 50 Hz (n=7, N=4, p<0.05; Fig. 5.3.3). At the maximal
stimulation frequency of 50 Hz, retigabine effect on DSM EFS-induced contraction
amplitude compared to control was 57.4±7.6% (n=7, N=4, p<0.05; Fig. 5.3.3B).
Pharmacological inhibition of Kv7 channels with XE991 (10 µM) increased the
amplitude of the EFS-induced contractions at stimulation frequencies ranging from (3.5 –
15 Hz) (n=6, N=5, p<0.05; Fig. 5.3.4). XE991 effect on DSM EFS-induced contraction
amplitude compared to control was greater at stimulation frequency of 12.5 Hz where
XE991 (10 μM, induced ~20% increase (n=6, N=5, p<0.05; Fig. 5.3.4B). These latter
EFS data suggest that Kv7 channels play a role in the nerve-evoked contractions.
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A

B

Figure 5.3.3. Retigabine decreases the amplitude of the EFS-induced contractions in human DSM isolated strips
in a wide range of stimulation frequencies. A) An original DSM tension recording illustrating the inhibitory effects
of 10 µM retigabine on 3.5–50 Hz EFS-induced contractions of human DSM. B) Frequency-response curves showing
that retigabine (10 μM) significantly decreased EFS-induced contractions at frequencies 10–50 Hz (n=7, N=4; *P<0.05,
***P<0.005).
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Figure 5.3.4. XE991 enhances the amplitude of the EFS-induced contractions in human DSM isolated strips in a
wide range of stimulation frequencies. A) An original DSM tension recording showing that XE991 (10 µM) effects
on 3.5–50 Hz EFS-induced contractions of human DSM. B) Frequency-response curves showing XE991 significantly
increases EFS-induced contractions at stimulation frequencies ranging from 3.5–15 Hz (n=6, N=5; *P<0.05).
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REMARKS
The above preliminary data are encouraging and suggest that several Kv7 channels
namely Kv7.4 and Kv7.5 channels are expressed in human DSM and play important
physiological roles in DSM spontaneous and nerve-evoked contractions. However,
additional evidence for these Kv7 channel proteins expression in human DSM should be
provided to clearly establish their functionality. The implications of these findings with
respect to the treatment of functional disorders of lower urinary tract such as overactive
bladder are that the Kv7 channels could be promising pharmacological targets to control
urinary bladder function.
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CHAPTER 6
GENERAL DISCUSSION AND CONCLUSIONS

The pathophysiology of OAB is a serious condition characterized by urgency, frequent
urination, and abnormal increase in DSM contractility. Despite, numerous attempts to
treat the disorder with antimuscarinics and now with beta3-AR agonists, OAB still
remains a serious public health issue because of the tremendous impact that it has on
patients’ quality of life. In an effort to alleviate the discomfort of millions of patients, we
initiated these studies which aimed to propose an alternative therapeutic approach for the
treatment of OAB. K+ channels have been shown to be key regulators of smooth muscle
excitability and contractility in various species, however, information about their
expression and functional role in the DSM was limited. Plus, there was a tremendous gap
in knowledge about the role of these ion channels in the DSM of humans. Our hypothesis
suggests that K+ channels and beta3-AR are major regulators of DSM contractility and
excitability and could represent promising pharmacological targets for the treatment of
OAB. Throughout my PhD training, I collected data to test our hypothesis and prove our
concept. Four major conclusions can be drawn from our studies. 1) Several Ca2+activated K+ channels including BK and SK3 channels are key regulators of human DSM
spontaneous and nerve-evoked contractions. 2) We found a strong correlation between
the decrease in BKα subunit expression and the lack of BK channel activity in the
pathophysiology of NDO. 3) We demonstrated that there is a functional link between
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beta3-AR and BK channels during nerve-evoked contractions in rat and human DSM and
that beta3-AR play a minor role in guinea pig DSM. 4) Finally, several Kv channels
including Kv2 and Kv7 channels regulate DSM excitability and contractility. These data
suggest that pharmacological modulation of K+ channels (BK, SK3, Kv2, and Kv7
channels) or beta3-AR affect DSM contractility and excitability, therefore making K+
channels and beta3-AR likely drug targets for the treatment of OAB.

Ca2+-activated K+ channels expression and regulation of human DSM spontaneous
phasic and nerve-evoked contractions.
In order to assess whether Ca2+-activated K+ channels play a role in human DSM
spontaneous and nerves evoked contractions, we first had to demonstrate their molecular
expression in the DSM. For this purpose, we employed, RT-PCR, qPCR, western blot
and immunostaining techniques to show mRNA and protein expression of these ion
channels. A previous work published by our laboratory has already demonstrated the
mRNA and protein expression of the pore-forming BKα-subunit as well as the regulatory
β1 and β4 subunits in human DSM (75). However, evidence for SK and IK channels in
human DSM was still lacking. Here, we successfully identified SK and IK channels
molecular expression in human DSM. More specifically, we demonstrated via qPCR
analysis that among SK and IK channels, the SK3 channel was the most highly expressed
at the mRNA level in human DSM cells (Fig. 3.2.1). The qPCR data were further
confirmed by protein expression of SK3 channel and lack of IK channel protein
expression in human DSM (Fig. 3.2.3-4). The protein expression of these K+ ion
channels in the DSM of humans suggests at first glance that the channels might be
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physiologically active. We then used several modulators to test these Ca2+-activated K+
channels individually. In human DSM, isolated strips, we found that pharmacological
inhibition of BK channels with iberiotoxin, a BK channel blocker, increased DSM
spontaneous phasic contraction amplitude, muscle force, and tone (Fig. 3.1.2). Similarly,
pharmacological blockade of SK channels with apamin, a SK channel blocker increased
human DSM spontaneous phasic contraction amplitude, muscle force, duration, and
muscle tone (Fig. 3.2.5). We also found that TRAM-34, a selective IK channel inhibitor
had no effect on human DSM contractility (Fig. 3.2.6). The key role of BK channels in
human DSM has further been demonstrated by a recent study which suggests that
pharmacological activation of BK channels with NS1619, a BK channel activator
decreases human DSM excitability and contractility (80). Similar findings on SK
channels also revealed that pharmacological activation of SK channels with SKA-31, a
SK channel activator hyperpolarizes the cell membrane and decreases DSM contractility
in humans (144). Taken together, the aforementioned data suggest that Ca2+-activated K+
channels including BK and SK3 channels are major regulators of human DSM
contractility and excitability. The ability of BK and SK3 channels to increase human
DSM contractility upon inhibition and decrease DSM contractility upon activation
represents a unique opportunity to consider these ion channels in the treatment of bladder
dysfunctions including overactive and underactive bladder.
After determining the role of both BK and SK3 channels in human DSM under normal
physiological conditions, we expanded our studies by investigating BK channels roles
under pathophysiological conditions of NDO. The molecular analysis of BK channel
mRNA expressions by qPCR revealed a discrepancy in BKα subunit mRNA expression
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between NDO and control patients. We found that in NDO patients the BKα mRNA
relative expression level was significantly lower (~15.8 – fold) compared to control
patients (Fig. 3.1.1). Given the fact that the pore-forming α subunits ensure the
movement of K+ ions across the cell membrane and therefore DSM excitability, it is
expected that any changes in BKα channel subunits expression could significantly
hamper the channel’s ability to regulate DSM excitability and contractility (22, 109, 130,
131, 146). Consistent with this assumption, we found that NDO DSM had abnormally
elevated contractility in comparison to controls (Fig. 3.1.2). Additionally, unlike in
control DSM, inhibition of the BK channel with iberiotoxin failed to affect DSM
contractility in NDO DSM suggesting that in NDO patients DSM, the BK channel
function might be altered (Fig. 3.1.2). Therefore, we suggest that the abnormal increase
in DSM contractility observed in NDO patients is due to the significant reduction in BKα
subunit expression. As a consequence, we propose that targeting BK channels by either
pharmacological or genetic manipulation could be a promising therapeutic strategy to
treat OAB, and especially NDO.
The beta3-AR induced relaxation of the DSM nerve-evoked contraction is mediated
via activation of BK channels.

Beta3-ARs are known to be important facilitators of bladder relaxation because of their
ability to control DSM spontaneous phasic and nerve-evoked contractions as well as
TBKC that contribute to DSM excitability (22, 79, 134). Recently, the FDA has approved
the use of mirabegron, a selective beta3-AR agonist for the treatment of OAB (27, 90,
157). The mechanism by which beta3-AR induces relaxation of the DSM myogenic
contraction is suggested to be mediated via activation of BK channels (79, 130).
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However, the functional link between beta3-ARs and BK channels during nerve-evoked
contractions has never been investigated. In our study, we address this mechanism by
first testing our approach in rodents followed by humans.

The first animal model that we chose was the guinea pig. Guinea pigs are commonly used
laboratory animals which based on our own experience have DSM tissue that usually
generate stable spontaneous phasic contractions. Additionally, guinea pig DSM cells are
relatively easy to isolate for single-cell RT-PCR/qPCR or patch-clamp electrophysiology.
The molecular expression of beta3-ARs in guinea pig DSM cell has never gain
consensus. To clarify whether beta3-ARs are expressed in guinea DSM cells, we first
developed a technique called “single-cell” RT-PCR. This approach allow us to conduct
RT-PCR experiments on a poll of isolated DSM cells only while eliminating
contamination from other cell types such as neurons, fibroblasts, interstitial cells, which
are present within the DSM tissue (1, 2, 30, 74, 75, 77). Our results showed that beta3ARs are expressed in guinea pig DSM cells at the mRNA level (Fig. 4.1.1); however, we
could not confirm their protein expression because no specific beta3-AR antibody was
commercially available. The pharmacological activation of beta3-ARs with BRL37344,
a beta3-AR agonist had limited effects on guinea DSM spontaneous contractions (Fig.
4.1.3). The BRL37344 effect on spontaneous contractions was partially suppressed in the
presence of atropine, a muscarinic receptor antagonist, suggesting that the BRL37344
effect could have been mediated via inhibition of muscarinic receptors directly. Such
effects have previously been reported by other groups (22, 93, 111). Furthermore, it has
been suggested that at high concentrations BRL37344 may also non-selectively activate
beta1-ARs and/or beta2-ARs (150). Additional electrophysiological experiments
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performed by Dr. Hristov supported the idea that beta3-ARs, although expressed in
guinea pig DSM, do not regulate the DSM excitability. Perforated patch-clamp
experiments revealed no effect of BRL37344 on whole-cell steady-state K+ current,
TBKCs amplitude and frequency, and the resting membrane potential (Table 4.1.1). We
further assessed BRL37344 effects on guinea pig DSM nerve-evoked contractions.
Although, we observed a significant decrease in contraction amplitude by BRL37344
(Fig. 4.1.7), this BRL37344 effect was once again suppressed by atropine, suggesting
that BRL37344 acted directly on muscarinic receptors rather than beta3-ARs during
nerve stimulation (Fig. 4.1.9). Moreover, we employed another beta3-AR agonist, L755,507,

and found that this latter compound had no effect on the nerve-evoked

contractions in the absence or presence of atropine suggesting that beta3-ARs do not play
any role in the nerve-evoked contraction of guinea pig DSM (Fig. 4.1.10). Based on the
aforementioned observations, we concluded that although expressed in guinea pig DSM
cells at the mRNA level, beta3-ARs play a minor to no functional role or that in guinea
pig DSM beta3-ARs have distinct pharmacological profiles compared to beta3-ARs in
other species. As a consequence, we concluded that the potential functional link between
beta3-AR and BK channels could not be investigated in guinea pig DSM.

Next, we addressed the functional link between beta3-AR and BK channels in rat DSM.
Rat was chosen because previous studies have shown that beta3-ARs are expressed in rat
DSM tissue (46). Additionally, it has been proven that in rat DSM, activation of beta3AR with BRL37344 increased TBKCs frequency, and hyperpolarized the cell membrane
(79). Our data showed that unlike in guinea pig DSM, stimulation of beta3-AR receptors
with BRL37344 caused a significant decrease of the nerve-evoked contraction in rat
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DSM isolated strips in the presence or absence of atropine (Figs. 4.2.1-3). We also found
that the BRL37344 effect was mediated via inhibition of both the cholinergic and
purinergic components of the nerve-evoked contraction. In the presence of atropine,
which was used to block the cholinergic component of the nerve-evoked contractions, we
found that BRL37344 decreased the amplitude of the nerve-evoked contractions at all
stimulation frequencies tested suggesting that BRL37344 inhibits the purinergic
component of the nerve-evoked contractions (Fig. 4.2.3). In the presence of α,βmethylene-ATP and suramin which were used to block the purinergic component of the
nerve-evoked contractions, BRL37344 decreased the amplitude of the EFS-induced
contractions at all stimulation frequencies tested suggesting that BRL37344 inhibits the
cholinergic component of the nerve-evoked contractions (Fig. 4.2.4). After confirming
that beta3-ARs regulate rat DSM nerve-evoked contractions, we next addressed the
functional link between beta3-AR and BK channels during nerve-evoked contractions.
During myogenic contractions, it was previously shown that pharmacological blockage of
BK channels with iberiotoxin opposes beta3-AR-mediated relaxation in rats DSM (79).
We found that similar to what was observed during myogenic contractions, the
BRL37344 inhibitory effects on rat DSM nerve-evoked contractions was significantly
decreased when BK channel was antagonized by iberiotoxin (Fig. 4.2.5). The iberiotoxin
effects reported here originates from direct inhibition of BK channels in DSM since
immunohistochemical analysis have previously shown that BK channels are expressed in
DSM but not in the bladder nerves that innervate the DSM (161). Collectively, our data
suggest that BK channel activity is critical for the beta3 adrenergic receptor-induced
attenuation of the nerve-evoked contractions in rat DSM.
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After developing our strategy in laboratory animals, we could then confidently proceed to
the investigation of the functional link between beta3-AR and BK channels in human
DSM. Previous studies have demonstrated that beta3-AR are expressed in human DSM
(46) and that beta3-ARs could represent as much as 97% of all beta-AR expressed in
human DSM (168). We found that low concentrations of BRL37344 (10 nM–1 µM)
decreased the amplitude of nerve-evoked contractions in human DSM suggesting that
beta3-ARs play an important role in opposing human DSM nerve-evoked contractions.
Our data are also consistent with previous findings showing that KUC-7322 and
GW427353, two other selective beta3-AR agonists, also decreased carbachol-induced
and nerve-evoked contractions in human DSM (14, 81, 156). Like in rat DSM, we found
that in the presence of atropine, BRL37344 decreased the amplitude of the nerve-evoked
contractions in human DSM in a wide range of stimulation frequencies (Fig. 4.3.3). Also,
in the presence of suramin and α,β methylene-ATP, BRL37344 also significantly
decreased the amplitude of the nerve-evoked contractions in human DSM (Fig. 4.3.4).
These latter findings suggest that BRL37344 inhibits both cholinergic and purinergic
contractions of human DSM. Similarly to our findings in rat DSM nerve-evoked
contractions, iberiotoxin shifted the concentration-response curves for the BRL37344
inhibitory effects on human DSM nerve-evoked contractions suggesting that functional
BK channels play an important role in the beta3-AR mediated relaxation of human DSM
nerve-evoked contractions (Fig. 4.3.1).
Taken together, we were finally able to demonstrate that the beta3-AR-agonist-mediated
relaxation of DSM nerve-evoked contractions is BK channel-dependent, emphasizing the
critical role of BK channels in DSM physiology. While the functional link between
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beta3-AR and BK channels is prominent in rats and humans, this was not the case in
guinea pig DSM since the role of beta3-AR during nerve-evoked contractions could not
be demonstrated. These findings suggest critical species difference between rats, humans,
and guinea pigs.

Kv2 and Kv7 channels expression and regulation of DSM contractility.
Kv channels represent the largest and the most diverse group of K+ channels identified in
the human genome with more than 40 members. Kv channels have the potential to
become promising drug targets for the treatment of various pathologies because of their
ability to regulate excitability and contractility in smooth muscles as well as in neurons.
Unfortunately, information about their physiological role in numerous organs more
specifically in the DSM is scarce. What makes the investigation of individual Kv
channels difficult in any organ is the lack of selective pharmacological tools that will
allow investigators to study each channel separately. During my PhD training, I
investigated the expression and physiological roles of several Kv channels including Kv2
and Kv7 channels in the DSM. These studies were made possible because selective Kv2
and Kv7 channels have been recently discovered and made commercially available.
Before addressing the functional roles of both Kv2 and Kv7 channels in the DSM,
molecular expression of these channels had to be demonstrated. The investigation of Kv2
channels molecular expression in human DSM cells was performed by Dr. Chen. She
revealed the expression of Kv2.1 and Kv2.2 channels in human DSM cells at both mRNA
and protein levels (Fig. 5.1.1-3). In human DSM cells, I provided the first molecular
evidence for Kv7.4 and Kv7.5 channels at the mRNA level (Fig. 5.3.1). The expression
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pattern of Kv2 channels in human were similar to that of rat where Kv2.1 and Kv2.2 were
also found in DSM cells (29). Comparable observation was made about Kv7 channels
expression between human and rats. Like our findings in human DSM, studies by others
revealed Kv7.4, Kv7.5, and arguably Kv7.1 channels mRNA expression in rat DSM (121,
149). Unlike rats and humans, guinea pig DSM cells expressed Kv7.1, Kv7.2, Kv7.3, and
Kv7.5 channels at both mRNA and protein levels (Fig. 5.2.1-3). These results indicate
that the expression pattern of Kv2 and Kv7 channels in the DSM may vary depending on
the species.
To assess the Kv2 channels functional roles in human DSM, we used stromatoxin-1
(ScTx1), a selective Kv2.1 and Kv2.2 channel blocker. Pharmacological blockade of Kv2
channels in human DSM isolated strips significantly increased the spontaneous phasic
contraction amplitude and force in human DSM isolated strips (Fig. 5.1.6), consistent
with our previous findings in rat and guinea pig DSM (29, 77). Our results also show that
ScTx1 significantly increases the amplitude of nerve-evoked contractions in human DSM
isolated strips (Fig. 5.1.7) indicating the functional role of these channels in human DSM
nerve-evoked contractions. These data are consistent with our earlier animal studies (29,
77), and revealed that KV2-containing channels also work to oppose human DSM
contractility under physiological conditions.
In human DSM isolated strips, we also found that pharmacological activation of Kv7
channels with retigabine, a Kv7.2-7.5 channels activator, induced relaxation of the
spontaneous phasic and nerve-evoked contractions (Fig. 5.3.2-4). Similar retigabine
effects were also observed in guinea pig DSM spontaneous phasic and nerve-evoked
contractions (Fig. 5.2.6 and 5.2.11). Additionally, L-364373, a selective Kv7.1 channel
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activator was shown to attenuate the guinea pig DSM isolated strips spontaneous phasic
and nerve-evoked contractions (Fig. 5.1.7 and 5.2.11). On the other hand,
pharmacological blockade of Kv7 channels increases DSM contractility. In human DSM
isolated strips, XE991, a non-selective Kv7 channel blocker was shown to enhance
spontaneous phasic and nerve-evoked contractions. And in guinea pig DSM isolated
strips, application of XE991 or linopiridine, another Kv7 channel blocker was reported to
increase spontaneous phasic and nerve-evoked contractions. The retigabine effects
reported in our studies are in line with previous reports which demonstrated that
intravesical administration of retigabine increased micturition volume and voiding
intervals in freely moving conscious rats (148). Also in conscious rats with capsaicininduced irritated bladders, retigabine was shown to strongly reduce bladder rings
contractility, reduce bladder pressure, and delay voiding, plus the retigabine effect on
bladder rings was blocked by XE991 (149). The retigabine effect on nerve-evoked
contractions reported in our study is somehow similar to previous studies in rats DSM
(136). The aforementioned study reported that retigabine (1 – 30 μM) inhibited EFSinduced contraction amplitude generated by 20 Hz in a concentration-dependent manner
(136). The authors also reported that the retigabine relaxant effects on the EFS-induced
contractions were antagonized by 10 μM XE991 suggesting that Kv7 channels, more
precisely Kv7.4 and Kv7.5 channels, regulate rat DSM neurogenic contractions since
only Kv7.4 and Kv7.5 but not Kv7.1, Kv7.2, and Kv7.3 channels were present at the
mRNA level in rat bladder (121, 136).
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IMPLICATIONS AND FUTURE DIRECTIONS
The pathophysiology of OAB is generally poorly understood and the current
pharmacological treatments which include antimuscarinics and beta3-AR agonists have
yet to be proven infallible. Throughout my PhD training, I explored several K+ channels
and have found that BK, SK3, Kv2, and Kv7 channels are major regulators of human
DSM contractility. I also found that pharmacological activation of beta3-AR induced
relaxation of DSM nerve-evoked contractions in humans. These data suggest that the
aforementioned K+ channels and beta3-AR could represent pharmacological targets for
some types of bladder dysfunctions.
There could be two direct clinical benefits for modulating the aforementioned K+
channels in the DSM. Targeting BK, SK3, Kv2, or Kv7 channels with channel opening
agents will decrease DSM contractility and contribute to alleviate detrusor overactivity
observed in OAB patients. Alternatively, targeting BK, SK3, Kv2, and Kv7 channels with
selective inhibitors will increase DSM contractility, and thus have clinical application for
the treatment of detrusor underactivity. The major contribution of our studies was that we
provided for the first time, evidence for a direct correlation between NDO and BK
channel expression and function. Therefore, it is possible that by increasing BK channels
expression in the DSM through genetic manipulation, detrusor overactivity can be
reduced in NDO patients.
It is critical that future studies be initiated to develop agents which could selectively
target one or more of these K+ channels in the lower urinary tract exclusively in order to
reduce potential collateral effects as BK, SK3, Kv2, and Kv7 channels expression has
been reported in other human tissues (19, 20, 31, 42, 84, 103, 135). Further studies should
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investigate molecular differences between the aforementioned K+ channels in the DSM
and other organs in order to design organ specific compounds with limited side effects,
therefore providing a unique advantage over antimuscarinic drugs. Compound such as
retigabine which is currently used for epilepsy treatment could find use in the treatment
of OAB if its molecular structure is modified to make it impermeable to the blood-brain
barrier and therefore reduce potential side effects in the brains. Clinical trials for selective
BK, SK3, Kv2, or Kv7 channels agents would need to be performed to validate such
assumption and assess the efficacy and therapeutic safety window.
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